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Introduction 
The incidence of type 2 diabetes mellitus (DM2) is rapidly increasing, partially due to 
population growth, aging and a western lifestyle, leading to an increase in the prevalence 
of obesity (1). In 2007 almost 750,000 diagnosed individuals with diabetes mellitus were 
registered at the Dutch general practitioners’ database, of which over 90% had DM2 (2). In 
the coming years, this number will increase to an estimated number of 1.3 million around 
2025. Obviously, this will lead to a heavy burden on the health care system, as DM2 is 
associated with increased morbidity and mortality. Cardiovascular disease (CVD) accounts 
for over 60% of the DM2 associated morbidity and mortality (3-5).  
 
 ‘Traditional’ cardiovascular risk factors, such as obesity, dyslipidaemia or hypertension 
often characterize individuals with DM2. These risk factors possibly interact with each 
other and other factors although such interactions are not easy to quantify (6). A 
hypothetical model of the interactions among some of these ‘traditional’ and ‘non-
traditional’ risk factors is shown in Figure 1, where one can appreciate that while some of 
these factors tend to cluster, others appear to be independent of each other. Most of 
them may actually be common antecedents for both DM2 and CVD, supporting the 
hypothesis that both DM2 and CVD arise separately from a “common soil” (7). Consistent 
with this hypothesis, some of these ‘non-traditional’ cardiovascular risk factors predict 
incident DM2 (8, 9). Low-grade inflammation, endothelial dysfunction, and abnormalities 
of coagulation are all associated with (central) obesity and insulin resistance and may 
thereby become common antecedents of both DM2 and CVD.  
 
In the prediabetic stage the clustering of risk factors is better known as the metabolic 
syndrome (MetS). This is a construct defined by the coexistence of central obesity, 
dyslipidaemia, elevated blood pressure, and impaired glucose metabolism. Overall, MetS 
is associated with approximately a 5-fold increased risk of incident DM2 (10), a 2-fold 
increase in risk of CVD, CVD mortality and stroke, and a 1.5-fold increase in risk of all-
cause mortality (11). 
 
Several definitions for MetS have been proposed of which the ones from the National 
Cholesterol Education Programme Adult Treatment Panel III (NCEP-ATP III) and 
International Diabetes Federation (IDF) are the most widely used (12, 13). These 
definitions use the same set of traits for diagnosing MetS, i.e., impaired glucose 
metabolism, hypertension, central obesity, high triglycerides and/or low high-density 
lipoprotein (HDL) cholesterol, only differing by the fact that the IDF definition required 
central obesity plus any 2 other traits, whereas NCEP required any 3 out of 5 traits. In 
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2009, NCEP and IDF agreed that, for uniformity reasons, central obesity was not an 
obligatory component anymore for the diagnosis of MetS (14).  
 
 
Figure 1. Interaction of risk factors in the pathogenesis of cardiovascular disease. Adapted from Fonseca et al (6) 
 
Nevertheless, central obesity remains a key factor at the root of the association between 
MetS and DM2 on the one hand and CVD on the other, as (central) obesity is both 
associated with incident DM2 (15, 16) and CVD (17, 18). Although the pathophysiological 
mechanism(s) linking (central) obesity to CVD are not completely understood, it is known 
that an increase in adipose tissue elicits pathophysiological processes which are involved 
in the development of atherosclerosis, such as low-grade inflammation, insulin resistance, 
hypertension and dyslipidaemia. Adipose tissue is an active endocrine and paracrine organ 
that releases a large number of cytokines and adipokines, such as leptin, adiponectin, 
interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α), that affect not only body weight 
homeostasis, but also  affect insulin resistance, glucose metabolism, lipid levels, blood 
pressure, coagulation, fibrinolysis, low-grade inflammation and atherosclerosis (19). 
 
Epidemiological studies investigating associations between (central) obesity and 
cardiovascular outcomes generally use anthropometric estimates of (central) obesity, such 
as body-mass index (BMI), waist circumference and waist-to-hip-ratio (WHR). These 
measures are not always an accurate reflection of a person’s true amount of fat mass (and 
distribution). For example, in the young, BMI does not distinguish between fat and lean 
Insulin resistance 
Central obesity 
Microalbuminuria 
Cardiovascular disease 
Endothelial dysfunction 
Dyslipidaemia 
Abnormal haemostasis 
Autonomic Neuropathy 
Hypertension 
Low-grade inflammation 
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(non-fat) mass and in the elderly, lean mass decreases which can result in a paradoxically 
unchanged or decreased BMI despite an unchanged or even increased fat mass (20). 
Sophisticated imaging techniques, such as magnetic resonance imaging (MRI), computed 
tomography (CT) and dual-energy absorptiometry (DXA), are able to distinguish between 
fat and lean masses in the total body and in specific body regions, thereby enabling a 
more precise appreciation of the metabolic and cardiovascular risks associated with body 
fat distribution (20, 21).  
 
Surrogate markers of CVD 
 
The use of surrogate markers of CVD is very common in epidemiological research. This is 
due to the fact that for most clinical research questions, the expected event rate of 
cardiovascular events is low resulting in the need for a large sample size and long duration 
of follow-up to obtain adequate statistical power (22). A surrogate marker is defined as a 
characteristic that can objectively be measured and evaluated as an indicator of normal 
biologic or pathogenic processes or as a physiologic response to a therapeutic intervention 
(23). The criteria for a useful surrogate marker are efficiency (i.e. the surrogate marker 
should be relatively easy to evaluate), linkage (i.e. the quantitative and qualitative 
relationship between the surrogate marker and the clinical endpoint should be established 
on the basis of epidemiological and clinical studies), and congruence (the surrogate should 
produce parallel estimates of risk and benefits that are related to the target disease 
processes as endpoints) (23, 24). Increased levels of these surrogate markers potentially 
detect individuals with an unfavourable intermediate phenotype, i.e. those who have a 
higher risk for future cardiovascular events. In this thesis we will mainly focus on the 
following intermediate phenotypes of CVD: endothelial dysfunction, microalbuminuria, 
cardiovascular autonomic dysfunction (C-AD), arterial remodeling and thrombin 
generation. As mentioned above, these adverse intermediate phenotypes may help us to 
give insight in the biological process and identify individuals with a higher risk of CVD, 
which could have implications for treatment and prevention programmes.  
 
Endothelial dysfunction 
 
Endothelial dysfunction is thought to be one of the first events in the process leading to 
atherosclerosis and is a good predictor of future cardiovascular events (25-27). Normal 
functions of endothelial cells include decreasing vascular tone, maintaining vascular 
permeability and limiting coagulation, platelet adhesion and aggregation (28). Endothelial 
dysfunction is thought to be present when its properties, either in the basal state or after 
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stimulation, have changed in a way that is inappropriate with regard to the preservation of 
organ function. It is commonly associated with deficiencies of nitric oxide (NO) and 
prostacyclin bioavailability. A closely related event is binding of mononuclear cells, such as 
monocytes and T-lymphocytes, to the endothelium, which is mediated by adhesion 
molecules present on the endothelial surface, such as soluble vascular cell adhesion 
molecule (sVCAM-1), soluble intercellular adhesion molecule (sICAM-1) and soluble 
endothelial selectin (sE-selectin). This process leads to foam cell and in a later stage to 
plaque formation.  
 
Endothelial function can be assessed both biochemically and functionally and possibly by 
microalbuminuria (28). Biochemical assessment can be done by measuring biomarkers, 
such as sVCAM-1, sICAM-1, Von Willebrand factor and sE-selectin. Functional assessment 
measures the ability of a blood vessel to dilate after a stimulus (e.g. ischaemia-induced 
shear stress) (Figure 2). Brachial artery flow-mediated vasodilation (FMD) is a noninvasive 
method of assessing arterial endothelial function in vivo. Because endothelial injury is an 
early event in atherogenesis, it has been suggested that an abnormal FMD may precede 
the development of structural changes in the arterial wall. It is known that FMD is 
impaired in subjects with DM2 (29, 30). The metabolic syndrome and higher levels of body 
fatness, particularly a central pattern of fat distribution, have been inversely associated 
with FMD (31-35). However, these findings were restricted to relatively young individuals 
and whether these results can be generalized to older individuals is unknown. 
Furthermore, the potential role of peripheral lean mass has not been studied. 
 
 
 
Figure 2: An example of a flow-mediated dilation curve by Pyke et al(36) --- shear rate, ― diameter. 
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Microalbuminuria and autonomic dysfunction 
 
Microalbuminuria is a strong independent risk marker for CVD in both diabetic (37, 38) 
and non-diabetic individuals (39, 40). Microalbuminuria is defined as an urinary albumin 
excretion of 20-200 μg/min, or 30-300 mg/24 hour (41). There are several mechanisms by 
which microalbuminuria could be associated with CVD (42). It is unlikely that 
microalbuminuria itself causes cardiovascular mortality (i.e. that microalbuminuria is a risk 
factor for CVD). A more plausible explanation is that microalbuminuria and CVD have a 
common underlying risk factor or pathophysiological process(es). For example, endothelial 
dysfunction precedes and predicts the onset of microalbuminuria, e.g. by an increased 
glomerular pressure and vasopermeability, and is also associated CVD. Cardiovascular 
autonomic dysfunction could potentially also be one of the explaining factors behind the 
microalbuminuria-CVD relationship (43, 44) as it is associated with both microalbuminuria 
and CVD (vide infra).  
 
Cardiovascular autonomic dysfunction refers to dysfunction of the non-voluntary, non-
sensory nervous system affecting mostly the internal organs, including the cardiovascular 
system (45, 46). Common symptoms of C-AD are disturbances of the heart rate, such as 
resting tachycardia, orthostatic hypotension and an inadequate increase of the heart rate 
during exercise. Furthermore, damage to the autonomic nerves can decrease symptoms of 
coronary artery disease and thus lead to silent myocardial infarction (47, 48). 
Cardiovascular autonomic dysfunction is independently associated with microalbuminuria, 
which could potentially be explained by a reduced nightly drop in blood pressure and/or a 
disturbance in glomerular arteriolar autoregulation; (43) in addition, C-AD is 
independently associated with cardiovascular mortality (Figure 3A) (49, 50). Thus, C-AD 
could, in part, explain the risk of CVD associated with microalbuminuria. Alternatively, it is 
also possible that both microalbuminuria and C-AD are associated with cardiovascular 
mortality by different biological pathways (Figure 3B). The role of autonomic dysfunction 
in the association between microalbuminuria and cardiovascular mortality has up till now 
not been investigated in a prospective setting. 
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Figure 3A. Cardiovascular autonomic dysfunction as a risk factor for both microalbuminuria and cardiovascular 
mortality. 3B. Microalbuminuria and cardiovascular autonomic dysfunction are associated with cardiovascular 
mortality by independent biological mechanisms. -----> non-causal relationship —> causal relationship 
 
 
Arterial remodeling 
 
Increased intima-media thickness (IMT) is an early marker of atherosclerosis and has 
independently been associated with CVD (51, 52). Traditionally, research on ischaemic 
stroke risk mainly focused on carotid IMT and relatively little attention was paid to 
variations in arterial diameter accompanying wall thickening. Arterial remodeling is the 
structural change of the blood vessel in response to changes in blood flow and 
circumferential stretch to restore normal shear stress and wall tension, respectively (53-
55). It is characterized by wall thickening (indicated by an increase in IMT) and diameter 
widening (indicated by an increase in interadventitial diameter (IAD)).  
 
Three different patterns of arterial remodeling have been identified (Figure 4): inward 
(characterized by a decrease in lumen diameter (LD) resulting from a greater change in 
IMT than in IAD), outward (characterized by an increase in LD caused by a greater change 
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in IAD than in IMT), and compensatory (characterized by LD preservation despite changes 
in IMT and IAD) (54).  
Maladaptive remodeling (i.e. an increase in tensile stress despite increases in IMT and IAD) 
may be associated with stroke as it has been shown that in ischaemic stroke wall tension 
was higher at the affected side of the carotid artery (56). Individuals with DM2 have been 
characterized with a maladaptive pattern of remodeling of the carotid artery (57).  As 
mentioned above, patients with MetS, but without DM2, are still at high risk for CVD 
mortality and stroke (11), a phenomenon which is better known as the ‘ticking clock’ 
hypothesis (58). It is thus of interest to ascertain the extent to which MetS is already 
associated with (maladaptive) remodeling of the carotid artery, which would be in line 
with the hypothesis that damage already occurs long before DM2 becomes overt. To 
better understand the dynamic process of arterial remodeling, an investigation of carotid 
structural and functional changes as function of changes in MetS status over time in the 
context of a longitudinal study is needed.  
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Figure 4: Different patterns of arterial remodeling 
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Hypercoagulability / thrombin generation   
 
DM2 is associated with a prothrombotic state, i.e. increased platelet activation and 
aggregation (primary haemostasis), increased activation of the coagulation cascade 
(secondary haemostasis), decreased fibrinolysis (in part due to upregulation of  
plasminogen activator inhibitor-1 (PAI-1)) (59). Thrombin is a key enzyme of secondary 
haemostasis by combining pro- and anticoagulant functions through controlled regulation 
of the cascade activity (60, 61). DM2 has been associated with thrombin activation 
markers (prothrombin fragments 1.2 and thrombin-antithrombin complexes TAT) (62-64). 
However, given the complexity of the coagulation system, which involves several 
interrelated procoagulant and anticoagulant pathways, measuring the plasma levels 
and/or activities of individual proteins is of limited usefulness in epidemiological studies 
and clinical management of hypo- and hypercoagulable states. 
 
Therefore, an automated method (Calibrated Automated Thrombogram, CAT) that 
quantitatively measures thrombin generation in vitro in plasma after activation of the 
coagulation cascade with tissue factor (TF), phospholipids and calcium chloride (CaCl2) has 
been developed (65). This method generates a thrombin generation curve that mimics the 
overall plasma coagulability potential when a thrombogenic stimulus (e.g. TF release after 
plaque rupture) appears (Figure 5). This curve is characterized by a lag (initiation) phase, 
followed by a thrombin burst (propagation), which is then eventually completely inhibited 
by plasma protease inhibitors (termination). The endogenous thrombin potential (ETP) is 
reflected by the area under this curve, which represents the total amount of active 
thrombin that is formed after activation of the coagulation cascade.  
 
ETP is thought to provide a more reliable estimation of coagulation under 
pathophysiological conditions than the single point measurement of activation markers 
such as prothrombin 1.2 fragments or TAT complexes (67). Furthermore, ETP has been 
shown to be a good indicator of a hypercoagulable state in, for example, studies among 
individuals using oral contraceptives, prior venous thromboembolism or circulating lupus 
anticoagulans (65, 68-70). Up till now, only one small case-control study has investigated 
the association between DM2 and thrombin generation according to this method (71). No 
studies have been performed at the population level. Establishing such an association is a 
necessary step to ascertain its potential value as a tool to estimate atherothrombotic risk 
in individuals with impaired glucose metabolism (IGM) and/or DM2. Furthermore, from an 
aetiological point of view, it is not clear whether any such association is independent of 
other risk factors that typically characterize these individuals (e.g. hypertension and 
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central adiposity) or, alternatively, is explained by these risk factors and their associated 
pathophysiological mechanisms. 
 
 
Figure 5: An example of a thrombin generation curve obtained by means of the CAT method in normal 
individuals. The parameters derived from the thrombin generation curve are: lag time (the time in which ~10 nM 
of thrombin is formed), peak height (the maximum amount of formed thrombin), and ETP (the area under the 
curve). From: van Veen  et al. (66) 
 
 
Adipose tissue also has both direct and indirect effects on coagulation (72). Direct effects 
are for example synthesis of tissue factor and PAI-1 by adipose tissue, whereas indirect 
effects are mainly mediated by effects of adipose tissue-derived factors, such as leptin and 
adiponectin, on platelet activation and increased secretion of proinflammatory cytokines 
by the liver which in turn affect coagulation. A recent pilot study in children has shown 
that extreme obesity is associated with increased plasma-based thrombin generation (73). 
No studies have investigated the association between body fat mass and thrombin 
generation according to the CAT method in adults. In addition, the extent to which 
different regions of body fat and lean mass contribute to or protect against a 
hypercoagulable state as estimated by this method are also unknown.  
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Study population 
 
In this thesis we made an attempt to further study the above mentioned surrogate 
markers, or indeed, intermediate phenotypes, for CVD, by making use of the data of the 
Hoorn Study and the Amsterdam Growth and Health Longitudinal Study. 
 
The Hoorn study is a Dutch population-based cohort study on glucose metabolism and its 
complications which started in 1989 and consisted of 2484 participants (74). All 
participants were of Caucasian origin and between 50 and 75 years old at the time of 
inclusion. All subjects had a 75-g oral glucose tolerance test (OGTT), except those 
diagnosed previously with diabetes, as indicated by treatment with oral glucose-lowering 
drugs or insulin (Chapter 3).  
 
Between 1996 and 1998, a 2nd examination (1st follow-up) was carried out. From the 
initial cohort, 150 people had died and 108 had moved out of Hoorn before 1996. One 
hundred forty other people were not invited because of logistical reasons. Of the 
remaining 2086 people who were invited for the follow-up examination, 1513 (72.5%) 
participated (75).  
 
In 2000–2001, a 3rd examination (2nd follow-up) was carried out among surviving 
participants who gave their permission to be recontacted (Chapters 2,4,6,7). All 
participants who had diabetes, as determined by an oral glucose tolerance test (OGTT) or 
by diabetes treatment (n=176), at the 1st follow up visit were invited. In addition, a 
random sample of participants who had normal glucose tolerance (n=705) or impaired 
glucose tolerance (n=193) at the 1st follow up visit were invited. Of the 1074 individuals 
invited, 648 (60.3%) participated. The main reasons for nonparticipation in the 2000–2001 
follow-up examination were lack of interest (30%) or comorbidity (23%). Other reasons 
were high age (7%), unwillingness to travel (6%), participation considered too time-
consuming (6%), miscellaneous reasons (15%) and 13% gave no reason (76). At this follow-
up examination the DXA (body composition) measures, arterial properties, thrombin 
generation parameters and biomarkers of endothelial function were measured. 
 
Amsterdam Growth and Health Longitudinal Study (AGAHLS). For Chapter 5 we used data 
derived from the AGAHLS, an observational longitudinal study that started in 1976 with a 
total inclusion of 698 boys and girls (mean age of 13.1±0.8 years) (77). Briefly, its initial 
goal was to describe the natural development of growth, health and lifestyle of 
adolescents, and to investigate life-course relationships between biological and lifestyle 
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risk factors. In the year 2000 (8th measurement round), when subjects’ mean age was 
36.6 (±0.6) years, measurements of large artery properties by means of non-invasive 
ultrasound were included for the first time in this cohort, and obtained in 373 subjects 
(78). In 2006, complete follow-up of arterial measurements were obtained in 297 of these 
individuals (79). 
 
Objectives of this thesis 
 
Specifically, we formulated the following research questions: 
1. Is an adverse body composition, i.e. more central fat mass, but also less 
peripheral fat and/or lean mass associated with endothelial dysfunction, as 
ascertained by FMD and/or by biomarkers and could any association be explained 
by body-composition-related levels of low-grade inflammation and/or insulin 
resistance? 
2. Is the association between microalbuminuria and (cardiovascular) mortality 
explained by cardiovascular autonomic dysfunction? 
3. Is MetS in non-diabetic individuals associated with maladaptive remodeling of the 
carotid artery? 
4. Are changes in carotid artery structural and functional properties related to 
changes in MetS-status in a 6-yr longitudinal study in otherwise healthy young 
adults? 
5. Is total body fat mass associated with hypercoagulability as estimated by plasma-
based thrombin generation and what is the role of different body regions in this 
respect? 
6. Are impaired glucose metabolism and DM2 independently associated with 
thrombin generation in plasma and to what extent can this association be 
explained by traditional risk factors? 
 
Outline of this thesis 
 
In Chapter 2 the association between body composition and endothelial dysfunction was 
addressed and the potential mediating role of low-grade inflammation and/or insulin 
resistance were analysed. The role of cardiovascular autonomic dysfunction in the 
association between microalbuminuria and cardiovascular mortality was examined in 
Chapter 3. In Chapter 4 we investigated whether MetS in non-diabetic individuals was 
associated with maladaptive remodeling of the carotid artery; subsequently, the 
longitudinal association between MetS and carotid artery properties in young adults was 
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investigated in Chapter 5.  We explored the relation between body composition and 
thrombin generation, and investigated which regional body fat depots contributed to this 
association in Chapter 6. In addition, we examined the potential mediating role of low-
grade inflammation, insulin resistance and adiponectin. In Chapter 7, we focused on the 
association between glucose metabolism status and thrombin generation and investigated 
whether any such association could be attributable to ‘traditional’ cardiovascular risk 
factors. Finally, in the general discussion (Chapter 8) methodological and 
pathophysiological issues are presented and implications and suggestions for future 
studies are addressed.   
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Abstract  
 
Objective - To investigate first, the extent to which an adverse body composition is 
associated with ED; and, second, whether any such associations could be explained by 
low-grade inflammation (LGI) and/or insulin resistance (HOMA2-IR).  
 
Design - We studied 475 individuals from the Hoorn Study (mean age, 68.9±6.1 years, 245 
women). Body composition was assessed by whole body dual-energy absorptiometry. 
Endothelial dysfunction was measured functionally, by flow-mediated dilation (FMD) and 
by circulating biomarkers (summarized into an ED score, with a higher score indicating 
more ED). Associations were examined with multiple linear regression models and 
mediation analyses according to the ab product of coefficients method. 
 
Results - After adjustment for age, sex, glucose metabolism status, prior cardiovascular 
disease and lifestyle factors, total and central fat mass were positively associated with the 
ED score [ß=0.16 (95% CI 0.03; 0.28) and ß =0.16 (0.03; 0.29) respectively] and inversely, 
although not statistically significantly, with FMDmax. Peripheral fat mass was not associated 
with the ED score or FMDmax. There was a significant favourable association between 
peripheral lean mass and FMDmax [ß =0.15 (0.00; 0.30)], but not with the ED score. The 
association between total and central fat mass and the ED score was, to a great extent, 
mediated by LGI and HOMA2-IR. In contrast, LGI or HOMA2-IR did not mediate the 
association between peripheral lean mass and FMDmax. 
 
Conclusion - Higher levels of central, but not peripheral fat mass were adversely 
associated with ED, which was attributable to body-composition-related LGI and insulin 
resistance. Peripheral lean mass was favourably associated with endothelial function, 
suggesting that sarcopenia may also play a role in the decline of endothelial function in 
elderly individuals.  
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Introduction 
 
Endothelial dysfunction (ED), whether measured functionally (flow-mediated dilation - 
FMD) or by determining the levels of circulating biomarkers, such as soluble vascular cell 
adhesion molecule 1 (sVCAM-1), soluble intercellular adhesion molecule 1 (sICAM-1), Von 
Willebrand factor (vWF) and soluble endothelial selectin (sE-selectin), is associated with 
cardiovascular disease (CVD) (1-4).  
 
A decline in endothelial function is evident with advancing age (5-7). Age-related changes 
in body composition, which are typically characterized by increases in body fatness (8, 9), 
may play a role herein. Indeed, numerous studies have linked excessive body fat to ED 
[reviewed in (10)] and pathobiological mechanisms such as obesity-related low-grade 
inflammation (LGI) and insulin resistance, all of which are intertwined, have been 
proposed to explain such an adverse link (10-13). However, only few studies have been 
performed in older individuals (14, 15) and most, if not all, have focused mainly on the 
association of total or central body fatness with ED (11, 14-21). The extent to which 
peripheral fat mass correlates with ED is unclear. Evidence suggests that peripheral body 
fat may actually be protective against metabolic and cardiovascular risk factors (22-26) 
and disease (27), but whether this could reflect favourable associations with ED needs to 
be examined. Also, the potential beneficial role of lean mass has not been taken into 
account. Indeed, after middle age, changes in body composition are typically characterized 
not only by increases in fat mass but also by decreases in lean mass (8, 9). Sarcopenia, i.e. 
the loss of skeletal muscle and function with ageing, which may be a marker of poor 
nutrition and/or physical activity levels, is a major contributor to frailty in older adults, but 
may also affect ED and thereby cardiovascular health as well through mechanisms such as 
inflammation and/or insulin resistance (28). Studies examining the associations between 
lean mass and measures of ED are lacking, however. 
 
In view of these considerations, we investigated, in a population-based cohort of elderly 
individuals: first, the extent to which an adverse body composition, i.e. more central fat 
mass but also less peripheral fat and/or lean mass is associated with ED, as ascertained by 
FMD and/or by circulating biomarkers; and, second, whether any such associations could 
be explained by body-composition-related levels of LGI and/or insulin resistance.  
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Materials & Methods 
 
Subjects and study design   
The Hoorn Study is a cohort study on glucose tolerance and CVD in a general Caucasian 
population of 50-75 years old (n=2484), which started in 1989 as has been described 
extensively before (25, 29, 30). Follow-up examinations of this cohort were performed in 
1996–1998 and 2000-2001 when arterial properties, including a full FMD protocol (by 
means of non-invasive ultrasonography) and body composition (by means of dual-energy 
absorptiometry (DXA)) were measured for the first time (25, 31). For this follow-up 
examination, all participants who had diabetes, as determined by a 75-g oral glucose 
tolerance test, or by treatment (n=176) (29), and random samples of participants who had 
normal glucose tolerance (n=705) or impaired glucose metabolism (n=193) at the 1996-
1998 examination were invited. Of the 1074 individuals invited, 648 (60.3%) participated 
in the 2000-2001 follow-up examination; main reasons for non-participation were lack of 
interest (30%) or comorbidity (23%); other reasons included high age (7%), unwillingness 
to travel (6%), participation considered too time-consuming (6%) and miscellaneous 
reasons (15%), and 13% gave no reason (25). For the present study we excluded 173 of 
these 648 individuals due to missing data on DXA measurements (n=25), incomplete (i.e. 
only baseline diameter) or qualitatively unsatisfactory ultrasound examinations (n=158) 
and/or no assessments of circulating markers of ED (n=12). These individuals were older 
and had a more adverse risk factor profile than the 475 included in this study 
[Supplemental Table 1 – online only material]. 
The Ethical Review Committee of the VU University Medical Centre approved the 
study protocol and all participants gave their written informed consent. 
 
Body composition 
Individuals underwent a whole body DXA scan using the fan beam technology (QDR-2000, 
software version 7.20D, Hologic, Brussels, Belgium) to obtain measures of lean tissue, fat 
and bone mineral masses for the total body and for standard body regions. Regions of the 
head, trunk, arms and legs were distinguished with the use of specific anatomic landmarks 
(25). In the analyses we used fat and lean soft tissue masses from the trunk, arms and 
legs. Peripheral fat mass was calculated by adding the fat mass of the legs to that of the 
arms, and peripheral lean mass was calculated by adding the lean mass of the legs to that 
of the arms (22, 23).   
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Endothelial dysfunction 
Brachial artery flow-mediated dilation (FMD) and nitroglycerin-mediated dilation (NMD)  
Individuals underwent an ultrasound examination of FMD and NMD according to the 
guidelines of the International Brachial Artery Reactivity Task Force (32). The 
measurement protocol has been described in detail previously (31, 33). Briefly, baseline 
diameter (mean of three measurements) was assessed with the use of an ultrasound 
scanner equipped with an 7.5 MHz linear probe (350 series, Pie Medical, Maastricht, The 
Netherlands) that was connected to a PC equipped with vessel wall movement detection 
software and an acquisition system (Wall Track System, Pie Medical, Maastricht, The 
Netherlands). Baseline peak flow velocity (mean of two measurements) was determined 
by pulsed-wave Doppler from a sample volume in the centre of the artery at a 60◦ angle. A 
pressure cuff, placed on the forearm, was then automatically inflated and kept constant at 
supra-systolic pressure (SBP) (brachial SBP +100mmHg) in order to induce forearm 
ischemia. After 5 min the cuff was released leading to an increase in blood flow and 
hereby in shear stress, which served as the stimulus for FMD response. Maximum peak 
flow velocity was measured within 15 s after the cuff release, and measures of arterial 
diameter were subsequently measured at 45, 90, 180 and 300s. Next, 15 min of rest were 
taken to re-establish baseline conditions. Baseline diameter (mean of 3 measurements) 
and peak flow velocity (mean of two measurements) were re-determined as described 
above. Nitroglycerin (400 µg, Nitrolingual Spray, Pohl-Boskamp, Germany) was then 
administered sublingually; after 5 min, diameter (mean of 3 measurements) and peak flow 
velocity (mean of 2 measurements) were again determined. 
 
In some individuals measures of brachial diameter were missing at one (n=36), two (n=14) 
or three (n=7) out of the 4 post cuff release time points. For these individuals, we imputed 
the missing post cuff release diameter(s) with a longitudinal regression method (34). 
Specifically, we regressed the repeated post cuff release measures of diameter available 
on baseline diameter and time with the use of generalized estimating equations. Because 
the relationship between time and diameter is not linear, time was treated as a 
categorical (dummy) variable to approximate the FMD response curve by estimation of 
the predicted diameter at each exact time point (i.e. at 45, 90,180 or 300s after cuff 
release) based on the observed baseline and post cuff-release measures obtained (35). 
The predicted values hereby estimated were used to replace the missing value(s). Peak 
FMD (FMDmax, in mm) was then calculated as maximum post-occlusion diameter – 
baseline diameter and was used in the analyses as main dependent variable.  NMD (in 
mm), that is, endothelium-independent vasodilation thought to reflect smooth muscle cell 
function, was calculated as diameter at 5min post nitroglycerin ingestion - baseline 
diameter.  
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Circulating markers of endothelial dysfunction and low-grade inflammation  
Levels of sICAM-1, sVCAM-1, sE-selectin, C-reactive protein (CRP), serum amyloid A (SAA), 
interleukin 6 (IL-6), interleukin 8 (IL-8) and tumour necrosis factor-α  (TNF- α) were 
assessed in serum samples by a multi-array detection system based on electro-
chemiluminescence technology [MesoScaleDiscovery (MSD), SECTOR Imager 2400, 
Gaithersburg, Maryland, USA] (36, 37). In addition, levels of vWf and of CRP were (also) 
determined in citrated plasma by means of ELISA, as described in detail elsewhere (36). All 
these markers were standardized to common units by transformation into z-scores [i.e. 
(individual value–population mean)/population SD] and aggregated into: an overall 
circulating markers of endothelial dysfunction score (hereafter referred to as ED score), by 
averaging the z-scores of sICAM-1, sVCAM-1, sE-selectin and vWf; and an overall 
circulating markers of LGI score, by averaging the z-scores of CRP (mean of zCRPMSD and 
zCRPELISA), SAA, IL-6, IL-8, TNF-α and sICAM-1. Because sICAM-1, is expressed by both 
monocytes and the endothelium (38) it may be included in both overall scores (36, 37).  
 
Covariates 
Health status, medical history, medication use, and smoking, dietary (including alcohol 
consumption) and physical activity habits were assessed by questionnaires (30, 39). Levels 
of fasting plasma glucose, insulin, estimated glomerular filtration rate (eGFR), total, HDL- 
and LDL-cholesterol, triglycerides, brachial systolic blood pressure and diastolic blood 
pressure were measured/estimated as described elsewhere (29, 30, 40). Insulin resistance 
was calculated by means of the web-based Homeostasis Model of Assessment (HOMA2-
IR) (41) and subjects’ glucose metabolism status according to the WHO 1999 definition 
(42).  
 
Statistical analyses 
All analyses were performed by using the Statistical Package for Social Sciences (SPSS) 
version 18.0 (SPSS Inc., Chicago, IL). Comparisons of the clinical characteristics across 
tertiles of the main outcome variables (ED score or FMDmax) were investigated with 
analysis of variance (ANOVA) for continuous variables and chi-square test for frequency 
data. Variables with a skewed distribution, i.e. triglycerides, CRP, IL-6, IL-8, SAA, HOMA2-IR 
and the physical activity score were loge transformed prior to the analyses.  
 
We used multiple linear regression models to investigate the extent to which, first, total 
body fat%, and second, regional body composition (i.e. trunk fat, peripheral fat and 
peripheral lean mass, mutually adjusted for each other) were independently associated 
with the ED score and/or FMD. These analyses were adjusted for age, sex, glucose 
metabolism status, prior CVD and lifestyle risk factors (i.e., smoking habits, physical 
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activity, total energy intake and alcohol consumption) as potential confounders (model 1). 
Additional adjustments included baseline diameter and/or increments in peak systolic 
velocity (models 2-4), in analyses with FMDmax as dependent variable only. The adjustment 
for baseline diameter was done to enable comparison with other studies. It should be 
noticed, however, that such adjustment may not be appropriate in the context of the 
present study (observational cohort), because an assumption of equal baseline diameters 
between groups of individuals does not hold (as in randomized controlled trials); this 
adjustment may thus lead to an overestimation of the strength of the associations when 
the study determinants are positively associated with baseline diameter, which is turn is 
known to be  inversely associated with FMDmax (43).  
In the model with body composition as main determinant we excluded trunk lean 
mass because of its very high correlation with peripheral lean mass (Pearson’s r>0.945), 
which would disturb the stability of the regression analyses when included in the models 
due to multi-colinearity (tolerance<0.1).  
 
Mediating role of insulin resistance and/or low-grade inflammation  
The mediating role (i.e. extent and significance) of variable(s) reflecting pathobiological 
mechanisms hypothesized to be in the pathway between a given determinant (X) and 
outcome (Y) was ascertained by quantitative appreciation of the attenuation in the 
strength of the association (β) between X and Y after adjustment for the potential 
mediator(s) (M) (44, 45). Accordingly, we used the ‘ab product of coefficients’ method (45) 
to investigate the mediating role of LGI (M1) and/or HOMA2-IR (M2) in the associations 
described above. These analyses entail a series of steps, the details of which are explained 
and illustrated in Figure 1 (see also legend). To ascertain statistical significance by any of 
the mediating ‘effects’ we used the SPPS macros provided by Preacher & Hayes to 
compute bootstrapped (bias-corrected) confidence intervals (5,000 samples) for the size 
of the specific mediation ‘effect’ by M1 and/or by M2, hereby accounting for the 
distribution of the ab products which is often skewed (46). These analyses enabled the 
appreciation of whether any of the proposed mediators exerted a predominant role in the 
associations investigated, thus contributing to a better understanding of potential 
operative pathophysiological mechanisms (44-46). 
All results are shown as standardized regression coefficients (ß) and their 
respective 95% confidence intervals (CIs). A two-sided probability value of <0.05 was 
considered statistically significant.  
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Results 
 
Table 1 shows  general characteristics, as well as  body composition, biomarkers of LGI, 
HOMA2-IR, biomarkers of ED  and the brachial artery properties and FMDmax of the 
individuals included in this study (n=475), stratified by tertiles of the ED score or FMDmax. 
In general, the cardiovascular risk profile was worst at the most adverse levels of the ED 
score and/or FMDmax, i.e. at their highest or lowest tertiles, respectively.  
Some risk factors seemed to be specifically associated with the ED score (i.e. male sex, 
weight, insulin, HOMA2-IR, total-to-HDL cholesterol ratio, triglycerides and trunk fat mass) 
or FMD (height, total calorie intake, peripheral lean mass). The ED score and FMDmax were 
inversely and significantly, thought modestly, correlated with each other (Pearson’s r=-
0.156, p<0.01). 
 
Total body fat, regional body composition and endothelial dysfunction 
Total body fat % was positively and significantly associated with the ED score [β=0.16 (95% 
CI 0.03; 0.28) and inversely, although not statistically significant, with FMDmax (Table 2, 
model 1).  
When the contribution of body composition to ED was examined in more detail, we 
observed a significant adverse association between trunk fat and the ED score [β=0.16 
(95%CI 0.03; 0.29)], but not with FMDmax [β =-0.04 (-0.17; 0.13)] and a significant 
favourable association between peripheral lean mass and FMDmax [β=0.15 (0.00; 0.30)], 
but not with the ED score. In contrast to trunk fat, peripheral fat mass was not associated 
with the ED score [β=-0.03 (-0.17; 0.12)] and, similarly to trunk fat, peripheral fat was not 
associated with FMDmax [β=-0.02 (-0.17; 0.13)] – Figure 2.   
 
Adjustments for baseline diameter and ΔPSV. Despite the inverse association between 
baseline diameter and FMDmax [β= -0.16 (-0.28; -0.04)], adjustments for baseline diameter 
did not affect the magnitude of the associations between total fat % or trunk or peripheral 
fat masses and FMDmax, (Table 2, models 2) since none of these were significantly 
associated with baseline diameter. The associations between peripheral lean mass and 
FMDmax became stronger after adjustments for baseline diameter [β=0.23 (0.08; 0.39)], 
which was explained by a positive association between peripheral lean mass and baseline 
diameter [β=0.76 (0.66; 0.86)]. Adjustment for ΔPSV did not affect any of the associations 
mentioned above (Table 2, models 3). 
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Figure 1. Illustration of a simple (panels A and B) and a multiple mediation models (panels A and C), in the 
context of the present study.  
Panel A shows the association of an independent variable X (i.e. body fat % or trunk fat, peripheral fat or 
peripheral lean masses) on a dependent variable Y (i.e. ED score or FMDmax), after adjustments for age, sex, 
glucose metabolism status, prior CVD, smoking status, physical activity, daily energy intake and alcohol 
consumption (covariates); path c is represented by a standardized regression coefficient (β), and represents total 
‘effect’ of X on Y. 
Panel B illustrates how the role of a single mediator (M) is assessed in simple mediation analyses. Mediation is 
considered to be present when the strength of the β between X and Y (path c) decreases by a nontrivial amount 
after further adjustment for a M [i.e. low-grade inflammation (LGI score) or insulin resistance (HOMA2-IR)]; this 
figure thus represents both the direct ‘effect’ of X on Y (path c′) and the indirect ‘effect’ of X on Y through M, the 
later being quantified by the product of the 2 paths linking X to Y through that mediator (path a * path b or ab). 
These paths are quantified by βs retrieved from two separate regression models including all covariates, one 
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examining the association between X and M (path a) and the other the association between M and Y 
independently of also X (path b). 
Panel C summarizes how the role of two mediators (M1 and M2) is quantified in a multiple mediation analyses; 
this figure thus represents both the direct effect of X on Y (path c′) and the indirect effect of X on Y through each 
of the Ms. The specific indirect effect of X on Y through M1 is defined by the product of the two paths linking X to 
Y through that mediator, i.e., a1b1; similarly, the specific indirect effect of X on Y through M2 is defined as a2b2. 
Paths a1 and a2 are estimated as in simple mediation, but paths b1 and b2 now also include mutual adjustment 
for each other. The total indirect effects of X on Y is the sum of the two specific indirect effects, i.e., a1b1 + a2b2; 
The total effect of X on Y is thus the sum of the direct effect and all of the indirect effects: c = c′ + (a1b1 + a2b2).  
ED score: circulating biomarkers of endothelial dysfunction score; FMDmax: flow-mediated dilation; LGI score: low-
grade inflammation score; HOMA2-IR: insulin resistance derived from the homeostasis model assessment. 
 
  
Table 1. General characteristics of the study population according to tertiles (T) of the circulating markers of endothelial dysfunction (ED) score or maximal flow-mediated 
dilation (FMD) 
Characteristics 
Circulating markers of endothelial dysfunction (ED) score  Flow-mediated dilation (FMD) 
T1 (n=158) T2 (n=159) T3 (n=158) p-trend  T1 (n=158) T2 (n=159) T3 (n=158) p-trend 
Age, years 67.6 ± 5.6 68.2 ± 5.9 71.0 ± 6.3 <0.001  71.7 ± 7.0 68.4 ± 5.5 66.7 ± 4.5 <0.001 
Sex, % men 43 49 53 0.072  50 43 53 0.653 
Height, cm 169 ± 9 170 ± 9 170 ± 9 0.733  169 168 171 0.004 
Weight, kg 75 ± 12 77 ± 11 79 ± 12 0.006  77 ± 12 75 ± 11 78 ± 12 0.721 
Body mass index, kg/m2 26.1 ± 3.2 26.6 ± 3.2 27.3 ± 3.6 0.001  27.1 ± 3.7 26.5 ± 3.2 26.3 ± 3.1 0.035 
Fasting glucose, mmol/l 5.8 ± 0.7 6.2 ± 1.6  6.5 ± 1.5 <0.001  6.4 ± 1.4 6.2 ± 1.6 5.8 ± 0.9 <0.001 
Insulin, pmol/l 48 [35-66] 54 [39-73] 70 [48-100] <0.001  57 [43-80] 54 [39-82] 54 [40-75] 0.251 
Insulin resistance (HOMA2-IR)  0.94 [0.67-1.27] 1.04 [0.77-1.43] 1.36 [0.98-1.98] <0.001  1.11 [0.84-1.55] 1.04 [0.76-1.62] 1.05 [0.77-1.48] 0.158 
Use of glucose-lowering 
medication %  
4 10 13 0.010  14 10 3 0.028 
Glucose metabolism status, % 
NGM/IGM/DM2  
61/26/13 56/23/21 31/35/34 <0.001  39/28/34 52/27/22 58/30/12 <0.001 
Total-to-HDL cholesterol ratio 4.1 ± 1.1 4.3 ± 1.2 4.5 ± 1.4 0.001  4.4 ± 1.3  4.2 ± 1.3 4.3 ± 1.1 0.547 
Triglycerides, mmol/l 1.20 [0.90-1.70] 1.30 [0.90-1.70] 1.40 [1.00-1.80] 0.005  1.30 [1.00-1.80] 1.30 [0.90-1.70] 1.30 [1.00-1.70] 0.103 
Use of lipid-lowering medication, % 9 15 16 0.072  20 12 8 0.003 
Systolic blood pressure, mm Hg 136 ± 17 140 ± 20 147 ± 19 <0.001  147 ± 19 141 ± 19 135 ± 17 <0.001 
Diastolic blood pressure, mm Hg 74 ± 8 75 ± 9 78 ± 10 0.002  78 ± 10 76 ± 9 74 ± 8 <0.001 
Use of antihypertensive 
medication, % 
22 33 39 0.002  49 25 20 <0.001 
eGFR, ml/min/1.73m2 82± 15 79 ±17 78 ± 16 0.070  78 ±18 82 ± 16 80 ± 14 0.404 
Total energy intake (kcal/day) 2008 ± 1027 1944 ± 446 1947 ± 585 0.466  1893 ± 518 1939 ± 573 2067 ± 992 0.033 
Ever smoker, % 56 58 65 0.098  67 56 55 0.039 
Alcohol intake, % none/ mod/higha 13/53/34 11/37/59 23/48/30 0.052  19/53/29 15/54/32 13/54/34 0.128 
Physical activity score (/1000) 6.18 [3.72-8.68] 4.38 [2.76-7.20] 4.66 [2.19-7.38] <0.001  4.05 [1.98-6.59] 5.44 [3.17-8.63] 5.37 [3.44-8.07] <0.001 
Prior cardiovascular disease, % 43 43 58 0.007  60 50 35 <0.001 
Body composition by DXA          
   Total body fat, % 34 ± 9 34 ± 9 35 ± 9 0.127  35 ± 9 35 ± 9 33 ± 9 0.014 
   Trunk fat mass, kg 12.2 ± 4.9 13.0 ± 4.8 14.4 ± 5.2 <0.001  13.8 ± 5.2 13.1 ± 4.7 12.7 ± 5.1 0.045 
   Trunk lean mass, kg  24.0 ± 4.8 24.6 ± 4.6 25.0 ± 4.7 0.063  24.4 ± 4.8 24.0 ± 4.6 25.2 ± 4.7 0.096 
   Peripheral fat mass, kg 11.5 ± 3.8 11.8 ± 4.1 12.0 ± 4.4 0.283  12.0 ± 4.3 11.9 ± 3.9 11.4 ± 4.2 0.202 
   Peripheral lean mass, kg 19.4 ± 4.9 19.5 ± 4.4  19.7 ± 4.6 0.607  19.3 ± 4.6 18.8 ± 4.5 20.5 ± 4.6 0.018 
 
 
        
  
Circulating markers of low grade inflammation (LGI)         
   Tumour necrosis factor α (ng/l) 7.8 ± 2.5 9.2 ± 3.1 9.7 ± 2.8 <0.001  8.9 ± 2.2 8.6 ± 3.0 9.1 ± 3.4 0.622 
    Interleukin-8 (ng/l) 13.3 [10.4- 17.4] 15.0 [11.5-18.8] 16.2 [12.8-21.7] <0.001  15.5 [12.3-20.2] 14.5 [11.7-17.9] 14.5 [11.0-19.7] 0.138 
    Interleukin-6 (ng/l) 1.25 [0.95-2.01] 1.40 [1.00-1.92] 1.75 [1.27-2.95] <0.001  1.69 [1.20-2.48] 1.43 [1.02-2.13] 1.33 [0.96-2.05] 0.015 
    C-reactive protein ELISA (mg/l)  1.21 [0.63-2.33] 1.85 [1.23-3.55] 3.16 [1.31-6.13] <0.001  2.16 [1.16-4.44] 1.85 [1.05-3.42] 1.56 [0.82-3.68] 0.013 
    C-reactive proteinMSD (mg/l)  1.23 [0.64-2.59] 2.05 [1.35-3.96] 3.30 [1.56-6.52] <0.001  2.47 [1.23-5.04] 1.96 [1.02-3.79] 1.71 [0.94-3.69] 0.022 
    Serum amyloid A (mg/l) 1.39 [0.85-2.45] 1.66 [1.08-2.73] 2.09 [1.16-4.42] <0.001  1.78 [1.10-3.13] 1.56 [0.96-3.07] 1.71 [1.00-2.78] 0.549 
    LGI score -0.36 ± 0.44 -0.04 ± 0.45 0.45 ± 0.73  <0.001  0.13 ± 0.63 0.01 ± 0.66 -0.09 ±0.65 0.003 
Circulating markers of endothelial dysfunction (ED)         
   Soluble intercellular adhesion 
molecule 1 (μg/l)b 
- - - -  268 ± 59  251 ± 56 242  ±  57 <0.001 
   Soluble vascular adhesion 
molecule 1 (μg/l) 
- - - -  413 ± 91 403 ± 98 389 ± 75 0.014 
   sE-selectin (μg/l) - - - -  19.8 ± 9.6 19.0 ± 7.6 18.1 ± 6.7 0.071 
   von Willebrand Factor (%) - - - -  164 ± 54 148 ± 47 148 ± 46 0.003 
   ED score - - - -  19.9 ± 74.4 -0.28 ± 70.9 -12.4 ± 59.4 <0.001 
Flow-mediated dilation (FMD)          
   Diameter           
   Baseline (µm) 4545 ± 699 4681 ± 801 4684 ± 721 0.096  - - - - 
   Maximum (µm) 4741 ± 701 4853 ± 788 4838 ± 725 0.244  - - - - 
   Absolute change (µm) 197 ± 125 172 ± 133 154 ± 133 0.004  - - - - 
   Relative change (%)  4 ± 3 4 ± 3 3 ± 3 0.002  - - - - 
   Peak Systolic Velocity           
   Baseline (cm/s) 55 ± 12 59 ± 13 60 ± 15 0.002  - - - - 
   After reactive hyperaemia (cm/s) 105 ± 27  108 ± 27 106 ± 24 0.752  - - - - 
   Absolute change (cm/s) 50 ± 23 49 ± 24 46 ± 19 0.117  - - - - 
   Relative change (%) 94 ± 44 87 ± 49 82 ± 37 0.009  - - - - 
Nitroglycerin-mediated dilation          
   Baseline diameter (µm) 4571 ± 683 4697 ± 806  4720 ± 727 0.083  - - - - 
   Maximum diameter (µm) 4997 ± 700 5085 ± 799 5089 ± 728 0.282  - - - - 
   Absolute change (µm) 464 ± 220 409 ± 178 413 ± 241 0.040  - - - - 
Data are means ± SD, frequencies (%) or medians [inter-quartile range]. NGM, normal glucose metabolism status; IGM, impaired glucose metabolism status; DM2, type 2 
diabetes; HOMA2-IR, Homeostasis Model Assessment of insulin resistance 
a defined as:  0 glasses/day (none), 1-2 glasses/day in men or 1 glass/day in women (moderate) and >2 in men or >1 glasses/day in women (high). 
b included in both the ED score as the LGI score 
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A 
B 
Figure 2. Associations between total body fat % (single bar) and regional body composition (clustered bars), 
measured by DXA, with the following markers of endothelial dysfunction: A, circulating markers of endothelial 
dysfunction (ED score); B, maximal brachial flow-mediated dilation (FMDmax). All data are adjusted for age, sex, 
glucose metabolism status, prior CVD, smoking status, physical activity, daily energy intake and alcohol 
consumption; clustered bars reflecting the independent associations of trunk fat, peripheral fat and peripheral 
lean masses are also mutually adjusted for each other. 
  
Table 2. Associations between body composition and endothelial dysfunction  
Main  
determinants 
Model Adjustments 
Main study outcomes 
ED score  FMDmax 
β 95%CI  β 95% CI 
Total body fat % 1 Age, sex, GMS, lifestyle RFsb, prior CVD 0.16† 0.03; 0.28  -0.09 -0.21; 0.04 
2 Model 1 + baseline diameter - -  -0.09 -0.21; 0.04 
3 Model 1  + Δ PSV - -  -0.08 -0.21; 0.04 
4 Model 1  + baseline diameter & Δ PSV - -  -0.09 -0.21; 0.04 
Trunk fat massa 1 Age, sex, GMS lifestyle RFsb, prior CVD 0.16* 0.03; 0.29  -0.04 -0.17; 0.09 
2 Model 1 + baseline diameter - -  -0.04 -0.17; 0.08 
3 Model 1 + Δ PSV - -  -0.04 -0.17; 0.09 
4 Model 1 + baseline diameter & Δ PSV - -  -0.04 -0.17; 0.08 
Peripheral fat massa 1 Age, sex, GMS lifestyle RFsb, prior CVD -0.03 -0.17; 0.12  -0.02 -0.17; 0.13 
2 Model 1 + baseline diameter - -  -0.01 -0.15; 0.14 
3 Model 1 + Δ PSV    -0.02 -0.17; 0.13 
4 Model 1 + baseline diameter & Δ PSV - -  -0.01 -0.15; 0.14 
Peripheral lean massa 1 Age, sex, GMS lifestyle RFsb, prior CVD -0.09 -0.25; 0.06  0.15* 0.00; 0.30* 
2 Model 1 + baseline diameter - -  0.23† 0.08; 0.39 
3 Model 1 + Δ PSV - -  0.15* 0.00; 0.30* 
4 Model 1 + baseline diameter & Δ PSV - -  0.23† 0.08; 0.39 
β are standardized regression coefficients and indicates the change in main outcome variable or potential mediator (in SD) per 1 SD increase in main determinant  
* p<0.05, † p<0.01, ‡ p<0.001 
amodels are mutually adjusted for the other body composition variables; b smoking, total energy intake, alcohol consumption and physical activity; 
CVD: cardiovascular disease; ED: endothelial dysfunction; FMD: flow-mediated dilation; GMS: glucose metabolism status; HOMA2-IR: Homeostasis Model Assessment of 
insulin resistance; LGI: low-grade inflammation; NMD: nitroglycerin-mediated dilation; PSV: peak systolic velocity; RFs: risk factors. 
  
Table 3. Association of total body fat percentage and body composition with the endothelial dysfunction (ED) score or maximal flow-mediated dilation (FMDmax) and the (total 
and independent) mediation role of low-grade inflammation and/or insulin resistance herein 
Main 
determinant 
Path Description 
Simple mediation analyses  Multiple mediation analyses 
By LGI score  By HOMA2-IR  By LGI & HOMA2-IR Independent 
mediation 
(%)a 
 95% CI   95% CI   95% CI 
Total body fat % C Body fat %  ED score 0.16
† 0.03; 0.28  0.16† 0.03; 0.28  0.16† 0.03; 0.28 - 
 a1 Body fat %  LGI score 0.25
‡ 0.12; 0.38  - -  0.25‡ 0.12; 0.38 - 
 a2 Body fat %  HOMA2-IR - -  0.48
‡ 0.34; 0.59  0.48‡ 0.34; 0.59 - 
 b1 LGI  ED score 0.57
‡ 0.50; 0.64  - -  0.54‡ 0.47; 0.62 - 
 b2 HOMA2-IR  ED score - -  0.29
‡ 0.19; 0.39  0.18‡ 0.09; 0.26 - 
 c’ Body fat %  Mediator(s)  ED score 0.02 -0.09; 0.12  0.02 -0.11; 0.15  -0.06 -0.17; 0.05 - 
 Mediation effects          
 Total indirect association through mediator(s) (c-c’) 0.14‡ 0.06; 0.23  0.14‡ 0.09; 0.21  0.22‡ 0.13; 0.32 - 
  Specific indirect association through LGI (a1b1) - -  - -  0.13
‡ 0.06; 0.21 59% 
  Specific indirect association through HOMA2-IR (a2b2) - -  - -  0.09
‡ 0.05; 0.14 41% 
 Comparison of specific indirect associations through LGI vs. HOMA2-IR - -  - -  -0.05 -0.14; 0.04 - 
Trunk fat mass C Trunk fat  ED score 0.16* 0.03; 0.29  0.16*  0.03 ; 0.29  0.16* 0.03; 0.29 - 
 a1 Trunk fat  LGI score 0.28
‡ 0.15; 0.41  - -  0.28‡ 0.15; 0.41 - 
 a2 Trunk fat  HOMA2-IR - -  0.53
‡ 0.42; 0.63  0.53‡ 0.42; 0.63 - 
 b1 LGI  ED score 0.57
‡ 0.50; 0.64  - -  0.54‡ 0.47; 0.62 - 
 b2 HOMA2-IR  ED score - -  0.30
‡ 0.20; 0.41  0.19‡ 0.10; 0.28 - 
 c’ Trunk fat  Mediator(s)  ED score 0.00 -0.11; 0.11  0.00 -0.13; 0.14  -0.09 -0.20; 0.02 - 
 Mediation effects          
 Total indirect association through mediator(s) (c-c’) 0.16‡ 0.08; 0.24  0.16‡ 0.08; 0.24  0.25‡ 0.16; 0.35 - 
  Specific indirect association through LGI (a1b1) - -  - -  0.15
‡ 0.08; 0.24 60% 
  Specific indirect association through HOMA2-IR (a2b2) - -  - -  0.10
‡ 0.05; 0.26 40% 
 Comparison of specific indirect associations through LGI vs. HOMA2-IR - -  - -  -0.05 -0.15; 0.03 - 
Peripheral fat 
mass 
C Peripheral fat mass  ED score -0.03 -0.17; 0.12  -0.03 -0.17; 0.12  -0.03 -0.17; 0.12 - 
a1 Peripheral fat mass  LGI score -0.11 -0.26; 0.04  - -  -0.11 -0.26; 0.04 - 
 a2 Peripheral fat mass  HOMA2-IR - -  -0.16* -0.28; -0.03  -0.16* -0.28; -0.03 - 
 b1 LGI  ED score 0.57
‡ 0.50; 0.64  - -  0.54‡ 0.47; 0.62 - 
 b2 HOMA2-IR  ED score - -  0.30
‡ 0.20; 0.41  0.19‡ 0.10; 0.28 - 
 c’ Peripheral fat  Mediator(s)  ED score 0.04 -0.08; 0.16  0.02 -0.12; 0.17  0.06 -0.06; 0.18 - 
 Mediation effects          
 Total indirect association through mediator(s) (c-c’) -0.07 -0.17; 0.02  -0.05 -0.12; -0.01  -0.09 -0.20; -0.00 - 
  
  Specific indirect association through LGI (a1b1) - -  - -  -0.06 -0.16; 0.02 66% 
  Specific indirect association through HOMA2-IR (a2b2) - -  - -  -0.03 -0.08; 0.01 33% 
 Comparison of specific indirect associations through LGI vs. HOMA2-IR - -  - -  0.03 -0.05; 0.13 - 
Peripheral lean 
mass 
c Peripheral lean mass  FMDmax 0.15* 0.00; 0.30  0.15* 0.00 ; 0.30  0.15* 0.00; 0.30 - 
a1 Peripheral lean mass  LGI score -0.23
† -0.29; -0.08  - -  -0.23† -0.29; -0.08 - 
 a2 Peripheral lean mass  HOMA2-IR - -  0.12 -0.05; 0.25  0.12 -0.05; 0.25 - 
 b1 LGI  FMDmax -0.01 -0.10; 0.08  - -  -0.03 -0.12; 0.06 - 
 b2 HOMA2-IR  FMDmax - -  0.10 -0.01; 0.21  0.09 -0.03; 0.20 - 
 c’ Peripheral lean mass  Mediator(s)  FMDmax 0.15 -0.01; 0.30  0.14 -0.01; 0.28  0.13 -0.02; 0.28 - 
 Mediation effects          
 Total indirect association through mediator(s) (c-c’) 0.00 -0.02; 0.03  0.01 -0.01; 0.04  0.02 -0.02; 0.06 - 
, are standardized regression coefficients 
All associations are adjusted for the following covariates: age, sex, glucose metabolism status, prior cardiovascular disease, smoking status, physical activity, daily energy 
intake and alcohol consumption; b paths include also adjustments for total body fat  % or trunk fat, peripheral fat and peripheral lean masses and, in multiple mediation 
analyses,  for other mediator.  
* p<0.05, † p<0.01, ‡ p<0.001 
a Calculated as proportion of the total indirect effects attributed to the specific mediators: e.g. (0.13/0.22)x100 for LGI and (0.09/0.22x100) for HOMA2-IR in the association 
between total body fat % and ED score.  
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Mediating role of insulin resistance and low grade-inflammation  
Total body fat % was significantly associated with a higher LGI score [β=0.25 (0.12; 0.38)] 
and with HOMA2-IR [β=0.48 (0.34; 0.59)] (Table 3, paths a1 and a2, respectively). In turn, 
LGI score [β=0.57 (0.50; 0.64)] and HOMA2-IR [β=0.29 (0.19; 0.39)] were significantly 
associated with the ED score (Table 3, paths b1 and b2 in simple mediation analyses), even 
when mutually adjusted for each other and total body fat % [[β=0.54 (0.47; 0.62) and 
β=0.18 (0.09; 0.26), paths b1 and b2 in multiple mediation analyses, respectively]. As a 
result, the association between total fat % and the ED score [β=0.16 (0.03; 0.28), path c] 
was strongly attenuated after adjustments for the two mediators [to β=     -0.06 (-0.17; 
0.05), path c’] and was no longer significant.  The magnitude of the attenuation, or the 
indirect association through the mediators (paths c-c’) was statistically significant [β=0.22 
(0.13; 0.32)] and due to significant and independent contributions by each of the 
mediators [β=0.13 (0.06; 0.21) and β=0.09 (0.05; 0.14), or ~59% and 41%, by LGI and 
HOMA2-IR, respectively]. The specific mediation effects by LGI or by HOMA2-IR were not 
statistically different from each another [β=-0.05 (-0.14; 0.04)].  
We found very similar results when the mediating roles of LGI and/or HOMA2-IR 
in the associations between trunk fat and the ED score were investigated (Table 3). 
 
Although peripheral fat mass was not significantly associated with the ED score, LGI and 
HOMA2-IR nevertheless played a significant mediating effect in this association [β=-0.09 (-
0.20; -0.00)], but paths a1 and a2, reflecting the favourable associations of peripheral fat 
with LGI and HOMA2-IR [β=-0.11 (-0.26; 0.04) and β=-0.16 (-0.28; -0.03), respectively] 
operated in opposite direction compared to  paths b1 and b2, reflecting the adverse 
associations between these two mediators and the ED score  [β=0.54 (0.47; 0.62) and 
β=0.19 (0.10; 0.28, respectively)]. Comparison of the independent mediating effects by LGI 
[β=-0.06 (-0.16; 0.02)] and HOMA2-IR [β=-0.03 (-0.08; 0.01)] showed a tendency for a 
predominant mediating effect by LGI (i.e. 66 vs. 33% respectively) but this was not 
statistically significant [β=0.03 (-0.05; 0.13), Table 3].  
 
In contrast, LGI or HOMA2-IR did not seem to play any significant mediating role in the 
beneficial associations between peripheral lean mass and FMDmax (Table 3). Indeed, 
although peripheral lean mass was significantly associated with lower LGI scores [β=-0.23 
(-0.19; -0.08)] it was not with HOMA2-IR [β=0.12 (-0.05; 0.25)], and neither LGI nor 
HOMA2-IR were independently associated with FMDmax after adjustment for study 
covariates and body composition [β=-0.03 (-0.12; 0.06) and β=0.09 (-0.03; 0.20), 
respectively]. Therefore, the beneficial association between peripheral lean mass and 
FMDmax [β=0.15 (0.00; 0.30) was only very slightly attenuated after adjustments for LGI 
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and HOMA2-IR [to β=0.13 (-0.02; 0.28)], and the magnitude of this attenuation was not 
significant [β=0.02 (-0.02; 0.06)]. 
 
Additional analyses 
The results did not differ when the analyses were confined to individuals with complete 
post-occlusion data only (n=418) (data not shown). Additional adjustment for blood 
pressure, eGFR, dyslipidemia, use of antihypertensive, lipid-lowering or glucose-lowering 
drugs did not materially affect any of the associations reported above (data not shown).  
Because sICAM-1 was included in both the LGI and ED scores, we also ran the mediation 
analyses excluding sICAM-1 from the LGI score. Results were not materially different from 
the ones reported in Table 3 though (data not shown). We have also examined and found 
no associations between body composition and NMD (data not shown). Finally, the results 
did not differ between men and women (p-values for interaction all ≥ 0.136). 
 
Discussion 
 
The present study has four main findings. First, and in line with many previous reports, 
higher levels of total body fat % were associated with ED. Second, when body composition 
was examined in more detail, we observed that such adverse associations could be 
attributed to accumulation of fat mass in the trunk, but not in the limbs. Third, we 
observed independent associations between higher levels of trunk fat mass and of 
peripheral lean mass with ED, the former was predominantly associated (adversely) with 
the circulating biomarkers of ED (ED score) and the latter was predominantly associated 
(favourably) with flow-mediated dilation of the brachial artery (FMDmax). Finally, the 
adverse association of total body fat %, as of trunk fat mass, with the ED score were 
explained (i.e. mediated), to a similar extent, by related higher levels of low-grade 
inflammation (LGI score) and insulin resistance (HOMA2-IR), but these two pathobiological 
mechanisms did not seem to explain the favourable association between peripheral lean 
mass and FMDmax.  
 
To the best of our knowledge, this is the first study that has examined, in an elderly 
population, the associations of the distribution of body fat and also lean mass (as 
ascertained by DXA) with ED (as ascertained by the levels of a large panel of biomarkers in 
the circulation and also by FMD). In addition, we have also explored the extent to which 
pathways such as LGI and insulin resistance could explain any such associations, and 
presented these findings in a comprehensive manner, hereby overcoming the problems of 
otherwise fragmented information in the epidemiological literature available thus far (e.g. 
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focused on paths a or b or paths c only, without linking the three under a conceptual 
pathobiological mechanistic model – see Figure 1). 
 
Trunk vs. peripheral fat. Our findings are consistent with the concept that excessive 
adipose tissue, especially when accumulated centrally, has more adverse effects on 
cardiovascular risk than does adipose tissue stored in peripheral depots. Indeed, it is 
becoming increasingly clear that peripheral fat depots are metabolically different from fat 
accumulated centrally (47) and may even carry beneficial effects on metabolic and 
cardiovascular health (22-26). In support of  this view, we observed that peripheral fat 
mass was not only favourably associated with insulin resistance, but also with LGI, such 
that these favourable associations seemed to deter, to some extent, the adverse impact of 
both LGI and insulin resistance on endothelial function, hereby explaining the lack of an 
adverse impact of peripheral fat on ED. 
 
Peripheral lean mass. It has been postulated that the U-shaped association between BMI 
and mortality may reflect the opposite effects of lean mass (favourable) and fat mass 
(adverse) on survival (48). So far, most studies on body composition and ED have been 
mainly focused on the deleterious effects of excessive fat mass and/or a central pattern of 
fat distribution (11, 14-21), disregarding the potential beneficial effects of lean mass 
herein. Our findings indeed suggest that, in elderly individuals, not only higher levels of 
central fat, but also lower levels of lean mass may be associated with ED. These findings 
support the view that sarcopenia, i.e. the degenerative loss of skeletal muscle mass and 
strength associated with aging, could play an important role in the progressive decline of 
endothelial function and related cardiovascular sequelae with ageing (28). Giving the 
increasing age of our population and therefore of the prevalence of sarcopenia, our 
findings have relevant clinical implications by emphasizing the need to carefully monitor 
losses in lean mass in weight-loss interventions among the elderly. Inclusion of physical 
exercise in  such interventions may be key in this regard (6). In this line it was recently 
shown that regular exercise improves endothelial function independently of changes in 
body weight (49). In addition, Haspicova et al have also shown a significant improvement 
in endothelial responsiveness during an oral glucose load in pre-menopausal obese 
women who lost 7% of their body weight, but not at the expense of lean mass (50). 
 
Endothelial dysfunction: ED score and FMDmax. The term endothelial dysfunction has been 
most often used to denote impairment of the endothelium-dependent vasodilation 
capacity, but may be better characterized by encompassing measures of endothelial 
activation as reflected by abnormalities in endothelial interactions with leukocytes, 
platelets and regulatory substances as well (51). Indeed, the endothelium actively 
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regulates vascular tone and permeability, the balance between coagulation and 
fibrinolysis, the composition of the subendothelial matrix, the adhesion and extravasation 
of leukocytes, and inflammatory activity in the vessel wall (52). Therefore, there is no ideal 
single test to (non-invasively) measure endothelial function, as it has many functions (53, 
54) and has many dimensions (55). By examining the association between body 
composition and both FMDmax and the ED score we have thus attempted to capture 
endothelial dysfunction as comprehensively as possible. This constitutes an advantage 
when comparing our study with the available literature, commonly reporting on FMD (11, 
14-17, 19) or one or few circulating biomarkers (18, 20, 21) only.  
 
Pathobiological mechanisms. Decreased nitric oxide (NO) availability, elevated endothelin-
1, insulin resistance, LGI and oxidative stress have been postulated as mechanisms for 
impaired endothelial function in older adults (6, 28).  The associations between total and 
central fat mass and ED were, indeed, and to a great extent, attributable to LGI and insulin 
resistance. The beneficial association between peripheral lean mass and ED, however, was 
not. Other sarcopenia-related factors, such as oxidative stress, could explain this beneficial 
association (6, 10, 56). It should be noted, however, that, in contrast to adipose tissue, a 
known source of pro-inflammatory cytokines and trigger of hyperinsulinaemia, both of 
which are intertwined and known to exert effects on the endothelium, the link between 
lean mass and ED may not be a causal one but a reflection of common underlying factors, 
such as physical activity and/or nutrition status, instead (10, 28, 49, 50). Both exercise 
training and dietary changes (e.g. increased fruit, vegetables intake and omega-3 fatty 
acids rich product, reduced sodium and saturated fat)  have been shown to improve ED 
through mechanisms such as improved NO availability, increased prostaglandin release, 
reduced free radical–mediated NO degradation, decreased oxidative stress and lower 
sympathetic vasoconstrictor tone (10, 28). Although our findings were adjusted for the 
levels of calorie intake (including alcohol) and physical activity, we can not fully rule out 
residual confounding due to imprecise and/or insufficient measurement of these factors 
by means of questionnaires (30, 39).  
 
Our study had some limitations that warrant discussion. First, because of its cross-
sectional design, any inferences about causality should be made with caution, and the 
direction of the pathways proposed may not be exclusive (for instance, insulin resistance 
may also be a consequence of ED). Second, one assumption of combining biomarkers into 
an overall score, as we did for the LGI and ED scores, is that each biomarker reflects, to a 
similar extent, the underlying pathophysiological process. It is however unknown whether 
this is the case for all of the biomarkers used in this study. The use of an overall score 
allowed us, however, to circumvent the problem of multiple testing otherwise present 
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when analyses would be conducted with each of the biomarkers separately. Third, 
determination of FMDmax at a specific time point - most often after 60s of cuff release, as 
in the original protocol proposed by Celermajer et al (57) – leads to a significant 
underestimation of its true value, as in some individuals FMDmax may occur after this time 
frame (58). With our FMD protocol, which included repeated measures at 45, 90, 180 and 
300 s after cuff release, we were able to circumvent this problem, but only for as much as 
FMDmax could be captured by these time points. More recent automated diameter analysis 
systems enable continuous measurement of post cuff release diameters at 3-5s time 
intervals, and thereby a more precise determination of the FMDmax (59). Therefore with 
our protocol we may still have underestimated FMDmax. However, this was non-differential 
and, if anything, led to an underestimation of the associations reported. Fourth, despite 
that trunk fat mass, as assessed by DXA, correlates highly with intrabdominal fat (60), it 
does not distinguish between subcutaneous and visceral fat in the trunk/abdominal area. 
Fifth, bias due to selective attrition (healthier sub-population attending the 2000-2001 
examination round and the portion of these included in the present study) could have 
caused an underestimation the ‘true’ associations examined in our study (61). Finally, we 
studied a white, elderly population and it remains to be established whether our findings 
can be generalized to other ethnicities and to younger individuals. 
 
In conclusion, in this study in elderly individuals, higher levels of total and central fat mass, 
but not peripheral fat mass, were adversely associated with ED, which could be 
attributable to adipose-tissue-related LGI and insulin resistance. Furthermore, there was 
an inverse, i.e. beneficial, association between peripheral lean mass and ED, suggesting 
that sarcopenia may also play an important role in the decline of endothelial function and 
related sequelae in these individuals.  
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ONLINE SUPPLEMENTAL MATERIAL 
Table S1. Comparison of the general characteristics and body composition of individuals included vs. excluded 
from the present study 
Characteristics 
Excluded (n=173) 
 Included (n=475) P-value 
na  
Age, years 173 73.1 ± 6.7  68.9 ± 6.1 <0.001 
Sex, % men 173 50  48 0.771 
Height, cm 172 168 ± 9.3  169 ± 8.8 0.019 
Weight, kg 172 81.4 ± 14.9  76.7 ± 11.8 <0.001 
Body mass index, kg/m2 172 29.0 ± 5.0  26.7 ± 3.4 <0.001 
Fasting glucose, mmol/l 171 6.4  ± 1.6  6.2 ± 1.4 0.036 
Insulin, pmol/l n 165 65 [43-96]  55 [40-78] <0.001 
Insulin resistance (HOMA2-IR)   165 1.28 [0.81-1.85]  0.94 [0.66-1.28] <0.001 
Use of glucose-lowering medication, 
%  
170 11.2  9.1 0.425 
Glucose metabolism status, % 
NGM/IGM/DM2    
164 35/34/31  50/28/22 0.002 
Total-to-HDL cholesterol ratio 170 4.3 ± 1.3  4.3 ± 1.3 0.998 
Triglycerides, mmol/l 170 1.3 [1.0-1.9]  1.3 [1.0-1.7] 0.483 
Use of lipid-lowering medication, % 165 21  13 0.014 
Systolic blood pressure, mm Hg 129 147 ± 21  141 ± 21 0.007 
Diastolic blood pressure, mm Hg 129 78 ± 9  76 ± 9 0.064 
Use of antihypertensive medication, % 170 69  46 <0.001 
Estimated glomerular filtration rate 
(eGFR), ml/min/1.73m2 
170 77 ± 19  80 ± 16 0.057 
Total energy intake, kcal/day 168 1909 ± 645  1967 ± 726 0.367 
Ever smoker, % 170 62  60 0.638 
Alcohol intake, none/moderate/highb 173 24/49/27  16/53/31 0.046 
Physical activity score (/1000) 170 3.37 [1.18-6.24]  4.92 [2.94-7.83] <0.001 
Prior cardiovascular disease, % 173 55.5  48.2 0.101 
Body composition by DXA      
Total body fat, % 148 37 ± 11  34 ± 9 0.005 
Trunk fat mass, kg 148 15.8 ± 13.2   13.2 ± 5.0 <0.001 
Trunk lean mass, kg 148 25.0 ± 4.8  24.5 ± 4.7 0.230 
Peripheral fat mass, kg 148 13.8 ± 6.0  11.8 ±4.1 < 0.001 
Peripheral lean mass, kg 148 19.8 ± 4.5   19.5 ± 4.6 0.533 
Data are means ± SD, frequencies (%) or medians [inter-quartile range].  
a n with data differs per variable;  
b defined as:  0 glasses/day (none), 1-2 glasses/day in men or 1 glass/day in women (moderate) and >2 in men or 
>1 glasses/day in women (high).  
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Abstract 
 
Objective — Microalbuminuria is associated with cardiovascular mortality, particularly 
among individuals with type 2 diabetes, but the mechanisms underlying this association 
are not completely understood. Microalbuminuria is known to be associated with 
cardiovascular autonomic dysfunction (C-AD), and C-AD in turn is associated with 
cardiovascular mortality. The purpose of this study, therefore, was to investigate whether 
C-AD can explain the relationship between microalbuminuria and cardiovascular mortality. 
 
Research Design and Methods— We studied 490 individuals from a population-based 
cohort of individuals aged 50–75 years who were followed for a median period of 13.6 
years. Microalbuminuria was defined as an albumin-to-creatinine ratio ≥2.0 mg/mmol in 
an early-morning spot-urine sample. Ten parameters reflecting different aspects of 
cardiovascular autonomic function were measured and compiled into a total score of C-AD 
(mean of separate z-scores). The association between C-AD and microalbuminuria was 
estimated by multiple linear regression, and relative risks (RRs) for cardiovascular 
mortality were estimated by Cox proportional hazards analyses. 
 
Results — After adjustments for age, sex, glucose tolerance status, and other risk factors, 
C-AD was associated with microalbuminuria (β=0.16 [95% CI 0.01– 0.33]), and both 
microalbuminuria (RR 2.09 [1.07– 4.08]) and C-AD (1.74 [1.04 –2.89]) were associated with 
cardiovascular mortality. These associations did not change after further mutual 
adjustment for C-AD (2.13 [1.09–4.17]) or microalbuminuria (1.76 [1.05–2.94]), 
respectively. 
 
Conclusions— Both microalbuminuria and C-AD are independently associated with 
cardiovascular mortality, and the excess mortality attributable to microalbuminuria 
cannot be explained by C-AD.  
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Introduction 
 
Microalbuminuria is associated with an increased risk of cardiovascular disease and 
mortality (1). This association is independent of other known cardiovascular risk factors 
such as hypertension, dyslipidemia, obesity, smoking, and impaired renal function (1,2). 
Several mechanisms, notably endothelial dysfunction and low-grade inflammation, have 
been proposed to explain, at least in part, the increased risk of cardiovascular mortality in 
individuals with microalbuminuria (3). Cardiovascular autonomic dysfunction (C-AD) could 
potentially constitute another such mechanism. 
 
Indeed, we as well as others have previously shown that C-AD is associated with 
microalbuminuria, especially in individuals with impaired glucose metabolism (IGM) and 
type 2 diabetes (4–6). Two proposed mechanisms explaining this association are, first, a 
disturbance in glomerular arteriolar autoregulation, which in turn may result in an inability 
to counteract glomerular hypertension (7), and, second, a reduced drop in nightly blood 
pressure due to C-AD, both of which may result in microalbuminuria (8). In addition, C-AD 
is associated with cardiovascular mortality (9,10) and can potentially link 
microalbuminuria to cardiovascular mortality by arrhythmogenic or atherogenic effects, 
for example, by promoting vascular calcification and arterial stiffness (11).  
 
In view of these considerations, we investigated, in a prospective cohort study, whether C-
AD can explain the relationship between microalbuminuria and cardiovascular mortality 
or, alternatively, whether both microalbuminuria and C-AD are independently associated 
with cardiovascular mortality. These hypotheses have never been investigated in the 
general population and could have clinical relevance because the first hypothesis suggests 
that C-AD should be targeted to decrease mortality risk in individuals with 
microalbuminuria and, conversely, the second hypothesis suggests that both 
microalbuminuria and C-AD can be used for estimating the risk of cardiovascular mortality. 
 
Research Design and Methods 
 
We used data from the Hoorn Study, a population-based cohort study on glucose 
metabolism and other cardiovascular risk factors in a general Caucasian population, which 
has been described in detail previously (12). In brief, men and women aged 50–75 years 
were randomly selected from the population register of the town of Hoorn, the 
Netherlands; 2,484 subjects participated (response rate 71%). Baseline examinations were 
conducted from October 1989 until February 1992. All subjects had a 75-g oral glucose 
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tolerance test, except those in whom type 2 diabetes had previously been diagnosed. An 
extensive metabolic and cardiovascular investigation was performed in an age-, sex-, and 
glucose tolerance–stratified, random subsample of 631 participants (89% of those invited), 
which is used in the present study (12).  
 
Participants without representative urine samples available (n = 45) and/or who did not 
complete at least 7 of the 10 autonomic function tests (n = 31), had a history of 
neurological disease (n = 5), and were using ACE inhibitors (n = 33) and/or drugs known to 
influence autonomic nerve function (namely antiparkinson drugs, phenytoin, 
antihistamines, or parasympatholytic, parasympathomimetic, and sympathomimetic 
drugs) (n=49) were excluded from the analyses. The present study, therefore, consisted of 
490 individuals: 305 with normal glucose metabolism, 71 with IGM (including those with 
impaired fasting glucose and/or impaired glucose tolerance), and 114 with type 2 
diabetes.  
The Hoorn Study was approved by the ethical review committee of VU University 
Medical Centre, Amsterdam, the Netherlands. Informed consent was obtained from all 
participants. 
 
Baseline measurements 
Urinary albumin concentration was measured in a first voided sample by rate 
nephelometry (Array Protein System, Beckman Coulter, Galway, Ireland) with a detection 
threshold of 6.2 mg/l (intra- and interassay coefficients of variation of 5 and 8%, 
respectively). Urinary creatinine was measured with a modified Jaffé method. 
Microalbuminuria was present if the albumin-to-creatinine ratio (ACR) was in the range of 
2.0–30 mg/mmol (5). The average value of the ACR was used if two representative 
samples (n = 154) were available. Excluding subjects with an ACR > 30 mg/mmol (i.e., 
macroalbuminuria, n = 4) did not materially affect any of the results, which are therefore 
presented for the entire group. 
 
Cardiovascular autonomic function tests were performed as described in detail elsewhere 
(9). In brief, participants were asked to refrain from smoking and drinking coffee for at 
least 2 h before the assessments. A light meal > 1 h before the measurements was 
allowed. Tests took place between 8:30 A.M. and 4:00 P.M. in a quiet location with room 
temperature of 19–22°C after a resting period of at least 10 min. Ten parameters of 
cardiac autonomic function were derived from the R-R interval and finger systolic blood 
pressure (SBP) continuous recordings by a computerized data analyses system developed 
locally by the Department of Medical Physics, VU University, Amsterdam, the Netherlands 
(13). Tests were performed under three conditions: during spontaneous breathing over 3 
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min in the supine position (mean of all normal to normal R-R intervals [MeanNN], SD of all 
normal to normal R-R intervals [SDNN], low-frequency [LF] power, high-frequency [HF] 
power, and LF/(LF + HF)), during six deep breaths over 1 min in the supine position 
(expiration-inspiration [EI] difference and baroreflex sensitivity [BRS]), and during an 
active change from lying to standing (SBP difference, R-R interval maximum [RRmax], and 
R-R interval maximum divided by minimum [RRmax/min]) (for further explanation of 
measurements, see supplementary Table A1, available in an online appendix at 
http://care.diabetesjournals.org/cgi/content/full/dc08-1544/DC1). We thus obtained 
results in four tests that reflect heart rate or blood pressure changes due to certain 
“maneuvers,” in this case deep breathing or standing up (i.e., EI difference, RRmax, 
RRmax/min, and SBP difference) (14), five tests of spectral analyses of heart rate 
variability (HRV) [i.e., MeanNN, SDNN, LF power, HF power, and LF/(LF + HF)] (15), and one 
BRS measurement (16). In addition, these tests were grouped into those representing 
predominantly parasympathetic (i.e., EI difference, RRmax, and HF power), sympathetic 
(i.e., SBP difference), or both functions (i.e., Mean-NN, SDNN, LF power, LF/(LF + HF), BRS, 
and RRmax/min) (15,16). BMI, waist-to-hip ratio (WHR), SBP and diastolic blood pressure 
(DBP), levels of fasting plasma glucose; A1C; insulin; total, HDL, and LDL cholesterol; 
triglycerides; creatinine; and smoking status were measured as described elsewhere 
(5,9,12). Glomerular filtration rate was estimated by the short Modification of Diet in 
Renal Disease equation. Hypertension was defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 
mmHg and/or the use of antihypertensive drugs. Prior cardiovascular disease (CVD) was 
defined when individuals had (any of the following): a history of myocardial infarction, 
abnormalities on a resting electrocardiogram (Minnesota codes 1.1–1.3, 4.1– 4.3, 5.1– 5.3, 
or 7.1), previous coronary bypass surgery or angioplasty, peripheral arterial bypass, or 
nontraumatic amputation, or an ankle-brachial index of <0.9 in either leg. 
 
Follow-up 
Data on the participants’ vital status up to 1 January 2005 were collected from the 
mortality register of the municipality of Hoorn. Information on cause of death was 
extracted from the medical records of the general practitioners and the local hospital and 
coded according to the ICD-9. Cardiovascular mortality, including sudden death, was 
defined by ICD-9 codes 390–459 and 798. Information on cause of death could not be 
obtained for 20 of the deceased individuals. All subjects were followed until death or end 
of follow- up, at which time they were censored. 
 
Statistical analyses 
Baseline characteristics between survivors and nonsurvivors were compared with the use 
of Student’s t or χ
 2
 tests. We computed z scores ([individual’s observed value - population 
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mean]/SD) for each of the 10 measurements of C-AD. All z scores (except SBP difference) 
were inverted and averaged into a total score (“C-AD total score”), so that higher values 
reflect greater C-AD. The association between microalbuminuria and C-AD total score was 
investigated with multiple linear regression analyses. Kaplan-Meier survival curves were 
plotted for cardiovascular mortality among individuals with normoalbuminuria versus 
microalbuminuria and similarly across tertiles of the C-AD total score, and differences 
between groups were tested with a log-rank test. Cox proportional hazards regression 
models were used to calculate the crude and adjusted relative risks (RRs) and respective 
95% CI of microalbuminuria (versus normoalbuminuria) and of the C-AD total score (per 
SD [= 0.605] increase) for cardiovascular and all-cause mortality. Two-sided P < 0.05 was 
considered statistically significant. All analyses were performed with SPSS (version 15.0).  
 
Results  
 
Subjects excluded from the analyses (n = 141) were older, more often had type 2 diabetes, 
and had a worse risk profile than the subjects included (n = 490) (data not shown). Median 
duration of the follow-up was 13.6 (range 0.52–15.19) years. During the follow-up period, 
141 (28.8%) participants died, of whom 53 (37.6%) died of CVD. At baseline, individuals 
who died had a worse C-AD total score, more often had microalbuminuria and were older, 
more often were men and had type 2 diabetes and hypertension, and had a higher A1C 
and WHR as compared with the survivors (Table 1). 
 
Association between microalbuminuria and C-AD  
C-AD total score was associated with microalbuminuria (β = 0.33 [95% CI 0.16–0.51]) 
(Table 2, model 1). After adjustment for potential confounding factors, C-AD total score 
was still borderline associated with microalbuminuria (0.16 [-0.01 to 0.33]) (Table 2, 
model 3). 
Comparable results were obtained when tests were combined on the basis of their 
methodology or on the part of the autonomic nervous system they predominately 
represent. All individual C-AD tests, except LF/(LF + HF), were positively associated with 
microalbuminuria (although not all statistically significantly so) (data not shown).  
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Table 1 - Baseline characteristics of survivors vs. non survivors 
 Survivors  Non-survivors 
Characteristics  All-cause mortality  Cardiovascular mortality  
 (n=349) (n=141) (n=53) 
Age (years) 62.4 (6.8) 67.1(6.4)* 67.7(6.7)* 
Sex (% men) 43.6 53.9* 50.9 
Glucose tolerance status (%)    
NGM 66.5 51.8 43.4 
IGM 14.0 15.6 17.0 
Type 2 diabetes 19.5 32.6* 39.6* 
HbA1c (%) 5.7 (1.1) 6.2 (1.4)* 6.4 (1.6)* 
Systolic blood pressure (mmHg) 136.2 (18.5) 142.8 (19.6)* 147.2 (21.6)* 
Diastolic blood pressure (mmHg) 82.0 (9.3) 83.3 (11.2) 84.4 (10.8) 
Use of blood-pressure-lowering 
drugs (%)a 
20.9 31.9* 32.1* 
Hypertension (%) 46.4 65.2* 69.8* 
History of CVD (%) 19.8 27.0 30.2 
(Ever) smokers (%) 59.6 71.6* 73.6 
WHR  0.90 (0.08) 0.94 (0.08)* 0.95 (0.08)* 
BMI (kg/cm2) 26.8 (3.7) 27.2 (3.9) 27.4 (3.8) 
Serum creatinine (µmol/l) 89.5 (16.1) 95.0(23.0)* 97.6 (30.6) 
eGFR (ml/min) 69 (11) 66 (13)* 64 (15)* 
Cholesterol (mmol/l) 6.61 (1.13) 6.73(1.31) 6.86 (1.19) 
HDL (mmol/l) 1.31 (0.37) 1.26 (0.34) 1.23 (0.31) 
LDL (mmol/l) 4.51 (0.99) 4.60 (1.13) 4.77 (1.05) 
Use of lipid-lowering drugs (%) 1.7 1.4 1.9 
Triglycerides (mmol/l) 1.50 [1.10-2.10] 1.70 [1.20-2.40]* 1.80 [1.25-2.40] 
EI-difference (ms) 162 [107-237] 131 [83-213]* 113 [79-183]* 
RRmax (ms) 254 (96) 217 (88)
* 223 (91)* 
RRmax/min  1.27 (0.16) 1.19(0.14)
* 1.21(0.13)* 
HF-power (ms2) 183 [85-438] 151[67-363]* 145 [77-330] 
LF-power (ms2) 239 [123-525] 160 [68-390]* 152 [63-307]* 
LF/(LF+HF) 0.56 (0.19) 0.52(0.21) 0.50 (0.21)* 
BRS (ms/mmHg) 9.01 (4.96) 7.91 (4.20)* 7.84 (4.14) 
SDNN (ms) 36 (16) 33 (19)* 32 (19) 
Mean NN (ms) 966 (147) 927 (156)* 935 (157) 
SBP-difference (mmHg) -6.42 (14.82) -6.32 (15.17) -6.45 (16.51) 
C-AD total score -0.08 (0.58) 0.22 (0.61)* 0.22 (0.65)* 
Microalbuminuria (%) 7.7 16.3* 24.5* 
Data are presented as frequencies (%), means (±SD) or medians [inter-quartile range (IQR)] 
* p <0.05 vs. survivors. NGM: normal glucose metabolism; IGM: impaired glucose metabolism; DM: type 2 
diabetes mellitus; CVD; cardiovascular disease; WHR: waist-to-hip ratio; BMI: body mass index; eGFR: estimated 
glomerular filtration rate; HDL: high density lipoprotein; LDL: low density lipoprotein; C-AD: cardiovascular 
autonomic dysfunction 
For detailed explanation of autonomic function tests and their abbreviations, see Table A1. 
a these include diuretics, alpha-blockers, beta-blockers, calcium channel blockers and other blood pressure 
lowering drugs but exclude ACE-inhibitors (because subjects using these drugs were excluded from the analyses). 
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Table 2 - Association between microalbuminuria and C-AD 
Dependent variable Model β 95% CI p-value 
C-AD total score 1 0.33 0.16; 0.51 <0.001 
 2 0.21 0.04; 0.38 0.016 
 3 0.16 -0.01; 0.33 0.067 
C-ADmaneuvers 1 0.34 0.15; 0.53 0.001 
 2 0.17 -0.01; 0.35 0.061 
 3 0.12 -0.07; 0.30 0.209 
C-ADBRS 1 0.40 0.08; 0.71 0.014 
 2 0.23 -0.08; 0.54 0.149 
 3 0.21 -0.11; 0.53 0.194 
C-ADHRV 1 0.31 0.12; 0.51 0.001 
 2 0.22 0.03; 0.41 0.025 
 3 0.16 -0.04; 0.35 0.110 
C-ADparasympathetic 1 0.45 0.22; 0.69 <0.001 
 2 0.28 0.05; 0.51 0.017 
 3 0.23 -0.01; 0.46 0.055 
C-ADsympathetic 1 0.14 -0.18; 0.44 0.394 
 2 0.13 -0.19; 0.44 0.433 
 3 0.11 -0.22; 0.44 0.503 
C-ADboth 1 0.32 0.14; 0.49 <0.001 
 2 0.23 0.06; 0.41 0.001 
 3 0.18 0.01; 0.36 0.041 
β, indicates difference in C-AD score between individuals with micro- vs. normoalbuminuria;  
Model 1: univariate analysis; 
Model 2: adjusted for sex, age and glucose tolerance status; 
Model 3: model 2 plus adjustments for hypertension, WHR, eGFR, LDL, HDL, triglycerides, smoking and prior CVD. 
 
 
 
Association of microalbuminuria and C-AD total score with cardiovascular and all-cause 
mortality 
Both microalbuminuria (RR 3.49 [95% CI 1.87– 6.53]) and C-AD total score (2.54 [1.60–
4.04]) were associated with cardiovascular mortality (Table 3, model 1; Fig. 1). These 
associations were attenuated after adjustment for age, sex, and glucose tolerance status 
(GTS) (2.23 [1.16–4.29] and 1.81 [1.11–2.94], respectively; model 2). Further adjustment 
for other cardiovascular risk factors only slightly further attenuated these RRs (model 3), 
and when the C-AD total score or microalbuminuria was added to these models, the RR 
attributable to microalbuminuria remained practically unchanged and both 
microalbuminuria (2.13 [1.09–4.17]) and C-AD total score (1.76 [1.05–2.94]) were 
independently associated with cardiovascular mortality (model 4). Both microalbuminuria 
and C-AD total score were also associated with all-cause mortality (Table 3, model 1). 
However, after adjustment for age, sex, GTS, and other cardiovascular risk factors, 
microalbuminuria (RR 1.33 [95% CI 0.83–2.13]), in contrast to C-AD total score (1.52 [1.11–
2.09]), was not independently associated with all-cause mortality (model 3). 
 
 
Chapter 3 
 
66 
Table 3 - Association of microalbuminuria or C-AD with cardiovascular and all-cause mortality 
Main determinant Model Cardiovascular mortality All-cause mortality 
  RR [95% CI] RR [95%CI] 
Microalbuminuria 1 3.49 [1.87-6.53] 2.12 [1.36-3.21] 
 2 2.23 [1.16-4.29] 1.46 [0.92-2.31] 
 3 2.09 [1.07-4.08] 1.32 [0.83-2.12] 
 4 2.13 [1.09-4.17] 1.33 [0.83-2.13] 
C-AD total score 1 2.54 [1.60-4.04] 2.11 [1.58-2.81] 
 2 1.81 [1.11-2.94] 1.62 [1.20-2.20] 
 3 1.74 [1.04-2.89] 1.52 [1.11-2.08] 
 4 1.76 [1.05-2.94] 1.52 [1.11-2.09] 
Model 1: univariate analysis; 
Model 2: adjusted for sex, age and glucose tolerance status; 
Model 3: model 2 plus adjustments for hypertension, WHR, eGFR, LDL, HDL, triglycerides, smoking and prior CVD; 
Model 4: model 3, with additional adjustment for respectively C-AD or microalbuminuria; 
RR: relative risk of micro- vs. normoalbuminuria, or per standard deviation (=0.605) increase in C-AD total score. 
 
 
Additional analyses 
The associations described above were also investigated by examining autonomic function 
tests combined on the basis of their methodology or on the part of the autonomic nervous 
system they predominantly represent (supplementary Table A2, available in an online 
appendix). These additional analyses showed that overall all different groups of tests were 
associated with increased mortality risk, that these associations were attenuated when 
further adjusted for age, sex, GTS, and other risk factors; and that none of the specific 
group of tests explained the association between microalbuminuria and mortality. The 
associations reported in Table 3 did not materially change after additional adjustment for 
use of lipid- or blood pressure–lowering drugs and the presence of leukocytes in urine 
(tested by microscopy and scored as positive whenever there were more than five 
leukocytes per high-power field) or when the dichotomous variable hypertension used in 
those models was replaced by either SBP or pulse pressure (a marker of arterial stiffness) 
or when analyses were adjusted for prior coronary heart disease instead of prior CVD 
(data not shown). Finally, we found no evidence of effect modification by GTS in the 
association between cardiovascular mortality and C-AD total score or microalbuminuria (P 
for interaction > 0.4 in both cases). 
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Figure 1. Kaplan-Meier survival plots for cardiovascular mortality among individuals with normo- versus 
microalbuminuria (A) and across tertiles of C-AD total score (B). 
 
Conclusions  
 
In this prospective study we found that both microalbuminuria and C-AD (estimated from 
the mean of 10 standardized tests) were independently associated with cardiovascular 
mortality in a cohort of elderly, Caucasian subjects with and without diabetes. Therefore, 
C-AD does not explain why microalbuminuria is related to cardiovascular mortality in 
either the general population or in diabetic subjects.  
Recently, HRV was found not to predict the decline of GFR but was independently 
associated with cardiovascular mortality in middle-aged type 1 diabetic subjects with 
overt nephropathy (17). In another study, investigating the independent predictive role of 
GFR, microalbuminuria, and cardiovascular autonomic neuropathy showed the latter to 
also be associated with all-cause and cardiovascular mortality in subjects with diabetes 
(18). These findings are in line with those reported herein. Hitherto, no other prospective 
studies examining the relation of microalbuminuria and C-AD with cardiovascular 
mortality have been reported. The independent association of both microalbuminuria and 
C-AD with cardiovascular mortality reported herein indicates that they are linked to 
cardiovascular mortality by different biological pathways. Several mechanisms linking C-
AD to cardiovascular mortality have been proposed (e.g., QT interval prolongation and 
silent myocardial ischemia) (19). Microalbuminuria may be linked to CVD by a common 
pathophysiological process (such as endothelial dysfunction or chronic low-grade 
inflammation) (3). However, the possibility that microalbuminuria reflects the presence of 
a set of undiscovered factors that are causally related to CVD remains to be further 
elucidated. Our study shows that C-AD is an unlikely candidate in this regard.  
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Microalbuminuria is an established risk indicator for CVD. Furthermore, aggressive 
treatment of microalbuminuria by inhibiting the renin-angiotensin aldosterone system has 
been shown to decrease renal and cardiovascular risk in individuals with diabetes (20). 
There is some evidence that C-AD is also a useful risk indicator for CVD, especially in 
subjects at high risk (type 2 diabetes, hypertension, or prior CVD) (9,21), and this study 
reinforces that observation. However, whether the improvement in C-AD, e.g., with 
exercise training or blood pressure– or lipid-lowering drugs (22–24), leads to a better 
prognosis is unknown. In our study, additional adjustment for use of β-blockers or lipid-
lowering drugs had no effect on the associations reported. Therefore, the clinical 
relevance of treating C-AD in the general population remains unclear and needs to be 
further examined.  
 
The strengths of our study are the relatively large, truly population-based and prospective 
design with a long follow-up period. In addition, we characterized subjects’ C-AD as 
comprehensively as possible by conducting 10 autonomic function tests, which are 
thought to reflect all aspects of cardiovascular autonomic function. Previous cross-
sectional studies evaluating the relationship between microalbuminuria and C-AD used 
less extensive autonomic function tests (4,6). Because we included all three groups of GTS, 
we were able to analyze possible effect modification of GTS in the relationship between 
the main determinants, C-AD and microalbuminuria and cardiovascular mortality (but 
found none).  
 
There are several limitations to our study. First, each of the test parameters of autonomic 
function was measured with moderate levels of reproducibility (reliability coefficient 50%) 
(13). Therefore, the results were combined into a C-AD total score, which enabled us to 
circumvent, at least partially, this problem. Specifically, the results herein reported with 
the C-AD total score were more powerful than results obtained on the basis of each 
individual test (separately), because these results would be more strongly affected by 
misclassification (likely to be random), causing an underestimation of the strength of the 
associations. Indeed, the associations between each individual test result with 
cardiovascular mortality were in accordance, although with lower strength, with those as 
reported herein with the C-AD total score (data not shown). In addition, this approach had 
the advantage of circumventing the problem of multiple testing (type I errors) that would 
have occurred when the associations with each test were analyzed separately. However, 
because each test may represent different parts of autonomic function, some overlapping 
but others complementary, our C-AD total score does not allow the distinction of potential 
different contributions of sympathetic and parasympathetic functions to cardiovascular 
mortality. Therefore, we examined the autonomic function tests combined on the basis of 
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their methodology or on the part of the autonomic nervous system they predominantly 
represent in the additional analyses. The results of these alternative combinations of 
autonomic function tests were comparable to those of the C-AD total score 
(supplementary Table A2), but we acknowledge that these analyses may not have been 
specific enough, as most authors agree that a clear distinction between parasympathetic 
or sympathetic dysfunction cannot be made on the basis of these tests. Altogether, we 
feel that the advantages (i.e., reduced misclassification and avoidance of type I errors 
without impairment of etiological validity) of the approach used by us outweigh the 
disadvantages. Second, the spectral analyses were performed during 3 min. Measurement 
of HRV during a longer period may be more reliable, although measurements obtained in 
time periods as short as 2 min correlate highly with 24-h measurements (25). Third, 
evaluation of subjects’ C-AD was conducted at baseline only, and, therefore, we were not 
able to evaluate deterioration of autonomic function during follow-up. Fourth, for most 
participants microalbuminuria was defined on an ACR measured in one urine sample only. 
Because microalbuminuria is quite variable from day to day we cannot fully exclude the 
possibility that some subjects were misclassified. However, we tried to avoid this problem 
by collecting urine overnight and expressing albumin excretion as ACR. In addition, 
analyses in the 154 participants for whom two samples were available yielded essentially 
similar results (data not shown). Finally, we studied an elderly, Caucasian population, and 
it is not known whether our results can be generalized to other ethnic groups or to 
younger individuals.  
 
In summary, we have shown that both microalbuminuria and C-AD are independently 
associated with cardiovascular mortality in an elderly, Caucasian population of individuals 
with normal glucose metabolism, IGM, and diabetes. These results suggest that 
microalbuminuria and C-AD are related to cardiovascular mortality by different biological 
pathways. Therefore, it may be useful to treat not only microalbuminuria but also C-AD in 
populations at high risk of cardiovascular mortality.  
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SUPPLEMENTAL TABLES 
Table A1 - Overview of the ten measurements of cardiovascular autonomic function 
Measurement Unit Definition 
During spontaneous breathing over 3 min in supine position 
Mean NN ms the mean of all normal to normal, i.e. sinus rhythm, R-R intervals 
SDNN ms the standard deviation of all normal to normal i.e. sinus rhythm, R-R 
intervals 
LF-power ms2 Low frequency power, in absolute units: energy in the power spectrum  
  between 0.04 and 0.12 Hz 
HF-power ms2 High frequency power, in absolute units: energy in the power spectrum 
  between 0.12 and 0.40 Hz 
LF/ (LF+HF)  the ratio of LF-power to the sum of LF- and HF-power 
During six deep breaths over 1 min in supine position 
EI-difference ms the mean expiration-inspiration difference in R-R intervals over 
  six consecutive breaths* 
BRS ms mmHg-1 A measure of baroreflex sensitivity, computed as gain, i.e. ratio of the  
  energy in the cross-spectrum of systolic blood pressure and R-R intervals,  
  and the energy in the power spectrum of the R-R interval; all between 0.05  
  and 0.15 Hz and with a squared coherence (γ2) of 0.5 or higher 
During an active change in position from lying to standing 
RRmax  ms the difference between the mean R-R interval during 1 minute of rest prior  
  to standing up and the minimum R-R interval within 15 seconds after  
  standing up 
RRmax/min  maximum R-R interval between 15 and 30 seconds after standing up divided 
  by minimum R-R interval within 15 seconds after standing up 
SBP difference mmHg systolic blood pressure after standing up (mean of 1.5-2 minutes after  
  standing) minus systolic blood pressure in supine position   
*The frequency of breathing at six breaths per minute was dictated by the investigator. When off-line spectral 
analysis showed that breathing was not performed at the appropriate frequency, the record was discarded.  
RR-intervals were obtained from an electrocardiogram by a hardware QRS detector with an accuracy of one 
millisecond. Blood pressure was recorded using the FinapresTM device (Finger Arterial Blood Pressure, Ohmeda 
BP2000); SBP values were obtained from the 200 Hz sampled continuous blood pressure signal by means of an 
automatic procedure, which was verified by visual inspection. 
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Table A2 - Association between microalbuminuria and cardiovascular mortality before and after adjustment for 
different C-AD tests 
Main 
determinants  
Model A Model B Model C 
 RR [95% CI] RR [95% CI] RR [95% CI] 
Microalbuminuria 3.47 [1.86-6.49] 2.07 [1.06-4.04] 2.13 [1.09-4.16] 
C-ADmaneuvers
* 2.43 [1.59-3.71] 1.53 [0.95-2.47] 1.57 [0.97-2.55] 
Microalbuminuria  3.34 [1.64-6.81] 1.95 [0.92-4.16] 1.97 [0.92-4.19] 
C-ADBRS
 † 1.27 [0.90-1.80] 1.10 [0.77-1.56] 1.10 [0.77-1.58] 
Microalbuminuria 3.77 [1.99-7.13] 2.09 [1.05-4.15] 2.08 [1.04-4.15] 
C-ADHRV
‡ 1.96 [1.25-3.08] 1.60 [1.00-2.56] 1.60 [0.99-2.58] 
Microalbuminuria 3.49 [1.87-6.53] 2.09 [1.07-4.07] 2.11 [1.08-4.11] 
C-ADparasympathetic
§ 1.83 [1.30-2.59] 1.39 [0.95-2.04] 1.40 [0.96-2.04] 
Microalbuminuria 3.21 [1.58-6.56] 2.11 [0.99-4.52] 2.10 [0.95-4.48] 
C-ADsympathetic
|| 1.02 [0.75-1.38] 1.13 [0.81-1.56] 1.13 [0.81-1.57] 
Microalbuminuria 3.49 [1.87-6.53] 2.09 [1.07-4.07] 2.03 [1.04-3.99] 
C-ADboth
¶ 2.05 [1.29-3.26] 1.63 [1.02-2.63] 1.62 [1.00-2.62] 
Model A: univariate analysis (note: the RRs differ across the different sets of analyses due to different number of 
subjects who completed the specific tests under investigation; specifically, data on individual tests were missing 
due to incompletion or incorrect performance of the test or insufficient quality of the data for processing: 
maneuvers (n=4), BRS (n=60) and HRV (n=34)); 
Model B: analyses adjusted for age, sex, glucose tolerance status and other risk factors (= Model 3 in Table 3);  
Model C: Model B plus mutual adjustment for different C-AD tests and microalbuminuria; 
* Variables: EI-diff, RRmax, RRmax/min, SBP-diff (SD=0.66); 
† Variable:  BRS (SD=1.00); 
‡ Variables: MeanNN, SDNN, LF-power, HF-power, LF/(LF+HF) (SD=0.65); 
§ Variables: EI-diff, RRmax, HF-power (SD=0.82); 
|| Variable: SBP-diff (SD=1.00); 
¶ Variables: MeanNN, SDNN, LF power, LF/(LF+HF), BRS, RRmax/min (SD=0.60); 
RR: relative risk of micro- versus normoalbuminuria, or per standard deviation (SD) increase in each different C-
AD scores. For explanation of autonomic function tests and their abbreviations, see Table A1 
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Abstract 
 
Background - The metabolic syndrome (MetS) is associated with an increased risk of 
stroke. Arterial remodeling could play an important role herein as maladaptive remodeling 
is a risk factor for stroke. The purpose of this study was to investigate whether MetS was 
associated with maladaptive remodeling of the carotid artery and if any such association 
was independent of hemodynamic variables. 
 
Methods - We studied 385 (n = 195 women) nondiabetic, elderly subjects. A MetS z-score 
(average of sex-specific z-scores of the five MetS traits) was constructed. Intima-media 
thickness (IMT) and interadventitial diameter (IAD) were assessed by ultrasonography, and 
lumen diameter (LD), and circumferential wall stress (CWS) were calculated. Multiple 
linear regression analysis was used to investigate the association between MetS and 
carotid remodeling. 
 
Results - After adjustment for age, sex, height, prior cardiovascular disease (CVD), 
dyslipidemia, and smoking, MetS was independently associated with a greater IAD 
(regression coefficient (β) per S.D. increase in MetS z-score (95% confidence interval), 0.45 
mm (0.28; 0.63)), LD (0.41 mm (0.25; 0.58)) and CWS (5.56 kPa (3.71; 7.42)). These 
associations were attenuated after additional adjustment for inflammatory, metabolic and 
particularly hemodynamic variables, but remained statistically significant. No significant 
association was found between MetS and IMT (0.020 mm (−0.006; 0.046)). 
 
Conclusions - MetS is associated with maladaptive remodeling of the carotid artery, which 
is the result of changes in LD, IAD, and, to a lesser extent, IMT. This process is independent 
of hemodynamic variables. Whether this association and process will be observed in a 
broader population and explains the increased risk of stroke in MetS deserves further 
study.  
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Introduction 
 
The incidence of ischemic stroke increases with the increasing prevalence of the metabolic 
syndrome (MetS), a construct defined by the coexistence of central obesity, dyslipidemia, 
elevated blood pressure, and impaired glucose metabolism (1–4). The underlying 
pathophysiology of the MetS–stroke relationship, however, remains poorly understood, 
although it is likely that changes in both structural and functional arterial properties play 
an important role.  
 
Arterial remodeling, which is the change of structural arterial properties over time in 
response to inflammatory, metabolic, and/or hemodynamic alterations within the arterial 
environment, is thought to be an adaptive mechanism aimed at keeping shear stress 
within certain limits (5). It is characterized by an increase in intima-media thickness (IMT) 
and by widening of the interadventitial diameter (IAD). Maladaptive remodeling (i.e., 
remodeling accompanied by an increase in circumferential wall stress (CWS) and 
circumferential wall tension (CWT)) may be associated with stroke, as it has been shown 
that in stroke patients CWT was higher at the affected side (6). In addition to the above, 
three different patterns of arterial remodeling have been identified: inward, outward, and 
compensatory remodeling (7) of which inward and outward remodeling have been 
associated with stable and unstable plaque formation, respectively (7–9). 
 
In view of these considerations, we investigated the association between MetS and 
carotid remodeling in a population-based cohort. For the present study, we focused on 
MetS in nondiabetic individuals, because type 2 diabetes is known to be associated with 
maladaptive carotid remodeling (10). In addition, we explored whether the relationship 
between MetS and carotid remodeling (if any) was mediated by inflammatory, metabolic, 
or hemodynamic factors, as estimated by high-sensitivity C-reactive protein (hsCRP), the 
homeostatic model for the assessment of insulin resistance (HOMAIR) and adiponectin 
and pulse pressure (PP), and mean arterial pressure (MAP), respectively. 
 
Methods 
 
Study population  
For the present study, we used data from the 2,000 Hoorn Study follow-up examination 
and the Hoorn Screening Study. Details have been described elsewhere (11,12). 
Briefly, the Hoorn Study is a population-based cohort study of glucose metabolism and its 
complications, which started in 1989. A random sample of 50–75-year-old subjects was 
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taken from the population register of the town of Hoorn (59,000 inhabitants) in the 
Netherlands. Of the 3,553 subjects invited for the study 2,540 (71.5%) agreed to 
participate, of whom 56 were excluded from analyses because they were non-Caucasians 
(13). The original Hoorn Study cohort thus consisted of 2,484 subjects. In 2000–2001, a 
follow-up examination was carried out among surviving participants who gave their 
permission to be recontacted. Specifically, we invited all participants who had diabetes, as 
determined by a 75-g oral glucose tolerance test or by diabetes treatment (n = 176) and a 
random sample of participants who had normal glucose tolerance (n = 705) or impaired 
glucose tolerance (n = 193), at the 2nd examination. Of the 1,074 individuals invited, 648 
(60.3%) persons participated.  
 
Among the nonparticipants, the main reasons for nonparticipation in the 2000–2001 
follow-up examination were lack of interest (30%) or comorbidity (23%). Other reasons 
were advanced age (7%), unwillingness to travel (6%), participation considered too time-
consuming (6%), and miscellaneous reasons (15%), whereas 13% gave no reason (14). 
Additionally, we invited 217 individuals with type 2 diabetes mellitus from the Hoorn 
Screening Study, of whom 188 (87%) participated (12). All participants underwent a 
glucose tolerance test, except those with previously diagnosed diabetes (n = 67). Data on 
14 individuals were missing because of logistical problems. Glucose tolerance was defined 
according to the 1999 World Health Organization criteria. Altogether, this follow-up 
cohort thus consisted of 822 individuals (290 with normal glucose metabolism, 187 with 
impaired glucose metabolism, and 345 with type 2 diabetes). Because, we focused on 
MetS in nondiabetic individuals, all those with type 2 diabetes were excluded from the 
present study. The final eligible study population for present study thus consisted of 477 
individuals (15). The Hoorn study was approved by the local Ethical Review Committee 
and written informed consent was obtained from all participants. 
 
MetS 
We calculated a MetS z-score to take into account the continuous nature of the 
association between each of the MetS traits and cardiovascular disease (CVD). This MetS 
z-score was calculated as follows: for each of the individual traits of MetS a sex-specific z-
score was calculated according to the formula ((individual value – study population 
mean)/study population S.D.)) (15,16) The high-density lipoprotein-cholesterol z-score 
was inverted to indicate increasing risk with increasing value; the blood pressure z-score 
was based on the systolic value only, because systolic pressure has the strongest effect on 
stroke. The resulting five z-scores were then averaged into the overall MetS z-score. In 
addition, MetS was defined according to the updated National Cholesterol Education 
Program criteria (17). Accordingly, MetS was diagnosed when three or more of the 
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following five risk factors were present: (i) systolic blood pressure ≥ 130 mm Hg and/or 
diastolic blood pressure ≥ 85 mm Hg or current drug therapy for known hypertension; (ii) 
high-density lipoprotein-cholesterol < 1.03 mmol/l in men and < 1.29 mmol/l in women or 
current drug treatment for low high-density lipoprotein-cholesterol; (iii) triglycerides ≥ 1.7 
mmol/l or current drug treatment for hypertriglyceridemia; (iv) fasting plasma glucose ≥ 
5.6 mmol/l; and (v) waist circumference ≥ 102 cm in men and ≥ 88 cm in women. Finally, 
the participants were also classified according to the number of MetS risk factors present 
(i.e., 0, 1, 2, or ≥ 3). 
 
Carotid arterial properties 
Carotid wall properties were determined by ultrasonography as described in detail 
previously (11). Briefly, a single observer performed right carotid ultrasonography and 
measurements were taken at 10-mm proximal from the carotid bulb in the absence of 
clear carotid plaques, with the use of an ultrasound scanner equipped with a 7.5-MHz 
linear probe (350 Series; Pie Medical, Maastricht, the Netherlands). The scanner was 
connected to a PC equipped with vessel wall movement detection software and an 
acquisition system (Wall Track System; Pie Medical). This setup enables measurements of 
diastolic IAD (i.e., the difference in position of the anterior and posterior arterial wall 
markers) and IMT (i.e., the distance from the leading edge interface between lumen and 
intima to the leading edge interface between media and adventitia) (18,19). The mean IAD 
and IMT of three consecutive measurements were used in the analyses.  
From IAD and IMT, lumen diameter (LD) was calculated as LD (mm) = IAD – (2 · 
IMT). CWT and CWS can be calculated according to Laplace’s law; i.e., P × r/w, where P is 
central transmural pressure, which can be expressed as either “pulsatile” or “mean” 
pressure, r is the lumen radius of the carotid artery, and w is the carotid wall thickness 
(here taken as IMT) (20). For the present study, pulsatile and mean CWS and CWT were 
calculated as follows: pulsatile CWT (kPa) = PP (LD/2), where PP is the local carotid pulse 
pressure estimated by calibration (21) of the distension waveforms (22). Pulsatile CWS 
was calculated as CWS (kPa) = CWT/IMT. In addition, mean CWS and CWT were calculated 
as CWT (kPa) = MAP (LD/2) and CWS (kPa) = mean CWT/IMT (23,24). 
 
Other measurements 
Health status, medical history, medication use, and smoking habits were assessed by 
questionnaires (13). During the examination of the carotid artery in supine position, 
brachial artery systolic and diastolic pressures were assessed in the left upper arm at 5-
min interval over a 45-min period with an oscillometric device (Press-Mate, BP-8800; Colin 
Medical Instruments, San Antonio, TX). Brachial MAP was calculated as (2 × diastolic 
pressure + systolic pressure)/3 (25). We determined glucose (fasting and postload), 
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hemoglobin A1c, insulin, serum total, high-density lipoprotein and low-density 
lipoprotein-cholesterol, triglycerides, hsCRP, adiponectin, height, weight, waist 
circumference, hip circumference, waist-to-hip ratio, and body mass index (12–14). Insulin 
resistance was calculated according to the HOMA-IR model (26). Prior CVD was defined 
when individuals had any of the following: a history of myocardial infarction, transient 
ischemic attack, or ischemic stroke, abnormalities on a resting electrocardiogram 
(Minnesota codes 1.1–1.3, 4.1–4.3, 5.1–5.3, or 7.1), undergone coronary bypass surgery or 
angioplasty, peripheral arterial bypass or nontraumatic amputation and/or ankle-brachial 
index of <0.9 in either leg. 
 
Statistical analyses 
All analyses were conducted with SPSS (version 15.0; Chicago, IL). Linear regression 
analysis was used to analyze the relationship between the MetS z-score and the individual 
carotid properties. These analyses were then adjusted for age, sex, and height (model 1) 
and other potential confounders, i.e., low-density lipoprotein, use of lipid-lowering drugs, 
prior CVD, and smoking (model 2). Finally, the models were adjusted for inflammatory, 
metabolic, or hemodynamic potentially explanatory determinants, i.e., hsCRP (model 3), 
HOMA-IR (model 4A) and adiponectin (model 4B), MAP and PP (model 5A and B), 
respectively.  
All associations are reported as regression coefficients (βs) with their 95% 
confidence intervals. Assumption of linearity intrinsic to the method of data analyses 
adopted was checked by inspection of the residuals by predicted values scatter plots (27). 
After assessment of the main effects, interaction terms were introduced into the models 
to investigate whether the association between MetS and arterial remodeling differed 
between men and women or between subjects with normal glucose metabolism or 
impaired glucose metabolism. A two-sided P value of <0.05 was considered statistically 
significant, except for the interaction analyses where P values <0.10 were considered 
statistically significant. 
 
Results 
 
Of the 477 eligible participants, 92 were excluded from the present study, because of 
qualitatively unsatisfactory ultrasound examinations (mostly attributable to obesity) (n = 
28) and/or missing data on key variables (n = 83). The present study sample therefore 
consisted of 385 participants. The excluded participants were older, more obese, and had 
a higher blood pressure and fasting glucose level than those included (data not shown). 
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Clinical characteristics by MetS status 
The clinical characteristics of the study population according to the presence or absence of 
MetS are shown in Table 1. The prevalence of MetS (≥3 risk factors) was 35.3% (n = 136) 
and did not differ between men (34.7%, n = 66) and women (35.9%, n = 70).  
Participants with MetS had greater IAD, IMT, LD, MAP, and carotid PP compared with 
participants without MetS (Table 2). In addition, participants with MetS had greater CWS 
and CWT compared with those without MetS. Figure 1 shows the age-, sex-, and height-
adjusted mean values of the carotid properties according to the presence or absence of 
MetS.  
 
Table 1. Baseline characteristics according to absence or presence of MetS 
 Metabolic syndrome  
Characteristic Absent (n=249) Present (n=136) p-value 
Age (years) 68 ± 6 68 ± 6 0.937 
Sex (% male) 49.8 48.5 0.812 
    
Traits of MetS    
Systolic blood pressure (mmHg) 134 ± 18 145 ± 17 <0.001 
Diastolic blood pressure (mmHg) 74 ± 9 78 ± 8 <0.001 
HDL cholesterol (mmol/l) 1.56 ± 0.40 1.33 ± 0.40 <0.001 
Triglycerides (mmol/l) 1.00 [0.85-1.40] 1.80 [1.30-2.20] <0.001 
Fasting glucose (mmol/l) 5.49 ± 0.48 5.93 ± 0.46 <0.001 
Waist (cm) 88 ± 9 99 ± 9 <0.001 
    
Other characteristics    
(Current) smoking (%) 16 17 0.843 
Antihypertensive use (%) 17 36 <0.001 
Height (cm) 170 ± 9 170 ± 9 0.364 
BMI (kg/m2) 25.2 ± 2.5 28.3 ± 3.0 <0.001 
WHR  0.89 ± 0.08 0.95 ± 0.83 <0.001 
Total cholesterol (mmol/l) 5.8 ± 1.0 6.0 ± 1.0 0.150 
LDL cholesterol (mmol/l) 3.75 ± 0.92 3.78 ± 0.88 0.700 
Treatment with lipid-lowering drugs (%) 11 16 0.137 
Post-load glucose (mmol/l) 6.05 ± 1.58 7.12 ± 1.73 <0.001 
HbA1c (%) 5.7 ± 0.4 5.8 ± 0.4 <0.001 
Fasting insulin (pmol/l) 45 [34-57] 68 [50-92] <0.001 
HOMA-IR 1.66 ± 0.81 2.77 ± 1.31 <0.001 
Prior CVD (%) 43.0 50.7 0.144 
Microalbuminuria (%) 9.2 15.4 0.067 
Heart rate (bpm) 61 ± 8 64 ± 9 0.001 
HsCRP (mg/l) 1.40 [0.86-2.65] 2.17 [1.16-5.10] <0.001 
Adiponectin (mg/l) 12.86 ± 5.92 10.09 ± 4.59 <0.001 
Data are presented as mean ± SD or median [inter-quartile range (IQR)] 
MetS: metabolic syndrome; HDL: high-density lipoprotein; MAP: mean arterial pressure; BMI: body mass index; 
WHR: waist-to-hip ratio; LDL: low-density lipoprotein; HOMA-IR: Homeostasis Model Assessment for Insulin 
Resistance; CVD: cardiovascular disease; hsCRP; high-sensitivity C-reactive protein 
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MetS and lumen and IAD  
A greater MetS z-score was associated with greater LD. This association was attenuated 
after adjustment for age, sex, and height (Table 3, model 1) and other potential 
confounders (i.e., low-density lipoprotein-cholesterol, use of lipid-lowering drugs, 
smoking, and prior CVD) (Table 3, model 2), but remained statistically significant. 
Additional adjustment for low-grade inflammation (i.e., hsCRP) (Table 3, model 3) or 
metabolic factors (i.e,. HOMA-IR and adiponectin) (Table 3, models 4A and B) did not 
importantly change this association. However, the association was partially attenuated by 
adjustment for hemodynamic factors (i.e., MAP and PP) (Table 3, models 5A–B) but 
remained statistically significant. Similar results were found for the association between 
the MetS z-score and IAD (Table 3). 
 
Table 2. Carotid arterial properties according to the absence or presence of the metabolic syndrome 
 Metabolic syndrome  
Arterial property Absent (n=249) Present (n=136) p-value 
Interadventitial diameter 
(mm) 
7.63 ± 1.08 8.17 ± 1.18 <0.001 
Intima-media thickness 
(mm) 
0.83 ± 0.16 0.85 ± 0.16 0.132 
Lumen diameter (mm) 5.97 ± 0.98 6.46 ± 1.12 <0.001 
Mean arterial pressure  
(mmHg) 
94 ± 11 101 ± 9 <0.001 
Carotid pulse pressure  
(mmHg) 
58 ± 15 64 ± 17 0.001 
Pulsatile circumferential 
wall tension (kPa) 
23 ± 8 27 ± 9 <0.001 
Pulsatile circumferential 
wall stress (kPa) 
29 ± 9 33 ± 12 <0.001 
Mean circumferential 
wall tension (kPa) 
38 ± 8 44 ± 10 <0.001 
Mean circumferential 
wall stress (kPa) 
47 ± 12 53 ± 16 <0.001 
Results are expressed as means ± SD 
 
 
MetS and IMT 
A greater MetS z-score was associated with greater IMT. This association lost, however, 
statistical significance after adjustment for age, sex, and height (Table 3, model 1). MetS 
and circumferential wall tension and stress A greater MetS z-score was associated with 
greater pulsatile CWT and CWS. These associations were attenuated after adjustment for 
age, sex, and height (Table 3, model 1) and other potential confounders (Table 3, model 
2), but remained statistically significant. After additional adjustment for low-grade 
inflammation (Table 3, model 3), metabolic (Table 3, models 4A and B), or hemodynamic 
factors (Table 3, model 5A), the associations between the Mets z-score and CWT and CWS 
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remained statistically significant. When the analyses were repeated with the mean CWS 
and CWT (by replacing local PP in their formulas by MAP), similar results were obtained 
(Tables 4 vs. 3). 
 
Additional analyses 
Further adjustment for heart rate, (micro-)albuminuria, use of angiotensin-converting 
enzyme-inhibitors or angiotensin II receptor blockers did not materially alter any of the 
results (data not shown). Additionally, the results did not differ between men and women 
(P values for interaction all ≥0.250) or between those with normal glucose metabolism and 
impaired glucose metabolism (P values for interaction all ≥0.099). With regard to glucose 
tolerance status, a significant interaction term was found only for CWS (P value for 
interaction 0.099, all other P values for interaction were ≥0.315). Stratified analyses then 
showed that in those with normal glucose metabolism the association between the MetS 
z-score and CWS was stronger as compared to those with impaired glucose metabolism (β 
and 95% confidence interval: 8.03 kPa (5.34; 10.73)) vs. 4.89 kPa (2.09; 7.69), 
respectively).  
 
When the analyses were repeated by replacing the MetS z-score by the z-scores of the 
individual traits of MetS, analyses showed that blood pressure and waist circumference 
were the strongest determinants of carotid remodeling (Table 5). Finally, the results were 
not materially altered if the analyses were conducted with MetS expressed as a 
dichotomized variable (Tables 6 and 7) or according to the number of MetS traits present 
(data not shown). 
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Figure 1.  Age-, sex-, and height-adjusted mean values of LD, IAD, IMT, CWT and CWS according to the presence 
or abcence of MetS. *p< 0.05.  
CWS, circumferential wall stress; CWT, circumferential wall tension; IAD, interadventitial diameter; IMT, intima-
media thickness; LD, lumen diameter; MetS, metabolic syndrome 
 
  
Table 3. Carotid remodeling (pulsatile CWS and CWT) according to the MetS z-score  
 LD (mm) IAD (mm) IMT (mm) CWT (kPa) CWS (kPa) 
Model β 95% CI β 95% CI β 95% CI β 95% CI β 95% CI 
1 0.44c 0.27; 0.60 0.48c 0.31; 0.65 0.020 -0.006; 0.046 4.99c 3.67; 6.32 5.71c 3.87; 7.54 
2 0.41c 0.25; 0.58 0.45c 0.28; 0.63 0.020 -0.006; 0.046 4.87c 3.53; 6.20 5.56c 3.71; 7.42 
3 0.38c 0.20; 0.55 0.42c 0.23; 0.60 0.018 -0.010; 0.046 4.66c 3.25; 6.07 5.36c 3.40; 7.33 
4A 0.63c 0.43; 0.83 0.68c 0.48; 0.89 0.028 -0.004; 0.060 6.99c 5.41; 8.57 8.05c 5.84; 10.26 
4B 0.45c 0.28; 0.62 0.48c 0.30; 0.66 0.014 -0.014; 0.042 5.43c 4.04; 6.82 6.48c 4.56; 8.42 
5A 0.27b 0.09; 0.45 0.29b 0.10; 0.48 0.012 -0.017; 0.042 1.90b 0.56; 3.23 2.28a 0.34; 4.23 
5B 0.30c 0.13; 0.48 0.32c 0.14; 0.50 0.008 -0.020; 0.036 - - - - 
 
Table 4. Carotid remodeling (mean CWS and CWT) according to the MetS z-score  
 CWT (kPa) CWS (kPa) 
Model β 95% CI β 95% CI 
1 6.35c 4.95; 7.52 7.15c 4.74; 9.56 
2 6.21c 4.80; 7.61 6.99c 4.56; 9.42 
3 5.88c 4.40; 7.36 6.59c 4.00; 9.17 
4A 8.78c 7.14; 10.42 9.85c 6.95; 12.75 
4B 7.08c 5.63; 8.53 8.54c 6.03; 11.04 
5A - - - - 
5B 4.39c 3.02; 5.75 5.45c 2.93; 7.97 
Results are expressed as regression coefficients (β) and respective 95% CI. The regression coefficient β indicates the difference in arterial property (in units) per SD (=0.57) 
increase in the MetS z-score. ap <0.05, bp<0.01, cp<0.001; 
pulsatile CWT=local PP (LD/2), pulsatile CWS= pulsatile CWT / IMT 
mean CWT= MAP (LD/2), mean CWS= mean CWT / IMT 
Model 1: adjusted for age, sex, height; 
Model 2: adjusted for 1 + LDL-cholesterol, use of lipid-lowering drugs, prior CVD, smoking; 
Model 3: adjusted for 2 + ln-hsCRP; 
Model 4A: adjusted for 2 + ln-HOMA-IR; 
Model 4B: adjusted for 2 + adiponectin; 
Model 5A: adjusted for 2 + MAP;  
Model 5B: adjusted for 2 + local PP  
  
Table 5. Carotid arterial remodeling according to each MetS trait separately 
 LD (mm) IAD (mm) IMT (mm) Pulsatile CWT (kPa) Pulsatile CWS (kPa) 
MetS trait β 95% CI β 95% CI β 95% CI β 95% CI β 95% CI 
Blood 
pressure* 
0.31c 0.21; 0.40 0.35c 0.25; 0.45 0.021b 0.006; 0.037 5.66c 5.04; 6.28 6.23c 5.28; 7.19 
Waist-
circumference 
0.20c 0.11; 0.30 0.21c 0.11; 0.32 0.006 -0.009; 0.021 1.63c 0.82; 2.43 1.78b 0.68; 2.89 
Glucose 
tolerance 
0.07 -0.02; 0.17 0.10 0.002; 0.20 0.015 0.001; 0.030 0.67 -0.13; 1.47 0.18 -0.90; 1.27 
Triglycerides 0.11 0.01; 0.21 0.10 -0.003; 0.20 -0.006 -0.021; 0.009 0.43 -0.38; 1.23 1.13a 0.04; 2.22 
HDL† 0.05 -0.05; 0.15 0.05 -0.05; 0.15 -0.001 -0.016; 0.014 0.23 -0.57; 1.04 0.49 -0.60; 1.58 
ap <0.05, bp<0.01, cp<0.001; Regression coefficient (β) indicates the difference in carotid artery property (in units) per SD increase in the z-score of respective MetS trait.  
All models were adjusted for sex, age and height; 
* The blood pressure z-score reflects the systolic blood pressure z-score; 
† This z-score reflects the inverted HDL z-score;  
MetS: metabolic syndrome; LD: lumen diameter; IAD: interadventitial diameter; IMT: intima-media thickness; CWT: circumferential wall tension; CWS: circumferential wall 
stress; HDL: high-density lipoprotein 
 
Table 6. Carotid remodeling (pulsatile CWS and CWT) according to the presence or absence of MetS 
 LD (mm) IAD (mm) IMT (mm) CWT (kPa) CWS (kPa) 
Model β 95% CI β 95% CI β 95% CI β 95% CI β 95% CI 
1 0.48c 0.28; 0.67 0.53c 0.33; 0.74 0.027 -0.004; 0.058 4.12c 2.49; 5.74 4.40c 2.16; 6.63 
2 0.45c 0.25; 0.65 0.50c 0.30; 0.70 0.025 -0.006; 0.057 3.89c 2.26; 5.51 4.16c 1.92; 6.40 
3 0.41c 0.21; 0.61 0.46c 0.25; 0.67 0.023 -0.008; 0.055 3.50c 1.84; 5.16 3.73b 1.44; 6.02 
4A 0.60c 0.38; 0.82 0.66c 0.43; 0.89 0.032 -0.004; 0.067 4.85c 3.02; 6.69 5.23c 2.70; 7.77 
4B 0.48c 0.28; 0.69 0.52c 0.31; 0.73 0.019 -0.013; 0.052 4.87c 2.55; 7.20 4.27c 2.58; 5.96 
5A 0.32b 0.12; 0.52 0.36b 0.15; 0.57 0.019 -0.014; 0.052 1.23 -0.93; 3.39 1.28 -0.21; 2.76 
5B 0.37c 0.18; 0.57 0.41c 0.21; 0.61 0.018 -0.014; 0.049 - - - - 
Results are expressed as regression coefficients (β) and respective 95% CI. The regression coefficient β indicates the difference in arterial property (in units) between 
individuals with vs. without MetS. ap <0.05, bp<0.01, cp<0.001. 
Pulsatile CWT = local PP (LD/2), pulsatile CWS = pulsatile CWT/IMT. 
Model 1, adjusted for age, sex, height; Model 2, adjusted for 1 + LDL-cholesterol, use of lipid-lowering drugs, prior CVD, smoking; Model 3, adjusted for 2 + ln-hsCRP; Model 
4A, adjusted for 2 + ln-HOMAIR; Model 4B, adjusted for 2 + adiponectin; Model 5A, adjusted for 2 + MAP; Model 5B, adjusted for 2 + local PP. 
CVD, cardiovascular disease; CWS, circumferential wall stress; CWT, circumferential wall tension; HOMAIR, homeostasis model assessment for insulin resistance; hsCRP, high-
sensitivity C-reactive protein; IAD, interadventitial diameter; IMT, intima-media thickness; LD, lumen diameter; LDL, low-density lipoprotein; MAP, mean arterial pressure; 
MetS, metabolic syndrome; PP, pulse pressure. 
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Table 7. Carotid remodeling (Mean CWS and CWT) according to the presence or absence of MetS  
  CWT (kPa) CWS (kPa) 
Model β 95% CI β 95% CI 
1 6.07c 4.35; 7.78 6.16c 3.24; 9.08 
2 5.85c 4.14; 7.55 5.97c 3.06; 8.88 
3 5.35c 3.62; 7.09 5.38c 2.40; 8.35 
4A 7.22c 5.31; 9.14 7.31c 4.01; 10.60 
4B 6.59c 4.83; 8.35 7.34c 4.34; 10.34 
5A - - - - 
5B 4.50c 2.93; 6.06 4.74c 1.86; 7.62 
Results are expressed as regression coefficients (β) and respective 95% CI. The regression coefficient β indicates 
the difference in arterial property (in units) between individuals with vs. without MetS. ap <0.05, bp<0.01, 
cp<0.001; 
pulsatile CWT=local PP (LD/2), pulsatile CWS= pulsatile CWT / IMT 
mean CWT= MAP (LD/2), mean CWS= mean CWT / IMT 
Model 1: adjusted for age, sex, height; 
Model 2: adjusted for 1 + LDL-cholesterol, use of lipid-lowering drugs, prior CVD, smoking; 
Model 3: adjusted for 2 + ln-hsCRP; 
Model 4A: adjusted for 2 + ln-HOMA-IR; 
Model 4B: adjusted for 2 + adiponectin; 
Model 5A: adjusted for 2 + MAP;  
Model 5B: adjusted for 2 + local PP  
MetS: metabolic syndrome; LD: lumen diameter; IAD: interadventitial diameter; IMT: intima-media thickness; 
CWT: circumferential wall tension; CWS: circumferential wall stress; LDL: low-density lipoprotein; CVD: 
cardiovascular disease; hsCRP: high-sensitivity C-reactive protein; HOMA-IR: Homeostasis Model Assessment for 
Insulin Resistance; MAP: mean arterial pressure; PP: pulse pressure 
 
 
Discussion 
 
The present study on the association between MetS in nondiabetic individuals and carotid 
remodeling had four main findings. First, MetS was associated with a greater LD, IAD, and 
IMT, and significantly so for LD and IAD. Second, this constellation of findings identified a 
pattern of outward remodeling which was accompanied by greater CWS and CWT. The 
latter particularly suggests that the process of carotid remodeling in MetS is maladaptive. 
Third, the relationship between MetS and carotid remodeling was not explained by 
variables closely associated with waist circumference, i.e., hsCRP, adiponectin, or insulin 
resistance. In addition, hemodynamic factors only partially explained the MetS–carotid 
remodeling association. Taken both these observations into account, the present results 
suggest that the remaining factors constituting MetS (i.e., impaired glucose metabolism 
and dyslipidemia) may also influence the process of arterial remodeling. Finally, the 
association between MetS and carotid remodeling was similar in men and women. 
Whether this association explains the increased risk of ischemic stroke in MetS warrants 
further study.  
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The results of the present study—in nondiabetic individuals with MetS—are consistent 
with our earlier findings, which showed that type 2 diabetes was also associated with 
maladaptive carotid remodeling (10). Taken together, these findings thus support the 
“ticking clock” hypothesis, which suggests that the elevated CVD risk already starts well 
before the onset of type2 diabetes (27). This was further emphasized by the fact that, in 
the present study, unfavorable changes were seen in all carotid properties with an 
increasing number of MetS risk factors. In addition, the present results were independent 
of the presence of albuminuria, which extends our previous results on the association 
between renal function and carotid remodeling (24,28).  
 
The individual MetS component that contributed most to the maladaptive remodeling was 
blood pressure. This is in line with a previous report in this journal (29) and might be 
explained by its steady and pulsatile stress upon the arterial wall which causes fracturing 
of the (pressure-load-bearing) elastin and collagen network (30). We have shown herein 
that MetS was independently associated with both pulsatile and mean CWS and CWT, 
even after adjustment for, respectively, the steady (i.e., MAP) and pulsatile (i.e., PP) stress 
exerted by blood pressure. Our findings thereby extend the Glagov hypothesis (5) which 
originally stated that the process of arterial remodeling was mediated by shear stress only. 
This extension of the Glagov hypothesis has also been suggested by others (23,24).  
 
In addition to the above, MetS remained independently associated with maladaptive 
remodeling even after adjustment for hemodynamic factors, which suggests that the 
metabolic alterations in MetS (i.e., the combination of dyslipidemia, central fat 
distribution, and impaired glucose tolerance) play an additive role in the remodeling 
process in MetS. In this line, a Japanese study showed that dyslipidemia and mean CWT 
were positively associated in elderly individuals (31). The deleterious contribution of waist 
circumference, i.e., central obesity, may be explained by its association with adipocyte-
derived proinflammatory molecules, known to be involved in (maladaptive) arterial 
remodeling (32,33). In our study, low-grade inflammation as estimated by hsCRP did not 
explain this association. This suggests that other adipocyte-derived factors may play an 
important role. In this line, it has recently been shown that hypoadiponectinemia (which is 
related to central obesity) in experimental (34) and human (35) studies is associated with 
ischemic stroke. In the present study, subjects with MetS indeed had lower adiponectin 
levels than those without MetS, but the association between MetS and carotid remodeling 
was not explained by hypoadiponectinemia. The potential role of hypoadiponectinemia in 
stroke therefore warrants further study. Nevertheless, our results suggest that factors 
related to central obesity other than low-grade inflammation and hypoadiponectinemia 
may play a role.  
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Two previous studies investigated carotid remodeling in MetS (36,37). Both studies 
identified a pattern of outward carotid remodeling. The extent to which the pattern of 
remodeling in these studies was associated with normalized or increased CWT and CWS 
was not reported. Consequently, it is difficult to determine whether the changes reflected 
an adaptive or maladaptive process. Our study expands these previous data by showing 
that the arterial remodeling response in MetS is maladaptive (with increased CWS and 
CWT) and independent of inflammatory and hemodynamic factors as expressed by hsCRP 
and PP and MAP, respectively. The present results support the hypothesis that 
maladaptive remodeling constitutes one of the mechanisms that explain the MetS–stroke 
relationship.  
 
We used MetS expressed as a continuous variable to take into account the continuous 
nature between the MetS traits and CVD. This approach was more robust and avoided the 
loss of information that would occur with the use of dichotomized variables, and may 
therefore be more suitable for etiological research as reported herein (15,38,39).  
Nevertheless, results were similar when the associations with carotid properties were 
investigated with MetS defined as present/absent instead of the MetS z-score. The 
present study supports the view that not all MetS traits carry the same burden with 
respect to cardiovascular risk (39) as in our study blood pressure was the strongest 
determinant of the MetS–remodeling relationship. However, we have shown that the 
other MetS components together exert an additive, independent (metabolic) effect on the 
remodeling process.  
 
The present study had some limitations. First, due to its crosssectional design, any 
inferences about causality should be made with caution and further prospective studies 
are warranted. Second, no three-dimensional images of the carotid artery were obtained 
and therefore our assumptions regarding the geometry of the carotid artery may have 
caused us to underestimate the MetS–carotid remodeling relationship. In addition, 
ultrasound cannot discriminate between the intimal and medial layers of the artery. Third, 
it should be noted that the individuals excluded from the study were older, more obese, 
and had a higher blood pressure (i.e., had a worse risk profile). Therefore, the reported 
associations, if anything, may have been slightly underestimated. Finally, we studied a 
Caucasian, elderly population, and it remains to be established whether the results can be 
generalized to other ethnicities or to younger individuals. 
 
In conclusion, we have shown that MetS is associated with greater LD and IAD of the 
common carotid artery in nondiabetic subjects. This outward remodeling process is 
maladaptive, as shown by an increase in CWT and CWS. This association was independent 
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of low-grade inflammation and hemodynamic variables and therefore MetS exerts an 
additive metabolic effect on the remodeling process. Whether this association and 
process will be observed in a broader population and explains the increased risk of stroke 
in MetS deserves further study. 
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Abstract 
 
Maladaptive arterial remodeling may constitute a mechanism underlying the risk of stroke 
in individuals with the metabolic syndrome (MetS), but evidence supporting this 
contention derives from cross-sectional studies only. We, therefore, investigated, in 
apparently healthy adults, whether changes in MetS status between the ages of 36 and 42 
years (never [n=207, reference group], incident [n=31], recovery [n=23], and persistent 
[n=32]) were associated with changes in carotid interadventitial diameter, lumen 
diameter, intima-media thickness, circumferential wall tension and stress, and Young’s 
elastic modulus. All data analyses were adjusted for sex, height, and (changes in) age, 
lifestyle variables, low-density lipoprotein cholesterol, and use of antihypertensive 
medication. At baseline and as compared with the reference group, individuals with 
persistent MetS had significantly higher interadventitial diameter, circumferential wall 
tension, circumferential wall stress, and Young’s elastic modulus but not intima-media 
thickness. In the course of follow-up, these individuals (versus reference group) displayed 
significantly steeper increases in intima-media thickness (0.011 versus 0.005 mm/y), which 
were accompanied by significantly steeper increases in interadventitial diameter (0.077 
versus 0.032 mm/y) and lumen diameter (0.055 versus 0.023 mm/y) but not 
circumferential wall stress, which decreased (-0.34 versus 0.12 kPa/y). These findings 
suggest that increases in intima-media thickness in young adults with the MetS may 
primarily reflect an adaptive mechanism that attempts to restore local hemodynamic 
conditions to an equilibrium rather than atherosclerosis, per se. However, carotid 
adaptations did not restore circumferential wall stress to levels comparable with those of 
the reference group, and, therefore, outward remodeling was maladaptive. Importantly, 
individuals who recovered from the MetS restored carotid properties to levels comparable 
to the reference group, emphasizing the potential for reversibility. 
 
 
 
 
 
 
 
 
  
Chapter 5 
 
98 
Introduction 
 
Individuals with the metabolic syndrome (MetS), that is, clustering of elevated blood 
pressure (BP), central obesity, dyslipidemia, and impaired glucose metabolism, have an 
increase risk of incident cardiovascular disease, in particular, stroke (1). However, the 
underlying pathophysiology of the MetS-stroke relationship remains poorly understood.  
 
Numerous studies have linked the MetS to increased carotid intima-media thickness (IMT) 
(2) and or stiffness (3), and both higher levels of carotid IMT and stiffness predict incident 
cardiovascular disease, in particular, stroke (4,5). Maladaptive arterial remodeling may 
also constitute a mechanism linking the MetS to increased risk of stroke. Arterial 
remodeling, that is, the change of structural arterial properties over time in response to 
hemodynamic and/or metabolic factors operating within the arterial environment, is 
thought to be an adaptive mechanism aiming at keeping shear stress within certain limits 
(6). It is characterized by widening of the interadventitial diameter (IAD) and increases in 
IMT. This process is considered to be maladaptive when, despite remodeling, 
circumferential wall tension (CWT) and stress (CWS; also designated as tensile stress) 
remain elevated. Maladaptive arterial remodeling has been linked to stroke by the 
observation of higher carotid CWT at the affected side of stroke patients (7). Evidence 
thus far suggests that the MetS is associated with maladaptive arterial remodeling, but 
this is limited because it derives from cross-sectional studies only (8–12) not all of which 
reported on CWT and/or CWS together with IAD, lumen diameter (LD), and IMT (10–12). 
 
As snap-shots, cross-sectional studies do not enable a full appreciation of dynamic 
processes, such as that of arterial remodeling. For example, increases in IMT could 
precede and lead to subsequent increases in IAD and/or LD, or, alternatively, increases in 
IMT could result from increased IAD. A longitudinal study is, thus, necessary for a better 
understanding of the temporal relationships between carotid IMT and diameter. In 
addition, the appreciation of accompanying (changes in) levels of CWT and CWS can 
elucidate the extent to which any such observed pattern of arterial remodeling is 
maladaptive. In view of these considerations, we have examined changes in carotid artery 
structural and functional properties and local hemodynamic forces as a function of 
changes (in clustering of traits of) MetS status, in a 6-year longitudinal study among 
apparently health adults. 
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Methods 
 
Study Design and Population 
Data were derived from the Amsterdam Growth and Health Longitudinal Study, an 
ongoing observational longitudinal study that started in 1976 with a total inclusion of 698 
boys and girls (mean age, 13.1±0.8 years), as described in detail elsewhere (13). In the 
year 2000, when subjects’ mean age was 36.6 years (±0.6 years), measurements of large 
artery properties by means of non-invasive ultrasound were included for the first time in 
this cohort and obtained in 373 subjects (baseline data of the present study) (14–17). In 
2006, follow-ups of arterial measurements were obtained in 297 of these individuals, 293 
of whom had complete data on carotid artery properties and traits of the MetS at both 
time points (the sample of the present study). However, baseline characteristics from the 
80 individuals without complete follow-up data did not differ from those included (data 
not shown). Throughout the longitudinal period, anthropometric (body height, weight, 
and waist circumferences), biological (blood lipids and BP), and lifestyle (smoking status, 
alcohol consumption, and physical activity levels) variables were assessed according to 
standard procedures, as detailed elsewhere (14–17). The medical ethical committee of the 
VU University Medical Center in Amsterdam approved the study, and all of the 
participants gave written informed consent.  
 
Carotid Artery Properties and BP 
At baseline and at follow-up, carotid properties were obtained by means of the same 
protocol and ultrasound equipment, as described in detail previously (please see online-
only Data Supplement) (14–17).  
LD was calculated as IAD - (2 · IMT) and the arterial wall cross-sectional (CSAIMT) 
as π · IMT · (IMT+LD); CWT and CWS were estimated according to Laplace’s law as MAP · 
(LD/2) and CWT/IMT, respectively, where MAP is mean arterial pressure (8,9,18,19). The 
Young’s elastic modulus (YEM) was estimated as IAD/(IMT · DC), where DC indicates the 
distensibility coefficient, which was calculated from IAD, distension, and local pulse 
pressure (14–17).  
 
Throughout the entire period of ultrasound imaging, systolic (SBP), diastolic (DBP), and 
MAP were assessed in the left arm at 5-minute intervals with oscillometric devices. 
Brachial pulse pressure was defined as SBP-DBP, and pulse pressure at the level of the 
carotid artery was calculated by calibration of the diameter-distension waveforms 
obtained at this and the brachial arteries, as described by Van Bortel et al (20). 
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Definition of the MetS and Changes in MetS Status Over Time 
At follow-up, subject levels of BP were obtained during the arterial assessments only, that 
is, while subjects were in supine position. We, therefore, deemed the use of the SBP/DBP 
cutoff values proposed by established definitions of the MetS (eg, National Cholesterol 
Education Program/International Diabetes Federation) inappropriate, because these are 
based on readings in the sitting position, which are higher. In addition, levels of fasting 
plasma glucose were not available at baseline, and, therefore, we used glycated 
haemoglobin (HbA1c) as a marker of glucose metabolism instead. The presence of MetS 
traits was defined on the basis of the highest sex-specific quartiles of SBP or DBP, waist 
circumference, triglycerides, and HbA1c and the lowest sex-specific quartile of high-
density lipoprotein cholesterol, as measured at baseline. The cutoff values thereby 
derived are presented in Table S2 (available in the online-only Data Supplement) and were 
used to classify presence or absence of MetS traits at follow-up. Subjects were then 
assigned to 4 categories according to the number of traits present, that is, 0, 1, 2, and ≥3, 
and the latter category was used to identify individuals’ clustering of traits indicative of 
the MetS (hereafter referred as “with MetS”). 
Subjects were classified further into the following 4 groups of changes in MetS 
status, including never (no MetS at baseline and follow-up; n=207), incident (MetS at 
follow-up but not at baseline; n=31), recovery (MetS at baseline but not at follow-up; 
n=23), and persistent (MetS at both baseline and follow-up; n=32). 
 
Statistical Analysis 
We first examined the validity of the classification of participants’ MetS status as adopted 
herein by testing whether the observed clustering of ≥ 3 traits occurred at levels above 
those that could be dictated by chance alone (21). This was confirmed by an observed 
prevalence of the MetS at baseline that was twice higher that which could be expected by 
chance alone (Figure S1).  
 
Generalized estimating equations, which is a statistical method appropriate for analyses of 
repeated and, thus, correlated data (22), were used to test differences in carotid artery 
properties, at baseline and at follow-up, and their changes over time between the 4 
groups of changes in MetS status. Groups were included in these analyses as a dummy 
variable and differences tested relative to the reference group (never); differences in 
changes, also relative to the reference group, were tested by means of group · time 
interaction terms (model specifications given in the online-only Data Supplement). All of 
the analyses were adjusted for sex, height (as time-independent covariates), and age, 
smoking, alcohol consumption, physical activity, low-density lipoprotein cholesterol, and 
use of antihypertensive medication (as time-varying covariates) (22).  
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All data are reported in men and women combined, because we did not find any 
consistent significant interactions with sex. Triglycerides levels, which were positively 
skewed, were loge transformed before all data analyses. Statistical significance was set at 
P<0.05 and all analyses were carried out with the use of the STATA software package 
version 11.2 (STATA Corp, College Station, TX). 
 
Results 
 
General characteristics of the study population, at baseline and follow-up, are shown in 
Table 1, stratified by categories of change in MetS status.  
 
Carotid Properties and Their Changes by Categories of Change in MetS Status 
At baseline, individuals with persistent MetS had significantly higher levels of IAD, LD, 
CWT, CWS, and YEM, but not of IMT, than those who never developed the MetS (Table 2 
and Figure). In the course of follow-up, the persistent MetS group displayed significantly 
steeper increases in IMT (0.011 versus 0.005 mm/y), CSAIMT (0.38 versus 0.14 mm2/y), 
IAD (0.077 versus 0.032 mm/y), and LD (0.055 versus 0.023 mm/y), whereas changes in 
CWT (0.33 versus 0.27 kPa/y), CWS (-0.34 versus 0.12 kPa/y), and YEM (0.010 versus 0.002 
10
3
 · kPa/y) did not significantly differ from those observed in the reference group. Still, at 
follow-up CWT, CWT, CWS, and YEM remained significantly higher in the group with 
persistent MetS versus those who never developed the MetS. Individuals who recovered 
from the MetS had, at baseline, higher levels of CWT and CWS than the group who never 
developed the MetS but displayed favorable changes in all of the carotid artery properties 
such that, at follow-up, none of these differed significantly from the group who never 
developed the MetS. On the other hand, individuals with incident MetS displayed 
significantly steeper increases in CWT (0.56 versus 0.27 kPa/y) and also more adverse 
patterns of change in the other carotid properties (albeit not significantly different), such 
that, at follow-up, these individuals had significantly higher IAD, CWT, and YEM than those 
who never developed the MetS.  
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Table 1. Characteristics of the study population at baseline and at follow-up by categories of changes in 
metabolic syndrome status 
  Metabolic Syndrome status 
Characteristics 
Time 
Never 
(n=207) 
Incident 
(n=31) 
Recovery 
(n=23) 
Persistent 
(n=32) 
Male sex, %  44.9 54.8 52.2 50.0 
Age, years Baseline 36.5±0.6 36.3±0.7 36.8±0.5 36.7±0.6 
 Follow-up 42.6±0.6 42.4±0.7 42.8±0.6 42.7±0.6 
Traits of the Metabolic Syndrome     
 Systolic blood pressure, mmHg Baseline 113.6±10.3 120.2±10.7 121.3±8.7 126.9±14.6 
 Follow-up 113.5±10.1 124.5±15.3 117.6±11.2 125.0±17.0 
 Diastolic blood pressure, mmHg Baseline 63.1±6.5 67.6±6.9 69.2±6.2 71.1±7.5 
 Follow-up 68.7±7.8 75.7±7.9 71.2±6.1 75.1±7.6 
 Waist circumference, cm Baseline 75.7±7.8 81.5±9.7 85.1±13.2 90.2±8.2 
 Follow-up 80.6±8.6 88.1±8.7 87.8±13.0 96.2±10.1 
 HDL cholesterol, mmol/L Baseline 1.48±0.35 1.44±0.33 1.12±0.26 1.09±0.25 
 Follow-up 1.81±0.42 1.63±0.39 1.54±0.32 1.36±0.36 
 Triglycerides, mmol/L Baseline 0.9 [0.7; 1.3] 1.2 [0.8; 1.5] 1.7 [1.1; 2.1] 1.8 [1.5; 2.9] 
 Follow-up 0.8 [0.7; 1.1] 1.5 [1.1; 2.1] 1.0 [0.7; 1.2] 1.6 [1.1; 2.4] 
 Glycated hemoglobin, % Baseline 5.2±0.4 5.3±0.4 5.4±0.4 5.5±0.4 
 Follow-up 5.3±0.2 5.7±0.9 5.4±0.2 5.6±0.3 
Other risk factors      
 Body mass index, kg/m² Baseline 23.2±2.6 24.9±2.8 26.3±3.7 28.0±3.0 
 Follow-up 23.6±2.9 25.9±2.6 26.4±3.9 29.2±4.0 
 LDL-cholesterol, mmo/L Baseline 2.89±0.80 3.24±0.84 3.33±0.93 3.42±0.88 
 Follow-up 2.70±0.74 2.89±0.94 3.25±0.93 2.94±0.78 
 Smokers, % Baseline 19.8 19.4 17.4 43.8 
 Follow-up 12.1 22.6 17.4 28.1 
 Alcohol drinkers, % Baseline 89.4 93.5 91.3 78.1 
 Follow-up 92.8 93.5 95.7 81.3 
 Physical activity, 10³METs/wk Baseline 4.2 [2.6-6.3] 4.1 [2.2-6.4] 4.1 [3.4-6.7] 4.0 [2.6-6.5] 
 Follow-up 2.7 [2.3-3.1] 2.6 [2.3-3.1] 2.6 [2.4-3.3] 2.7 [2.1-3.1] 
Anti-hypertensive treatment, % Baseline 1.0 0.0 4.3 9.7 
 Follow-up 1.9 6.5 0.0 18.9 
Carotid artery properties      
 Inter-adventitial diameter, mm Baseline 6.81±0.55 7.08±0.46 7.00±0.57 7.07±0.83 
 Follow-up 7.01±0.62 7.31±0.56 7.20±0.55 7.51±1.00 
 Lumen diameter, mm Baseline 5.57±0.54 5.79±0.46 5.78±0.58 5.79±0.79 
 Follow-up 5.71±0.62 5.95±0.50 5.91±0.52 6.11±0.92 
 Intima-media thickness, mm Baseline 0.62±0.10 0.64±0.10 0.61±0.06 0.64±0.12 
 Follow-up 0.65±0.11 0.68±0.14 0.64±0.11 0.70±0.13 
 Wall cross-sectional area, mm2 Baseline 12.1±2.3 13.0±2.2 12.2±1.6 12.9±3.2 
 Follow-up 13.0±2.6 14.2±3.3 13.3±2.7 15.2±4.2 
 Circumferential wall tension, 
kPa 
Baseline 29.9±4.7 32.7±4.4 33.2±5.4 34.8±7.4 
 Follow-up 31.3±5.6 35.8±4.9 34.0±4.1 36.7±7.5 
 Circumferential wall stress, kPa Baseline 49.1±11.4 52.1±10.8 55.5±12.5 55.9±14.2 
 Follow-up 49.9±13.1 54.4±11.0 54.0±10.0 53.6±12.9 
 Young’s elastic modulus, 
103•kPa 
Baseline 0.43±0.12 0.46±0.13 0.46±0.15 0.50±0.14 
 Follow-up 0.44±0.15 0.52±0.14 0.50±0.14 0.56±0.20 
Data are percentage, mean ± SD or median [inter-quartile range] 
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Table 2. Comparison of carotid artery properties across categories of changes in metabolic syndrome status 
Dependent  
variable 
Independent 
variable:  MetS 
status 
Baseline  Follow-up  6-year  
 95%CI   95%CI   95%CI 
IAD, mm incident 0.202 -0.001; 0.405  0.247 0.045; 0.448*  0.045 -0.097; 0.186 
 recovery 0.137 -0.094; 0.368  0.139 -0.093; 0.371  0.002 -0.159; 0.163 
 persistent 0.209 0.007; 0.410*  0.477 -0.278; 0.677‡  0.268 0.128; 0.408‡ 
LD, mm incident 0.158 -0.039; 0.353  0.187 -0.009; 0.382  0.029 -0.121; 0.179 
 recovery 0.164 -0.059; 0.388  0.152 -0.072; 0.377  -0.012 -0.183; 0.158 
 persistent 0.183 0.002; 0.364*  0.374 0.180; 0.567‡  0.191 0.042; 0.339† 
IMT, mm incident 0.020 -0.021 0.061  0.029 -0.012; 0.070  0.009 -0.032; 0.050 
 recovery -0.017 -0.064; 0.030  -0.010 -0.057; 0.037  0.007 -0.040; 0.054 
 persistent 0.010 -0.031; 0.051  0.051 0.011; 0.092*  0.041 0.001; 0.082* 
CSAIMT, mm
2 incident 0.78 -0.18; 1.73  1.09 0.14; 2.05*  0.33 -0.53; 1.18 
 recovery -0.04 -1.13; 1.06  0.14 -0.96; 1.23  0.17 -0.80; 1.14 
 persistent 0.63 -0.33; 1.58  2.03 1.05; 3.00‡  1.43 0.59; 2.28† 
CWT, kPa incident 2.22 0.52; 3.92*  3.97 2.28; 5.67‡  1.75* 0.29; 3.21 
 recovery 3.01 1.07; 4.96†  2.11 0.16; 4.06*  -0.90 -2.57; 0.76 
 persistent 5.11 3.39; 6.84‡  5.49 3.76; 7.22‡  0.38 -1.11; 1.87 
CWS, kPa incident 1.77 -2.46; 5.99  3.75 -0.57; 7.84  1.98 -2.28; 6.24 
 recovery 5.77 0.94; 10.58*  3.52 -1.31; 8.37  -2.25 -7.10; 2.60 
 persistent 7.21 2.91; 11.51†  4.41 0.09; 8.73*  -2.80 -7.11; 1.52 
YEM, 103•kPa incident 0.015 -0.037; 0.067  0.068 0.016; 0.120*  0.050 -0.008; 0.109 
 recovery 0.018 -0.041; 0.077  0.049 -0.011; 0.109  0.031 -0.038; 0.098 
 persistent 0.060 0.007; 0.113*  0.117 0.066; 0.168‡  0.048 -0.011; 0.107 
, regression coefficient: indicates differences in carotid artery property as compared with referent group (i.e. 
never); CI, confidence interval;  
IAD, inter-adventitial diameter; LD, lumen diameter; IMT, intima-media thickness; CSAIMT, wall cross-sectional 
area; CWT, circumferential wall tension; CWS, circumferential wall stress; YEM, Young’s elastic modulus;  
*p<0.05, †p<0.01, ‡p<0.001; all data are adjusted for age, sex, body height and (changes in) smoking status, 
alcohol consumption, physical activity, LDL-cholesterol and use of anti-hypertensive medication.   
 
Associations Between (Changes in) MetS Traits and (Changes in) Carotid Properties 
The associations of each trait of the MetS and their changes (as continuous variables) with 
(changes in) carotid artery properties are shown in Table 3 and can be summarized as 
follows. At baseline, higher levels of IAD and LD were primarily determined by higher 
levels of waist circumference, whereas higher levels of CWT, CWS, and YEM were 
determined by both higher levels of waist and BP; none of the traits of the MetS were 
associated with increased IMT, however. During the course of follow-up, increases in waist 
circumference also determined steeper increases in IAD, LD, and YEM, and increases in BP 
were main determinants of increases in these properties but also of CWT and CWS. 
Interestingly, increases in IMT were determined only by increases in HbA1c, which was 
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also implicated in steeper increases in IAD and CSAIMT. Changes in blood lipids did not 
affect changes in arterial properties. 
 
Table 3. Associations between (changes in) each metabolic syndrome trait and (changes in) carotid artery 
properties 
Independent  
variable: 
MetS trait Time 
Dependent variable 
IAD 
(mm) 
LD 
(mm) 
IMT 
(mm) 
CSAIMT 
(mm2) 
CWT 
(kPa) 
CWS 
(kPa) 
YEM 
(103•kPa) 
Systolic blood 
pressure 
  
Baseline -0.005 -0.016 0.008 0.15 2.62‡ 3.81‡ 0.039‡ 
Follow-up 0.091‡ 0.070† 0.015† 0.52‡ 3.51‡ 4.30‡ 0.078‡ 
∆ per 
year 
0.016‡ 0.014† 0.001 0.06* 0.15‡ 0.08 0.006‡ 
Diastolic blood 
pressure 
  
Baseline 0.035 0.018 0.010 0.27* 2.74‡ 3.85‡ 0.040‡ 
Follow-up 0.094‡ 0.085‡ 0.008 0.36† 3.68‡ 5.23‡ 0.074‡ 
∆ per 
year 
0.010* 0.011† -0.000 0.02 0.16‡ 0.23* 0.006‡ 
Waist 
circumference 
  
Baseline 0.066* 0.058* 0.005 0.23 1.19‡ 1.81† 0.019* 
Follow-up 0.118‡ 0.102‡ 0.009 0.46† 1.51‡ 1.74† 0.045‡ 
∆ per 
year 
0.009* 0.007* 0.001 0.04 0.05 -0.01 0.004† 
HDL-cholesterol 
  
Baseline -0.018 -0.021 0.001 -0.01 -0.43 -0.78 -0.008 
Follow-up -0.002 -0.012 0.004 0.05 -0.39 -0.75 -0.011 
∆ per 
year 
0.003 0.002 0.001 0.01 0.01 0.00 -0.000 
Ln-triglycerides Baseline -0.005 0.005 -0.003 -0.06 0.58* 1.23* 0.014 
Follow-up 0.040 0.053* -0.004 0.03 0.60† 1.13 0.023† 
∆ per 
year 
0.008 0.008 -0.000 0.02 0.00 -0.02 0.002 
Glycated 
hemoglobin 
Baseline -0.034 -0.014 -0.007 -0.22 -0.19 0.27 0.000 
Follow-up 0.016 0.003 0.005 0.13 0.10 -0.27 0.005 
∆ per 
year 
0.009* 0.007 0.002* 0.06* 0.05 -0.09 0.001 
Data are standardized regression coefficients and indicate the differences in carotid artery property per SD 
increase in MetS trait; this enables comparison of the strength of the associations with carotid properties 
between traits; CI, confidence interval;  
IAD, inter-adventitial diameter; LD, lumen diameter; IMT, intima-media thickness; CSAIMT, wall cross-sectional 
area; CWT, circumferential wall tension; CWS, circumferential wall stress; YEM, Young’s elastic modulus;  
*p<0.05, †p<0.01, ‡p<0.001; all data are adjusted for age, sex, body height and (changes in) smoking status, 
alcohol consumption, physical activity, LDL-cholesterol and use of anti-hypertensive medication.   
 
Additional Analyses 
When, as suggested (23), CWT and CWS were calculated at levels of DBP instead of MAP 
(because IMT and IAD are measured in diastole), we observed essentially the same 
patterns of changes and differences across groups as reported above (please see Figure 
S2). 
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Discussion 
 
The main finding of our study is that individuals with persistent MetS, as compared with 
individuals who never had the MetS, displayed significantly steeper increases in IMT and 
CSAIMT during the course of follow-up that were preceded by elevated levels of IAD, LD, 
YEM, and CWT and CWS already at baseline. This suggests that, among young individuals 
without overt signs of atherosclerosis, arterial enlargement and stiffening may precede 
and favor subsequent wall thickening to restore normal levels of wall tensile stress. 
Indeed, during the course of follow-up, IAD and LD increased further, and CWS tended to 
decrease among individuals with persistent MetS, although it remained significantly higher 
than that observed in individuals who never developed the MetS. Therefore, this pattern 
of arterial outward remodeling remained, to an important extent, maladaptive. Notably, in 
individuals who recovered from the MetS, all of the carotid artery properties were 
restored to levels that no longer differed from those who never developed the MetS. This 
is an important observation, because it points toward the reversibility of a pathobiological 
process that, if not interrupted in time, may carry adverse health consequences, such as 
stroke. To our knowledge, this is the first study that has examined, with a truly 
longitudinal design, the life course and temporal relationships between carotid artery 
structural and functional properties and local hemodynamic factors as a function of 
changes in the MetS. Being conducted among apparently healthy and young adults, our 
findings likely describe the early stages of accelerated arterial aging related to the MetS. 
 
Changes in carotid IMT and distension as a function of changes in MetS over the course of 
6 years among apparently healthy adults of comparable age have been reported recently 
in a large (n=1673), population-based study (24). Our findings are in agreement with this 
study, regarding the following: 1. the rates of changes in MetS status (never [74% versus 
71%], incident [12% versus 11%], recovery [4% versus 8%], and persistent [10% versus 
11%], respectively); 2. the patterns of changes in MetS traits (eg, steeper increase in DBP 
than SBP), even those that, at first glance, could seem counterintuitive (eg, overall 
increases in mean levels of high-density lipoprotein cholesterol with aging); and 3. the 
patterns of changes in IMT that were also steeper in those with persistent 
MetS only. We, thus, believe our findings, despite having been obtained with an adapted 
criterion to define MetS and in a smaller sample, do reflect true MetS-related arterial 
changes that occur in the course of young adult life. Data on concomitant changes in 
arterial diameter and hemodynamic forces were not provided in that study, however, thus 
not enabling the appreciation of MetS-related arterial remodeling processes.  
 
Chapter 5 
 
106 
 
 
Figure. Trajectories of changes in carotid artery properties by categories of change in metabolic syndrome status. 
A, IAD indicates interadventitial diameter. B, LUMEN D indicates lumen diameter. C, IMT indicates intima-media 
thickness. D, CSAIMT indicates wall cross-sectional area. E, CWT indicates circumferential wall tension. F, CWS 
indicates circiumferential wall stress. G, YEm indicates Young’s elastic modulus. All data are adjusted for sex, 
height and (changes in) age, smoking status, alchohol consumption, physical activity, low-density lipoprotein 
cholesterol, and use of antihypertensive medication; exact magnitude and statistical significance of differences 
between groups are given in Table 2. o, never; •, incident; , recovery; , persistent 
 
Our study investigated these variables and raised the question of whether increases in 
IMT in the context of persistent MetS reflect atherosclerosis, concluding that wall 
thickening could primarily reflect an adaptive mechanism that attempted to restore local 
hemodynamic conditions to an equilibrium rather than atherosclerosis, per se. Indeed, it 
has been proposed that, at levels < 0.9 mm, increases in IMT may reflect adaptive arterial 
remodeling (6,25). Still, because the observed pattern of outward remodeling was 
maladaptive, our findings may have implications for cardiovascular risk, particularly 
stroke. Indeed, 3 different patterns of arterial remodeling have been identified: inward 
(decrease in LD resulting from greater increase in IMT than IAD), outward (increase in LD 
because of greater change in IAD than IMT), and compensatory (LD preservation despite 
changes in IAD and IMT) (26). Of these, inward and outward have been linked to stable 
and unstable plaque formation, respectively (26,27). In addition, among several carotid 
geometric patterns, a pattern of hypertrophy with dilation, which is, thus, equivalent to 
the outward remodeling described in the present study, was also linked to the highest 
incidence of cardiovascular disease among elderly participants of the Cardiovascular 
Health Study (28). Although the extent to which young adults with the MetS showing signs 
of maladaptive outward remodeling are more likely to develop such kind of 
atherosclerotic complications later in life is not known, these observations emphasize the 
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clinical relevance of our findings. It further stresses the potential need for early preventive 
measures, because we observed that recovery from MetS led to reversibility of 
maladaptive outward remodeling. This resulted from beneficial changes in MetS traits, in 
particular, DBP, waist circumference, and HbA1c (Table S3 and Figure S3), all of which 
contributed also to arterial adaptations (Table 3).  
 
Because of the longitudinal design, we obtained a better insight into the sequence of 
carotid structural and functional adaptations related to the MetS. The observation that 
persistent MetS was not only associated with increased IAD and LD but also YEM (a 
marker of the elastic properties of the arterial wall material) already at baseline, suggests 
that loss of elasticity at the level of the media layer (ie, arteriosclerosis) could explain the 
arterial enlargement of individuals with the MetS. Consequently, the subsequent increases 
in IMT and CSAIMT could reflect wall changes occurring primarily at the level of the media 
rather than the intima (atherosis) layer. 
Increases in CSAIMT (although not IMT) were related to changes in SBP, and increases in 
IAD and LD were associated with both changes in SBP and DBP but more strongly with the 
former than the latter (Table 3). This points toward a stronger impact of the pulsatile 
component of BP on arterial remodeling. Indeed, when we additionally examined the 
extent to which the steeper increases in IAD, LD, IMT, and CSAIMT observed among 
individuals with persistent MetS could be explained by concomitant changes in BP, we 
observed that these were not affected when further adjusted for changes in DBP but were 
somewhat attenuated when adjusted for changes in local pulse pressure Table S4). 
Transmural pressure exerts a fatiguing effect on the load bearing elements of the arterial 
wall (ie, elastin and collagen), leading to degenerative changes and fracture of the 
extracellular matrix component that result in arterial enlargement (23). Nevertheless, the 
steeper increases in IAD, LD, IMT, and CSAIMT in individuals with persistent versus never 
MetS remained statistically significant after adjustments for BP, suggesting that other 
factors may be involved. Indeed, we observed that increases in these arterial properties 
were also determined by changes in HbA1c. This could reflect underlying cross-links 
between molecules in the arterial wall because of advanced-glycation end products, 
thereby contributing directly to accelerated arterial stiffening, as commonly observed 
among patients with (pre)diabetes mellitus (3). However, HbA1c was not related to YEM, a 
marker of the intrinsic elastic wall material. In addition, metabolic factors related to 
central adiposity, yet another MetS trait related to changes in IAD, LD, and YEM, can also 
play an additional disrupting role in the intricate process of arterial remodeling. These may 
include adipocytokine or systemic inflammatory factors, oxidative stress, vascular smooth 
muscle cell growth, and stimulation of the sympathetic nervous system (3,16). All together 
these observations suggest that clustering of elevated BP, abdominal obesity, and 
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impaired glucose metabolism may constitute a phenotype with the most adverse impact 
on arterial properties. This is in line with earlier cross-sectional observations (9), but 
because of the relatively small sample of the present study, we could not examine arterial 
changes associated with specific clusters of MetS traits further.  
 
There are additional limitations to our study. First, ultrasound does not distinguish the 
intima from the media layers of the carotid wall, thus not enabling full insight on whether 
wall thickening related to MetS was particularly associated with atherosis (intima) or 
arteriosclerosis (media). Second, IMT was measured at one arterial site, and although we 
took measures to ensure that follow-up examinations did not differ from baseline in this 
regard, at both time points, our measures do not capture possible variability in IMT along 
the arterial wall. Third, although good levels of reproducibility were obtained between 
observers involved in the baseline (I.F.) and the follow-up (F.S.) examinations, data on 
changes in arterial properties may have been obtained with some error. If anything, this 
may have led to an underestimation of the associations reported herein, because both at 
baseline and at follow-up observers were unaware of participants’ metabolic risk profiles 
(ie, nondifferential error). Fourth, the prevalence of the MetS as reported herein may not 
compare directly with that obtained with standard definitions, because it was estimated 
on the basis of risk factor distribution within the study population. Still, it served the 
purpose of identification of a phenotype (clustering of elevated MetS traits) and its change 
over time, which is suitable for the study of an etiologic research question, that is, its 
association with arterial remodeling. Last, our findings were obtained in relatively young 
and apparently healthy white adults and should be interpreted with caution with regard to 
older and higher-risk populations and other ethnicities. 
 
Perspectives 
 
We identified a pattern of outward carotid remodeling (ie, diameter widening and wall 
thickening, in this order) among individuals with persistent versus never MetS over the 
course of 6-year follow-up. This process was maladaptive because, despite remodeling, 
wall tensile stress was not restored to levels comparable to those who never had the 
MetS. Importantly, reversibility of maladaptive outward remodeling was achieved by 
recovery from the MetS. Maladaptive carotid remodeling may carry important 
implications for cardiovascular risk, particularly stroke. Prospective studies investigating 
the link between patterns of arterial remodeling in young adults with future 
cardiovascular outcome are further needed, to decide on the usefulness of screening and 
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implementation of appropriate preventive measures likely to deter related cardiovascular 
sequelae. 
 
Novelty and Significance 
What Is New? 
 We studied changes in carotid structural, functional, and local hemodynamic 
factors as a function of changes in MetS status over the course of 6-years follow-
up. 
 Given the longitudinal design, we could examine the temporal relationships 
between diameter and wall thickening and concomitant hemodynamic factors. 
What Is Relevant? 
 We observed the development of a pattern of maladaptive outward carotid 
remodeling among individuals with persistent MetS and a similar trend among 
individuals with incident MetS. 
 Recovery from the MetS restored initial adverse carotid adaptations to levels 
comparable to those who never developed the MetS. Wall thickening was 
preceded by wall widening. 
Summary 
 The development of maladaptive outward remodeling may explain the increased 
risk of cardiovascular disease, in particular, stroke, in individuals with the MetS. 
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-ONLINE SUPPLEMENT 
 
CLUSTERING OF METABOLIC SYNDROME TRAITS IS ASSOCIATED WITH MALADAPTIVE 
CAROTID REMODELING AND STIFFENING: A 6‐YEAR LONGITUDINAL STUDY 
 
Isabel Ferreira, Hanneke J. Beijers, Fleur Schouten, Yvo M. Smulders, Jos W. Twisk, Coen D. 
Stehouwer 
 
METHODS 
Carotid artery properties were assessed according to guidelines for user procedures and 
with the use of reproducible and valid methods and devices [Ultrasound scanner + Wall 
Track System 2 (WTS2), Pie Medical, Maastricht, the Netherlands] (1,2). Measures 
obtained in the year 2006 (by FS) (3) followed the exact same protocol as conducted in 
2000 (by IF, described in detail before(4-7)), with good levels of interobserver 
reproducibility (Table S1) (3). 
Briefly, all subjects abstained from smoking and caffeine-containing beverages on the day 
the 
measurements were performed, and these started after subjects had been resting in 
supine position for 15 min in a quiet, temperature-controlled, room. We obtained 
measurements of inter-adventitial 
diameter (IAD, in diastole), distension (ΔD, i.e. the systolic-diastolic variation in IAD) and 
intima-media thickness (IMT) as detailed elsewhere (1). The right common carotid artery 
was measured ~10 mm proximal to the beginning of the bulb; placement of the M-line 
was video-recorded and a print-out was obtained in order to ensure that follow-up 
measures, as obtained in 2006, were obtained at the exact same site (3). The means of 3 
measurements of IAD, ΔD and IMT were used in the analyses. 
 
Statistical analyses 
A simplification (without covariates adjustments) of the longitudinal models used in the 
present study is presented below (8): 
Dependent variable = ß0 + (ß1 x incident MetS) + (ß2 x recovery MetS) + (ß3 x persistent 
MetS) + (ß4 x time) + (ß5 x incident MetS x time) + (ß6 x recovery MetS x time) + (ß7 x 
persistent MetS x time) 
 
…where: 
ß0 = intercept (level of dependent variable in the never MetS group at time=0); 
ß1 = difference in dependent variable between incident MetS and never MetS groups at 
time=0; 
ß2 = difference in dependent variable between recovery MetS and never MetS groups at 
time=0; 
ß3 = difference in dependent variable between persistent MetS and never MetS groups at 
time=0; 
ß4 = change in dependent variable per year in the never MetS group; 
Metabolic syndrome and carotid remodeling in young adults 
 113 
ß5 = difference in 6-yr change in the dependent variable between incident MetS and never 
MetS groups; 
ß6 = difference in 6-yr change in the dependent variable between incident MetS and never 
MetS groups; 
ß7 = difference in 6-yr change in the dependent variable between incident MetS and never 
MetS groups; 
The value of the dependent variable at follow-up (i.e.t=6) for each group, can be 
estimated as: 
- ß0 + (6 x ß4) in the never MetS group: 
- ß1 + (6 x ß4) + ß5 in the incident MetS: 
- ß2 + (6 x ß4) + ß6 in the recovery MetS group; and by 
- ß3 + (6 x ß4) + ß7 in the persistent MetS group; 
Categories of change in MetS status was treated as dummy variable with never MetS as 
referent group. 
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Table S1. Inter-observer reproducibility of carotid artery properties 
Carotid artery 
property 
Observers  Differences between observers 
IF  FS  FS-IF 
Mean SD  Mean SD  Mean  SE 95%CI p-value ICC CV% 
Diameter, μm 6,475 481  6,493 451  16 88 -156; 188 0.859      0.93 2.7 
Distension, μm 550 206  523 204  -28 26 -78; 22 0.278 0.97 9.5 
IMT, μm 622 68  585 69  -35 20 -74; 4 0.080 0.77 6.2 
Data refers to a pilot-reproducibility study conducted prior to the follow-up examination between the observers 
who collected the baseline (IF) and the follow-up (FS) arterial data [n=8 (4 women); each ovserver obtained 3 
repeated measures of each property on each subject)]; ICC, intra-class correlation coefficient; CV, coefficient of 
variation. 
 
 
Table S2. Sex-specific cut-off values for each trait of the metabolic syndrome corresponding to the lower bound 
of the highest quartile (lowest for HDL-cholesterol) 
Trait of the metabolic syndrome Men Women 
   Systolic/diastolic blood pressure, mm Hg 128/72 117/67 
   Waist circumference, cm 90.1 76.5 
   HDL cholesterol, mmol/L 1.02 1.35 
   Triglycerides, mmol/L  1.9 1.3 
   Glycated hemoglobin, % 5.6 5.5 
  
 
 
FIGURE S1 Distribution of risk factor sums in the AGAHLS at baseline and at follow-up; bars represent observed 
frequencies and line represents the expected frequencies (from the binomial probability equations). 
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Table S3. Comparison of levels of metabolic syndrome’s traits across categories of changes in metabolic 
syndrome status 
Dependent variable 
Independent 
variable: 
 MetS status 
Baseline  Follow-up  6-year  
 95%CI   95%CI   95%CI 
SBP, mm Hg incident 5.4 2.1; 8.8†  10.1 5.2; 14.9‡  4.7 0.2; 9.1* 
 regressed 6.5 3.8; 9.3‡  3.2 -0.9; 7.2  -3.4 -8.2; 1.5 
 persistent 13.4 8.3; 18.5‡  11.2 5.2; 17.2‡  -2.2 -6.9; 2.5 
DBP, mm Hg incident 3.9 1.7; 6.2†  6.6 4.1; 9.1‡  2.7 0.3; 5.0* 
 regressed 5.3 2.9; 7.6‡  2.5 0.1; 4.9*  -2.8 -5.7; 0.1 
 persistent 8.2 5.4; 11.0‡  6.1 3.1; 9.2‡  -2.1 -4.5; 0.4 
WAIST, cm incident 3.9 1.7; 6.1†  6.2 4.2; 8.1‡  2.3 0.7; 3.9† 
 regressed 8.4 4.3; 12.4‡  6.0 1.9; 10.1†  -2.4 -4.0; -0.8† 
 persistent 13.9 11.3; 16.5‡  15.9 13.1; 18.7‡  2.0 0.1; 4.0* 
HDL, mmol/L incident 0.01 -0.10; 0.12  -0.14 -0.27; -0.01*  -0.15 -0.26; -0.04† 
 regressed -0.32 -0.43; -0.22‡  -0.23 -0.36; -0.10‡  0.09 -0.01; 0.19 
 persistent -0.35 -0.43; -0.26‡  -0.42 -0.53; -0.30‡  -0.07 -0.16; 0.01 
TRIG, mmol/L incident 1.09 0.93; 1.28  1.65 1.37; 1.99‡  1.51 1.29; 1.78‡ 
 regressed 1.67 1.43; 1.94‡  1.03 0.89; 1.20  0.62 0.50; 0.77‡ 
 persistent 2.00 1.69; 2.38‡  1.82 1.50; 2.22‡  0.92 0.78; 1.09 
HbA1c, % incident 0.14 -0.01; 0.29  0.36 0.03; 0.68*  0.22 -0.12; 0.55 
 regressed 0.27 0.11; 0.42†  0.03 -0.05; 0.11  -0.23 -0.37; -0.09† 
 persistent 0.29 0.13; 0.45†  0.31 0.20; 0.41‡   0.02 -0.12; 0.15 
, regression coefficient: indicates differences in levels of each trait of the metabolic syndrome as compared with 
referent group (i.e. never); CI, confidence interval;  
SBP, systolic blood pressure; DBP, diastolic blood pressure; WAIST, waist circumference, HDL, high-density 
lipoprotein cholesterol; TRIG, triglycerides; HbA1c, glycated hemoglobin; 
*p<0.05, †p<0.01, ‡ p<0.001; all data are adjusted for age, sex, body height and (changes in) smoking status, 
alcohol consumption, physical activity, low-density lipoprotein cholesterol and use of anti-hypertensive 
medication.   
Note that because triglycerides were loge transformed, differences (vs. reference group) are expressed as ratios. 
 
  
Table S4. 6-year changes in carotid structure properties by groups of change in MetS status, after further adjustments for changes in blood pressure 
Dependent  
variable 
Independent variable:  
 MetS status 
As reported in our 
manuscript§ 
 
+ adjustment for changes in 
DBP 
 + adjustment for  
changes in MBP 
 + adjustment for changes 
in local PP 
 95%CI   95%CI   95%CI   95%CI 
IAD, mm incident 0.045 -0.097; 0.186  0.006 -0.142; 0.151  -0.001 -0.147; 0.145  -0.031 -0.172; 0.109 
 recovery 0.002 -0.159; 0.163  0.006 -0.158; 0.171  -0.001 -0.163; 0.162  -0.005 -0.163; 0.153 
 persistent 0.268 0.128; 0.408‡  0.254 0.106; 0.403†  0.245 0.097; 0.394†  0.218 0.078; 0.359† 
             
LD, mm incident 0.029 -0.121; 0.179  0.018 -0.121; 0.179  -0.021 -0.175; 0.134  0.027 -0.123; 0.178 
 recovery -0.012 -0.183; 0.158  0.006 -0.183; 0.158  -0.028 -0.200; 0.145  -0.007 -0.177; 0.162 
 persistent 0.191 0.042; 0.339†  0.203 0.054; 0.352†  0.155 0.002; 0.308*   0.158 0.008; 0.309* 
             
IMT, mm incident 0.009 -0.032; 0.050  0.013 -0.029; 0.055  0.009 -0.033; 0.051  0.001 -0.040; 0.042 
 recovery 0.007 -0.040; 0.054  0.017 -0.031; 0.064  0.013 -0.035; 0.060  0.005 -0.042; 0.051 
 persistent 0.041 0.001; 0.082*  0.053 0.010; 0.095*  0.048 0.006; 0.091*  0.034 -0.005; 0.020 
             
CSAIMT, mm
2 
incident 0.33 -0.53; 1.18  0.30 -0.58; 1.18  0.20 -0.68; 1.08  0.13 -0.71; 0.98 
recovery 0.17 -0.80; 1.14  0.35 -0.64; 1.34  0.25 -0.73; 1.23  0.14 -0.82; 1.10 
persistent 1.43 0.59; 2.28†  1.60 0.71; 2.49‡  1.48 0.59; 2.37†  1.16 0.32; 2.01† 
, regression coefficient: indicates differences in carotid artery property as compared with referent group (i.e. never); CI, confidence interval;  
IAD, inter-adventitial diameter; LD, lumen diameter; IMT, intima-media thickness; CSAIMT, wall cross-sectional area; CWT, circumferential wall tension; CWS, circumferential 
wall stress; YEM, Young’s elastic modulus;  
DBP, diastolic blood pressure; MBP, mean blood pressure; PP, pulse pressure; 
*p<0.05, †p<0.01, ‡p<0.001; § as reported in Table 2 of our manuscript; all data are adjusted for sex, body height and (changes in) age, smoking status, alcohol consumption, 
physical activity, LDL-cholesterol and use of anti-hypertensive medication.   
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FIGURE S2 Trajectories of changes in A) circumferential wall tension (CWT) and B) circumferential wall stress 
(CWS) when both hemodynamic variables were estimated at diastolic levels of blood pressure; 
Data are adjusted for sex, body height and (changes in) age, smoking habits, alcohol consumption, physical 
activity, LDL-cholesterol and use of anti-hypertensive medication 
 
 
 
FIGURE S3. Trajectories of changes in metabolic syndrome traits by categories of change in metabolic syndrome 
status; A: systolic blood pressure (SBP); B: diastolic blood pressure (DBP); C: waist circumference (WAIST); D: 
HDL-cholesterol (HDL); E: triglycerides (TRIG); and F: glycated hemoglobin (HbA1c).  
Data are adjusted sex, body height and (changes in) age, smoking status, alcohol consumption, physical activity, 
LDL-cholesterol and use of anti-hypertensive medication (the exact magnitude and statistical significance of 
differences between groups are given in Table S3). 
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Abstract 
 
Objective —The association between obesity and cardiovascular disease and venous 
thromboembolism might, at least partially, be explained by a hypercoagulable state. The 
extent to which body fat mass and its distribution contribute to a hypercoagulable state is 
unknown. In this study, we investigated the association between body composition and 
thrombin generation and evaluated the potential mediating role of low-grade 
inflammation. 
 
Methods and Results—We studied 586 individuals from the Hoorn Study (mean age, 69.7 
± 6.5 years, 298 women) in whom body composition was assessed by whole body dual-
energy absorptiometry. Thrombin generation was measured using the Calibrated 
Automated Thrombogram. Multiple regression analyses showed a positive association 
between total body fat and thrombin generation in women but not in men. In addition, 
detailed analyses of regional body composition showed that central but not peripheral fat 
mass was associated with greater thrombin generation and that there was a trend toward 
an inverse association with peripheral lean mass. The reported positive associations were 
partially attenuated by low-grade inflammation, however. 
 
Conclusion — Body fat mass, in particular a central pattern of fat distribution, is associated 
with higher levels of thrombin generation in elderly women but not in men. This 
association may partially be explained by adiposity-related low-grade inflammation, but 
this hypothesis needs to be further investigated in mechanistic/prospective studies. 
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Introduction 
 
Obesity, in particular central obesity, is associated with cardiovascular disease (CVD) (1,2) 
Recent evidence also suggests an association between (central) obesity and incident 
venous thromboembolism (3,4). One proposed mechanism that could explain these 
associations, at least in part, is a hypercoagulable state in obese individuals (5). Indeed, 
thrombin is one of the key players in the coagulation cascade (6), and in vivo markers of 
thrombin generation have been positively associated with waist circumference in 
postmenopausal women (7). 
 
Recently, several new methods have become available that quantitatively measure 
thrombin generation in vitro after activation of the coagulation cascade with tissue factor 
(TF), phospholipids, and calcium chloride (CaCl2) (8). The Calibrated Automated 
Thrombogram (CAT) method is one such method (9). Specifically, it generates a thrombin 
generation curve that mimics the overall plasma coagulability potential when a 
thrombogenic stimulus appears (Figure 1A). This curve is characterized by a lag (initiation) 
phase, followed by a thrombin burst (propagation), which is then eventually completely 
inhibited by plasma protease inhibitors (termination). The endogenous thrombin potential 
(ETP), or the area under this curve, represents the total amount of active thrombin that is 
formed after activation of the coagulation cascade. The ETP has been shown to be a good 
indicator of a hypercoagulable state in, for example, individuals using oral contraceptives 
or with (prior) venous thromboembolism or circulating lupus anticoagulants (9–12). 
 
Evidence so far linking obesity to an individual’s coagulation potential assessed by this 
new method is very scarce and confined to children and adults with morbid obesity 
(13,14). In addition, the extent to which total fat mass and its distribution contribute to or 
protect against a hypercoagulable state is not known. It is also unknown what adiposity-
related underlying mechanisms may explain any such associations, but low-grade 
inflammation is a likely candidate in this regard. Indeed, levels of high-sensitivity C-
reactive protein (hsCRP) are increased in overweight and obese individuals (15), and in 
vivo, C-reactive protein infusion has been associated with increased thrombin generation 
(assessed by activation markers) (16).  
 
In view of these considerations, we investigated, in a large population-based cohort, the 
association between body composition and thrombin generation in plasma and evaluated 
whether any such associations were independent of other “traditional” cardiovascular risk 
factors, such as hypertension, dyslipidemia, smoking, and glucose metabolism status. In 
addition, we evaluated the potential “mediating” role of hsCRP in any such associations.  
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Methods 
 
Study Population 
The Hoorn Study is a population-based cohort study of glucose metabolism and its 
complications, which started in 1989, as described in detail elsewhere (17–19). Briefly, a 
random sample of 50- to 75-year-old subjects was taken from the population register of 
Hoorn (59,000 inhabitants) in the Netherlands. Of the 3553 subjects invited, 2540 (71.5%) 
agreed to participate, of whom 56 were excluded from analyses because they were 
nonwhite. The original Hoorn Study cohort thus consisted of 2484 subjects (18). Between 
1996 and 1998, a 2nd examination (1st follow-up) was carried out. From the initial cohort, 
150 people had died and 108 had moved out of Hoorn before 1996. One hundred forty 
other people were not invited because of logistical reasons. Of the remaining 2086 people 
who were invited for the follow-up examination, 1513 (72.5%) participated (17). In 2000–
2001, a 3rd examination was carried out among surviving participants who gave their 
permission to be recontacted. Specifically, we invited all participants who had diabetes, as 
determined by a 75-g oral glucose tolerance test or by diabetes treatment (n=176), and a 
random sample of participants who had normal (n=705) or impaired glucose tolerance 
(n=193) at the 2nd examination. Of the 1074 individuals invited, 648 (60.3%) participated. 
The main reasons for nonparticipation in the 2000–2001 follow-up examination were lack 
of interest (30%) or comorbidity (23%). Other reasons were high age (7%), unwillingness 
to travel (6%), participation considered too time-consuming (6%), and miscellaneous 
reasons (15%); 13% gave no reason (19). 
 
Detailed measurements of participants’ body composition by means of dual-energy x-ray 
absorptiometry (DXA) and thrombin generation parameters were obtained, for the first 
time, during the 3rd examination. Therefore, for the present study, cross-sectional 
analyses of data from this examination were conducted. We excluded 62 participants from 
the analyses for the following reasons: use of cumarin derivatives (n=24), and/or use of 
hormonal replacement therapy (n=2), and/or missing data on thrombin generation tests 
(n=31), and/or missing data on DXA measurements (n=25). The present study therefore 
consisted of 586 individuals.  
The Ethical Review Committee of the Vrije Universiteit University Medical Centre 
approved the study protocol, and all participants gave their written informed consent. 
 
Anthropometrics/Body Composition 
Weight and height were measured while participants were barefoot, wearing only light 
clothing. Body mass index (BMI) was calculated as weight (kg) divided by height (m) 
squared. Waist circumference was measured at the level midway between the lowest rib 
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margin and the iliac crest, and hip circumference was measured at the widest level over 
the greater trochanters. 
 
A whole body DXA scan was performed using the fan beam technology (QDR-2000, 
software version 7.20D, Hologic, Brussels, Belgium). This software provides estimates of 
lean tissue mass, fat mass, and bone mineral mass for the total body and for standard 
body regions. Regions of the head, trunk, arms, and legs were distinguished with the use 
of specific anatomic landmarks (19). In the analyses, we used fat and lean soft tissue mass 
from the trunk, arms, and legs. Peripheral fat was calculated by adding the fat mass of the 
legs to that of the arms, and peripheral lean mass was calculated by adding the lean mass 
of the legs to that of the arms (20). 
 
Thrombin Generation Parameters 
Venous blood samples were collected in 2000–2001, and 3.2% citrated platelet-poor 
plasmas were prepared by 2-step centrifugation: at 4000g for 15 minutes followed by 
centrifugation at 10 000g for 5 minutes. Plasmas were stored at -80°C until analysis in 
2008 and were not thawed before then. Thrombin generation in platelet-poor plasma was 
measured using the CAT method (9), which uses low-affinity fluorogenic substrate for 
thrombin (Z-Gly-Gly-Arg- AMC) to continuously monitor thrombin activity in clotting 
plasma. Thrombin generation was assessed according to manufacturer’s instructions 
(Thrombinoscope BV) in a 96-well plate fluorometer (Ascent Reader, Thermolabsystems 
OY, Helsinki, Finland) as previously described (21). Briefly, thrombin generation was 
determined in the presence of: 1 pM TF and 4 μM phospholipids in the absence and 
presence of 0.55 nM recombinant soluble thrombomodulin (Paion GmbH, Aachen, 
Germany). The 1 pM TF trigger was a commercial product (PPP Reagent Low, 
Thrombinoscope BV, Maastricht, the Netherlands). Three parameters were derived from 
these analyses: lag time (min), peak height (nM), and ETP [nM]. Finally, a thrombomodulin 
ratio was calculated by dividing the ETP and peak height obtained in the presence by those 
in the absence of thrombomodulin. Thrombomodulin activates the anticoagulant protein 
C pathway, and therefore this ratio represents the inhibition of thrombin generation by 
activation of the protein C pathway. At our laboratory, the intraassay coefficients of 
variation (CVs) are <5% (21), and the interassay CVs, obtained in 2 lots of normal-pool 
plasma in 25 independent runs during the present study, were < 11% for all thrombin 
generation parameters (calculated using EP Evaluator 8.0.0.90 software). 
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Other Measurements 
Health status, medical history, medication use, and smoking habits were assessed by 
questionnaires (18). Systolic blood pressure (SBP) and diastolic blood pressure, levels of 
plasma glucose (fasting and postload), insulin, total, high- and low-density lipoprotein 
cholesterol, triglycerides, and hsCRP were measured as described elsewhere (19). In 
addition, urinary albumin-to-creatinine ratio was measured in an early morning first-
voided urine sample, and accordingly, participants were classified as having 
microalbuminuria if the albumin-to-creatinine ratio was 2.0 to 30 mg/mmol. Hypertension 
was defined as SBP ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg, or the use of 
antihypertensive drugs (22).  
Prior CVD was defined when individuals had any of the following: a history of 
myocardial infarction, transient ischemic attack or ischemic stroke, abnormalities on a 
resting ECG (Minnesota codes 1.1 to 1.3, 4.1 to 4.3, 5.1 to 5.3, or 7.1), undergone coronary 
bypass surgery or angioplasty, peripheral arterial bypass or nontraumatic amputation, or 
ankle-brachial index of < 0.9 in either leg.  
 
Statistical Analyses 
Comparisons of the clinical characteristics according to sex were investigated with the use 
of the Student t test for continuous variables and χ
2
 test for frequency data.  
We used multiple linear regression analyses to investigate the associations between body 
composition and thrombin generation parameters. First, associations with DXA and 
anthropometric estimates of total body fat were examined. These analyses were adjusted 
for age, prior CVD, glucose metabolism, and smoking status (model 1) and other 
cardiovascular risk factors, ie, SBP (model 2), dyslipidemia (model 3), and 
microalbuminuria (model 4). Second, the contributions of the regional fat and lean mass, 
estimated by either DXA or anthropometrics, were analyzed in mutually adjusted models. 
In both sets of analyses, the potential mediating role of low-grade inflammation (hsCRP) 
was investigated by calculating the magnitude of the changes in the regression 
coefficients after further adjustment for this variable. All results are shown as 
standardized regression coefficients (β) and the respective 95% confidence intervals (CIs) 
and were performed in men and women separately. Assumption of linearity intrinsic to 
the method of data analyses adopted was checked by inspection of the residuals by 
predicted values scatter plots (23). We considered the stability of the models to be 
disturbed by multicolinearity if the tolerance was < 0.1 (23).  
A 2-sided probability value of < 0.05 was considered statistically significant. All 
analyses were performed by using the Statistical Package for Social Sciences (SPSS) for 
Windows, version 15.0 (SPSS Inc., Chicago, Ill). 
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Results 
 
Participants who were excluded from the analyses (n=62) were older; had a higher BMI 
and waist circumference; and more often had hypertension, dyslipidemia, diabetes, and 
prior CVD than those included (data not shown). The clinical characteristics of the 
participants included (n=586) are shown in Table 1, stratified by sex. Women had smaller 
waist but larger hip circumferences and higher levels of total, trunk, and peripheral fat but 
less lean mass than men. Men and women did not differ with respect to thrombin 
generation parameters. 
 
Total Body Fat and Thrombin Generation 
Total body fat percentage (as estimated by DXA) or BMI, both estimates of total body 
adiposity, were positively associated with lag time, peak height, and ETP in women, 
whereas no such associations were seen in men. These associations were independent of 
age, prior CVD, glucose metabolism, and smoking status (Table 2, model 1) and are also 
illustrated in Figure 1B, showing the differences in these parameters across categories of 
BMI. Additional adjustment for SBP (model 2), dyslipidemia (model 3), or 
microalbuminuria (model 4) only slightly attenuated the associations with lag time and 
peak height and ETP. The strengths of the associations were comparable for total both 
body fat percentage (estimated by DXA) and BMI.  
 
Regional Body Composition and Thrombin Generation 
DXA 
Trunk fat and peripheral fat mass were both positively associated with lag time, peak 
height, and ETP, again in women but not in men. Peripheral lean mass was positively 
associated with lag time only (Table 3, model 0). When adjusted for each other, trunk fat, 
not peripheral fat or lean masses, was the strongest correlate of lag time, peak height, and 
ETP (Table 3, model 2; Figure 2). Additional adjustment for SBP (model 3), dyslipidemia 
(model 4), or microalbuminuria (model 5) attenuated these associations only slightly. In 
these mutually adjusted analyses, if anything, there was a trend toward an inverse 
association between peripheral lean mass and peak height and ETP in women (Table 3, 
models 2 to 5; Figure 2), whereas no association was observed between peripheral fat and 
study outcomes (Table 3, models 2 to 5; Figure 2). 
 
Body composition and thrombin generation 
 127 
Table 1: Clinical characteristics of the study population  
Characteristic Men (n=288) Women (n=298) p-value 
Age, years 69.6 ± 6.3 69.9 ± 6.6 0.542 
Anthropometry     
Height, cm 176 ± 6 163 ± 6 <0.001 
Weight, kg 83 ± 12 73 ± 12 <0.001 
Body mass index, kg/m2 26.9 ± 3.5 27.5 ± 4.2 0.057 
Waist circumference, cm 99 ± 10 91 ± 12 <0.001 
Hip circumference, cm 101 ± 7 104 ± 9 <0.001 
DXA    
Total body fat, % 28 ± 7 42 ± 7 <0.001 
Trunk fat mass, kg 12.7 ± 5.5 14.7 ± 5.5 <0.001 
Trunk lean mass, kg 28.5 ± 3.1 20.8 ± 2.4 <0.001 
Peripheral fat mass, kg 9.5 ± 2.9 14.9 ± 4.6 <0.001 
Peripheral lean mass, kg 24.9 ± 3.4 17.0 ± 2.4 <0.001 
Metabolic and other variables    
Fasting glucose, mmol/l 6.25 ± 1.41 6.13 ± 1.41 0.322 
Glucose metabolism status, % 
       NGM/IGM/DM2    
 
46 / 31 / 23 
 
49 / 28 / 23 
 
0.602* 
Total cholesterol, mmol/l 5.38 ± 0.98 6.09 ± 0.96 <0.001 
LDL-cholesterol, mmol/l 3.46 ± 0.88 3.84 ± 0.89 <0.001 
HDL-cholesterol, mmol/l 1.25 ± 0.32 1.61 ± 0.41 <0.001 
Triglycerides, mmol/l 1.30 [1.00-1.70] 1.30 [0.90-1.70] 0.314 
Total cholesterol/HDL ratio 4.52 ± 1.24 4.03 ± 1.22 <0.001 
Lipid-lowering drugs, % 16 14 0.459 
Systolic blood pressure, mmHg 142 ± 19 143 ± 22 0.838 
Diastolic blood pressure, mmHg 84 ± 10 82 ± 12 0.162 
Antihypertensives, % 33 36 0.491 
Hypertension, % 67 64 0.775 
(Micro)albuminuria, % 17 11 0.067 
Platelet aggregation inhibitors, % 22 11 <0.001 
Current smoker, % 17 11 0.030 
Prior cardiovascular disease, % 49 48 0.812 
High-sensitivity C-reactive protein, mg/l 1.95 [1.16- 4.29] 1.98 [0.90- 4.25] 0.288 
Thrombin generation parameters    
Analyses without thrombomodulin    
Lag time, min 4.08 ± 0.92 4.00 ± 0.63 0.210 
ETP, nM*min 1188 ± 234 1183 ± 203 0.808 
Peak height, nM 185 ± 55 187 ± 55 0.765 
Analyses with thrombomodulin    
Lag time, min 3.99 ± 0.74 3.96 ± 0.64 0.687 
ETP, nM*min 801 ± 253 779 ± 236 0.290 
Peak height, nM 162 ± 58 162 ± 58 0.870 
TM-ratio    
ETPTM+/ETPTM-  0.66 ± 0.14  0.65 ± 0.13 0.196 
Peak heightTM+/ Peak heightTM-  0.85 ± 0.12 0.85 ± 0.09 0.963 
Results are expressed as mean ± SD, frequencies (%) or medians [inter-quartile range] *p for trend  
DXA: dual energy-absorptiometry; NGM: normal glucose metabolism; IGM: impaired glucose metabolism; DM2: 
type 2 diabetes; LDL: low-density lipoprotein; HDL: high-density lipoprotein; ETP: endogenous thrombin 
potential; TM: thrombomodulin 
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Figure 1. A, Example of a thrombin generation curve obtained by means of the CAT method in normal 
individuals. The parameters derived from the thrombin generation curve are: lag time (the time in which ~10nM 
of thrombin is formed), peak height (the maximum amount of formed thrombin), and ETP (the area under the 
curve). B, thrombin generation curves in women across categories of BMI: normal weight (BMI: 18.5-24.9 kg/m2), 
overweight (BMI: 25-29.9 kg/m2) and obese (BMI ≥ 30 kg/m2). Those who were overweight had 0.2%, 10.4%, and 
6.3% longer/higher lag time, peak height and ETP respectively, and those with obesity had 5.2%,  14.6% and 8.4% 
longer/higher lag time, peak height and ETP respectively, compared with those with normal weight (P for trend < 
0.04 for all). 
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Table 2. Associations of total body fat (according to DXA or anthropometrics) with thrombin generation 
parameters  
 Men 
  Lag time Peak height ETP 
Determinant  Model ß 95%CI ß 95%CI ß 95%CI 
Total body fat % (DXA) 0 0.01 -0.11; 0.12 0.03 -0.09; 0.14 0.00 -0.12; 0.12 
1 0.01 -0.11; 0.14 0.01 -0.12; 0.13 -0.02 -0.14; 0.11 
2 0.00 -0.12; 0.13 0.01 -0.12; 0.14 -0.02 -0.14; 0.11 
 3 -0.04 -0.17; 0.09 0.00 -0.13; 0.14 -0.03 -0.16; 0.11 
 4 0.01 -0.12; 0.13 0.01 -0.12; 0.13 -0.02 -0.14; 0.11 
Body mass index 0 -0.08 -0.19; 0.04 0.01 -0.11; 0.13 -0.03 -0.15; 0.09 
 1 -0.08 -0.20; 0.05 0.01 -0.11; 0.13 -0.04 -0.16; 0.09 
 2 -0.09 -0.21; 0.04 0.01 -0.11; 0.14 -0.04 -0.16; 0.09 
 3 -0.13* -0.26; -0.00 0.01 -0.12; 0.14 -0.05 -0.18; 0.08 
 4 -0.07 -0.20; 0.05 0.01 -0.11; 0.13 -0.04 -0.16; 0.09 
 
 Women 
  Lag time Peak height ETP 
Determinant  Model ß 95%CI ß 95%CI ß 95%CI 
Total body fat % (DXA) 0 0.16† 0.04; 0.27 0.14* 0.03; 0.26 0.22‡ 0.10; 0.33 
1 0.13* 0.01; 0.25 0.13* 0.01; 0.25 0.21‡ 0.10; 0.33 
2 0.14* 0.02; 0.26 0.11 -0.02; 0.23 0.19† 0.07; 0.31 
 3 0.11 -0.01; 0.22 0.13* 0.01; 0.25 0.21‡ 0.09; 0.33 
 4 0.13* 0.01; 0.25 0.13* 0.01; 0.24 0.21‡ 0.09; 0.33 
Body mass index 0 0.21‡ 0.10; 0.32 0.14* 0.03; 0.25 0.18† 0.06; 0.28 
 1 0.18† 0.06; 0.30 0.12 -0.01; 0.24 0.16† 0.04; 0.28 
 2 0.19† 0.07; 0.31 0.09 -0.03; 0.21 0.14* 0.02; 0.26 
 3 0.14* 0.03; 0.26 0.13* 0.01; 0.25 0.16† 0.04; 0.28 
 4 0.18† 0.06; 0.30 0.12 -0.01; 0.24 0.16† 0.04; 0.28 
ß, standardized regression coefficient; indicates the change in thrombin generation parameter (in SD) per 1 SD 
increase in determinant; CI, confidence interval;  *p <0.05, †p <0.01, ‡p <0.001; 
Model 0: crude; 
Model 1: adjusted for age, prior CVD, glucose metabolism and smoking status; 
Model 2: model 1 + SBP; 
Model 3: model 1 + total cholesterol/HDL ratio, ln-triglycerides; 
Model 4: model 1 + microalbuminuria. 
  
Table 3. Associations of regional body composition (according to DXA or anthropometrics) with thrombin generation parameters 
  Men Women 
  Lag time Peak height ETP Lag time Peak height ETP 
Determinant  Model ß 95%CI ß 95%CI ß 95%CI ß 95%CI ß 95%CI ß 95%CI 
DXA              
Trunk fat mass 0 -0.01 -0.13; 0.11 0.01 -0.11; 0.12 -0.01 -0.13; 0.11 0.22‡ 0.11; 0.33 0.13* 0.02; 0.25 0.18† 0.07; 0.30 
 1 -0.00 -0.13; 0.12 -0.00 -0.13; 0.12 -0.02 -0.15; 0.10 0.20† 0.07; 0.32 0.11 -0.02; 0.23 0.17† 0.04; 0.29 
 2 0.14 -0.08; 0.36 -0.11 -0.32; 0.11 0.01 -0.21; 0.23 0.20* 0.03; 0.37 0.15 -0.03; 0.32 0.17 -0.01; 0.34 
 3 0.12 -0.11; 0.34 -0.11 -0.33; 0.12 0.01 -0.22; 0.24 0.20* 0.03; 0.38 0.14 -0.04; 0.31 0.16 -0.01; 0.33 
 4 0.05 -0.19; 0.28 -0.13 -0.36; 0.10 -0.01 -0.25; 0.22 0.10 -0.09; 0.28 0.19 -0.00; 0.37 0.17 -0.02; 0.35 
 5 0.12 -0.11; 0.34 -0.12 -0.34; 0.11 -0.00 -0.22; 0.22 0.20* 0.03; 0.38 0.14 -0.04; 0.32 0.16 -0.02; 0.33 
              Peripheral fat 
mass 
0 -0.05 -0.17; 0.06 0.04 -0.08; 0.16 -0.02 -0.14; 0.09 0.13* 0.02; 0.24 0.07 -0.04; 0.18 0.14* 0.01; 0.24 
 1 -0.05 -0.17; 0.07 0.04 -0.08; 0.16 -0.03 -0.15; 0.09 0.12* 0.01; 0.24 0.06 -0.06; 0.17 0.12* 0.01; 0.24 
 2 -0.14 -0.35; 0.08 0.13 -0.09; 0.34 -0.04 -0.25; 0.18 -0.04 -0.20; 0.13 -0.01 -0.18; 0.16 0.06 -0.10; 0.22 
 3 -0.13 -0.34; 0.09 0.13 -0.09; 0.34 -0.04 -0.25; 0.18 -0.03 -0.20; 0.13 -0.03 -0.19; 0.14 0.04 -0.12; 0.21 
 4 -0.10 -0.31; 0.12 0.14 -0.08; 0.36 -0.03 -0.25; 0.19 0.04 -0.13; 0.21 -0.04 -0.21; 0.13 0.06 -0.11; 0.23 
 5 -0.12 -0.34; 0.10 0.13 -0.08; 0.35 -0.03 -0.24; 0.19 -0.04 -0.20; 0.13 -0.00 -0.17; 0.16 0.07 -0.10; 0.23 
              Peripheral lean 
mass 
0 -0.11 -0.23; 0.01 -0.02 -0.14; 0.09 -0.02 -0.14; 0.10 0.14* 0.03; 0.25 -0.02 -0.14; 0.07 -0.02 -0.14; 0.09 
 1 -0.12 -0.24; 0.01 0.00 -0.12; 0.13 -0.02 -0.14; 0.10 0.13 0.01; 0.25 -0.05 -0.17; 0.07 -0.08 -0.19; 0.04 
 2 -0.12 -0.24; 0.01 -0.00 -0.13; 0.12 -0.02 -0.14; 0.11 0.08 -0.05; 0.21 -0.09 -0.21; 0.04 -0.15* -0.27; -0.02 
 3 -0.11 -0.24; 0.01 -0.00 -0.13; 0.12 -0.02 -0.14; 0.11 0.08 -0.05; 0.20 -0.09 -0.21; 0.04 -0.14 -0.27; 0.02 
 4 -0.11 -0.24; 0.01 -0.00 -0.13; 0.13 -0.02 -0.14; 0.11 0.06 -0.07; 0.18 -0.08 -0.21; 0.05 -0.15* -0.27; -0.02 
 5 -0.11 -0.23; 0.02 0.00 -0.13; 0.13 -0.01 -0.14; 0.12 0.08 -0.05; 0.20 -0.09 -0.22; 0.04 -0.14* -0.27; -0.02 
Anthropometrics             
Waist 
circumference 
0 -0.08 -0.20; 0.04 0.03 -0.08; 0.15 0.01 -0.11; 0.13 0.20‡ 0.09; 0.31 0.16† 0.05; 0.27 0.15† 0.04; 0.26 
 1 -0.08 -0.20; 0.04 0.03 -0.09; 0.15 0.00 -0.12; 0.13 0.17† 0.05; 0.29 0.14* 0.01; 0.26 0.14* 0.01; 0.26 
 2 -0.08 -0.27; 0.12 0.10 -0.10; 0.29 0.17 -0.02; 0.37 0.10 -0.08; 0.28 0.19* 0.01; 0.37 0.08 -0.10; 0.25 
 3 -0.08 -0.28; 0.11 0.10 -0.10; 0.29 0.17 -0.02; 0.37 0.10 -0.08; 0.28 0.20* 0.02; 0.38 0.08 -0.09; 0.26 
 4 -0.15 -0.36; 0.05 0.09 -0.11; 0.29 0.17 -0.03; 0.37 0.04 -0.14; 0.22 0.21* 0.03; 0.39 0.07 -0.11; 0.26 
 5 -0.08 -0.28; 0.11 0.09 -0.10; 0.29 0.17 -0.02; 0.37 0.10 -0.08; 0.28 0.19* 0.00; 0.37 0.06 -0.12; 0.24 
              Hip 
circumference 
0 -0.07 -0.19; 0.05 -0.02 -0.13; 0.10 -0.08 -0.19; 0.04 0.18† 0.07; 0.29 0.08 -0.03; 0.20 0.14* 0.03; 0.26 
  
              
 1 -0.07 -0.19; 0.06 -0.01 -0.13; 0.11 -0.08 -0.20; 0.04 0.16† 0.04; 0.28 0.05 -0.07; 0.17 0.14* 0.01; 0.25 
 2 -0.01 -0.20; 0.19 -0.09 -0.28; 0.11 -0.22* -0.41; -0.02 0.09 -0.08; 0.26 -0.08 -0.24; 0.09 0.08 -0.09; 0.25 
 3 -0.01 -0.20; 0.18 -0.08 -0.28; 0.11 -0.22* -0.41; -0.02 0.11 -0.06; 0.27 -0.10 -0.27; 0.07 0.06 -0.11; 0.22 
 4 0.02 -0.17; 0.21 -0.08 -0.28; 0.11 -0.21* -0.41; -0.20 0.11 -0.05; 0.28 -0.08 -0.24; 0.09 0.08 -0.09; 0.25 
 5 0.00 -0.19; 0.20 -0.08 -0.28; 0.11 -0.21* -0.40; -0.02 0.09 -0.08; 0.26 -0.07 -0.24; 0.10 0.09 -0.08; 0.26 
ß, standardized regression coefficient; indicates the change in thrombin generation parameter (in SD) per 1 SD increase in determinant; CI, confidence interval   
*p <0.05, †p <0.01, ‡p <0.001; 
Model 0: crude; 
Model 1: adjusted for age, prior CVD, glucose metabolism and smoking status; 
Model 2: model 1 + the other body composition variables (DXA) or model 1+ either waist or hip circumference (anthropometrics); 
Model 3: model 2 + SBP;  
Model 4: model 2 + total cholesterol/HDL ratio, ln-triglycerides; 
Model 5: model 2 + microalbuminuria 
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Figure 2. Associations between total body fat percentage and regional body composition, measured by DXA, and 
the thrombin generation parameters in women. Error bars represent 95% CI around association estimates. All 
data are adjusted for age, prior CVD, glucose metabolism, and smoking status. Right panel shows the (mutally 
adjusted) contributions of trunk fat, peripheral fat, and lean masses to these associations.
Body composition and thrombin generation 
 133 
Waist and Hip Circumferences 
The associations between fat distribution as estimated by means of waist and hip 
circumferences and study outcomes mimicked to a large extent the associations obtained 
with trunk and peripheral fat and lean masses as estimated by DXA (Table 3, model 1). 
After adjusting for hip circumference, the association between waist circumference and 
lag time and ETP in women was attenuated, whereas the association with peak height was 
stronger (model 2). Further adjustment for cardiovascular risk factors (models 3 to 5), if 
anything, only slightly attenuated these associations. 
 
The anthropometric estimate of peripheral fat (ie, hip circumference) was positively 
associated with lag time and ETP in women (Table 3, model 1). These associations, 
however, disappeared after adjustment for waist circumference; and if anything, there 
was a trend toward a protective effect of hip circumference on peak height. Furthermore, 
there was a trend toward an inverse association between hip circumference and ETP in 
men (model 1), which became stronger after further adjustment waist circumference 
(model 2) and other cardiovascular risk factors (models 3 to 5).  
 
Potential Mediation Role of Low-Grade Inflammation 
The positive associations of estimates of total body fat (ie, total body fat percentage or 
BMI) and a central pattern of fat accumulation (ie, trunk fat mass or waist circumference) 
with the thrombin generation parameters observed in women were attenuated when 
further adjusted for hsCRP (Table 4). 
  
Table 4. Mediation by low-grade inflammation in the association between total or central fat and thrombin generation in women 
  Lag time  Peak height  ETP  
Determinant  Model ß 95%CI ‘Mediating 
effect’*  
ß 95%CI ‘Mediating 
effect’* 
ß 95%CI ‘Mediating 
effect’* 
DXA           
Total body fat % 1 0.13* 0.01; 0.25  0.13* 0.01; 0.25  0.21‡ 0.10; 0.33  
 2 0.10 -0.03; 0.22 23% 0.08 -0.05; 0.20 38% 0.16* 0.04; 0.28 24% 
Trunk fat mass 1 0.20† 0.07; 0.32  0.11 -0.02; 0.23  0.17† 0.04; 0.29  
 2 0.17* 0.04; 0.29 15% 0.05 -0.08; 0.18 55% 0.10 -0.03; 0.22 41% 
Anthropometric
s 
          
Body mass index 1 0.18† 0.06; 0.30  0.12 -0.01; 0.24  0.16† 0.04; 0.28  
 2 0.15* 0.03; 0.28 17% 0.07 -0.06; 0.19 42% 0.10 -0.02; 0.22 38% 
Waist 
circumference 
1 0.17† 0.05; 0.29  0.14* 0.01; 0.26  0.14* 0.01; 0.26  
 2 0.14* 0.01; 0.27 18% 0.09 -0.04; 0.22 36% 0.07 -0.03; 0.20 50% 
ß, standardized regression coefficient; indicates the change in thrombin generation parameter (in SD) per 1 SD increase in determinant; CI, confidence interval 
* Estimated as (ßmodel1 - ßmodel 2)/ ßmodel1 x 100;  
†p <0.05, ‡p <0.01;  
Model 1:  adjusted for age, prior CVD, glucose metabolism and smoking status;  
Model 2:  model 1 + ln-hsCRP
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Additional Analyses 
Additional adjustment for use of platelet aggregation inhibitors or lipid-, blood pressure–, 
or glucose-lowering drugs did not materially affect any of the reported associations (data 
not shown). Excluding the few individuals who had an albuminto-creatinine ratio above 30 
mg/mmol (ie, macroalbuminuria, n=5) from the analyses also did not materially affect any 
of the results. Associations that were similar to those described above but slightly less 
strong were found when, instead, we used the thrombin generation parameters estimated 
in the presence of thrombomodulin (data not shown). Finally, we also investigated 
whether the associations between body composition and thrombin generation 
parameters differed across age categories by adding interaction terms into our models, 
but no such interactions were found (probability value for all, > 0.10). 
 
Discussion 
 
The present study had 3 major findings: first, total body fat mass was positively associated 
with a prolonged lag time, higher peak height, and higher ETP in women but not in men. 
Second, of the regional fat depots, trunk fat contributed the most to these associations, 
whereas there was no association with peripheral fat and a trend toward an inverse 
association with peripheral lean mass. Finally, the association between body fat and 
thrombin generation was independent of traditional cardiovascular risk factors and was to 
an important extent attenuated by low-grade inflammation. 
 
Our findings are in line with a pilot study, performed in 13 extremely obese children, 
which reported a positive association between severe obesity (estimated by BMI) and lag 
time, peak height, and ETP (13), and with a recent study showing a significant, weight-loss-
related decrease in these thrombin generation parameters in 36 morbidly obese adults 2 
years after bariatric surgery (14). In addition, an association has been found between 
prothrombin 1.2 fragments and waist circumference in postmenopausal women (7) In the 
latter study, a trend towards an inverse association between hip circumference and 
prothrombin 1.2 fragments was described. Such an inverse association with hip 
circumference was also observed in our study, but more strongly so in men. This finding 
could reflect a protective role for either peripheral fat or lean mass. Our analyses with 
DXA estimates of regional body composition suggested that peripheral lean (but not fat) 
mass counteracted the adverse effects of central fat in this study.  
 
The prolonged lag time in individuals with greater levels of body fat may be attributable to 
increased TF pathway inhibitor levels, which is one of the main determinants of lag time at 
the low TF concentrations used (24) Elevated TF pathway inhibitor levels have been 
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reported in individuals with impaired glucose tolerance and type 2 diabetes (25), and it 
has been suggested that this could be due to related obesity (26). 
 
The reason why (central) body fatness was associated with thrombin generation only in 
women is unclear. Men and women differ with respect to total adiposity and fat 
distribution in that women store more fat in subcutaneous areas, especially in the gluteal 
and thigh regions, whereas men accumulate fat preferentially in the upper-body and 
visceral compartments. Effect modification by sex in the association between (central) fat 
and thrombin generation could be partially attributable to underlying hormonal 
differences between the sexes. For instance, sex-specific patterns in growth hormone 
secretion and aging-related changes in sex-steroid hormonal balance are associated with 
preferential accumulation of fat in the upper body (27), and both have been also 
associated with coagulation and thrombosis (28,29). In the present study, no such 
hormonal data were obtained, and therefore we cannot further determine their potential 
role. Other obesity-related sex-specific factors may, however, play a role as well. Several 
studies have found that (older) women have higher levels of low-grade inflammation than 
men with comparable levels of obesity and that the association between central obesity 
and hsCRP is stronger in women than men (30,31). Indeed, in the present study, the 
association between central fat mass and hsCRP was also stronger in women than in men 
(age, prior CVD, glucose metabolism, and smoking status adjusted standardized βwomen: 
0.33 [95%CI, 0.22 to 0.44] versus βmen: 0.23 [0.12 to 0.34]; probability value for interaction, 
< 0.10), and indeed, the associations between central fatness and thrombin generation in 
women were, to an important extent (up to 55%), attenuated by low-grade inflammation. 
Nevertheless, and albeit statistically significant, differences between men and women as 
reported in this study, as well as their underlying biological mechanisms, if any, need to be 
examined in future studies.  
 
Previous cross-sectional studies have shown positive associations between hsCRP and 
prothrombin 1.2 fragments in individuals with and without prior CVD (32,33). One 
proposed mechanism by which hsCRP, or low-grade inflammation in general, may lead to 
increased thrombin generation may be by inducing endothelial dysfunction, which in turn 
leads to increased TF secretion by monocytes (34), a phenomenon observed only in the 
presence of and through direct interaction with other leukocytes (35). On the basis of this 
evidence and also on the well-established association between (central) obesity and low-
grade inflammation (15), we hypothesized that low-grade inflammation could mediate the 
positive associations between (central) fatness and thrombin generation. Our findings 
indeed seemed to support this hypothesis. However, the relationship between 
inflammation and coagulation may be bidirectional, as activated coagulation proteases 
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may affect specific cellular receptors on inflammatory and endothelial cells, thereby 
modulating an inflammatory response (36). When we reanalyzed our data under this 
alternative hypothesis, we found no appreciable “mediation effects” of thrombin 
generation in the associations between (central) obesity and low-grade inflammation 
(hsCRP) (data not shown). An alternative hypothesis that we cannot discard on the basis of 
the design of the present study is that inflammation and thrombin generation are both 
elevated as a consequence of (central) obesity without being causally related to each 
other. Additional mechanistic studies investigating the cross-talk, if any, between hsCRP 
but also other proinflammatory adipose tissue-related factors (such as interleukin-6, 
intercellular adhesion molecule, serum amyloid A, and leptin) and thrombin generation, 
and the extent to which any such associations differ between sexes, are thus warranted.  
 
Not only an increased procoagulant activity but also a decreased anticoagulant activity 
may lead to higher thrombin generation. When thrombin generation is measured in the 
presence and absence of thrombomodulin, an estimate of the function of the 
anticoagulant protein C system is obtained. In our study, no association was found 
between body composition and the thrombomodulin ratio. This indicates that body fat 
and its distribution are not associated with abnormalities in protein C activation, which is 
in line with a previous study in individuals with morbid obesity (37).  
 
Strengths of our study were the assessment of both anthropometric and more precise 
estimates of body composition (DXA) and the investigation of how both types of estimates 
of body composition related to thrombin generation. We found that the strength of the 
associations between BMI and waist circumference or total body fat percentage and its 
distribution, measured by DXA, on the one hand and thrombin generation on the other 
were similar. This suggests that in large epidemiological studies on obesity-related 
hypercoagulability, anthropometric estimates of obesity/fat distribution might be a 
reliable alternative to DXA or other objective estimates of body composition when these 
are unavailable. In addition, the body composition–thrombin generation associations were 
investigated in a relatively large population-based group of extensively described 
individuals (17–19), which allowed adjustment for many other cardiovascular risk factors, 
such as hypertension, dyslipidemia, smoking, and microalbuminuria. Finally, the CAT 
method we used to estimate thrombin generation mimics the overall potential to clot 
whenever a thrombogenic stimulus (eg, TF release after plaque rupture) appears. In 
theory, this method may give a more reliable estimation of coagulation under 
pathophysiological conditions than the single-point measurement of activation markers, 
such as prothrombin 1.2 fragments or thrombin-antithrombin complexes (38). However, 
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prospective studies comparing the value of these measures in the prediction of 
prothrombotic events are needed to further clarify this issue. 
 
There are some limitations to our study. First, because of its cross-sectional design, any 
inferences about causality should be made with caution. Second, because fat measures 
are strongly related to each other, it can be argued that adjustment of these 
measurements for each other (eg, Table 3) was not adequate, leading to overcorrected 
models. However, although the regression coefficients changed considerably after mutual 
adjustments for other body composition variables, our analyses were not disturbed by 
multicolinearity (ie, tolerance was > 0.1 in all models). In fact, these analyses allowed us to 
tease apart the relative contributions of different fat depots and lean mass in the 
associations examined. Still, the clinical relevance of the obesity-related elevations in 
thrombin generation observed in the present study needs to be clarified, as the strength 
of the associations we found were, albeit significant, relatively weak (and body fatness 
explained only up to 5% of the variance in the parameters investigated). Third, despite the 
fact that trunk fat as assessed by DXA correlates highly with intraabdominal fat, it does not 
distinguish between subcutaneous and visceral fat in the trunk/abdominal region (39). 
Whether the associations of thrombin generation with visceral fat differ from those with 
(abdominal) subcutaneous fat need to be further examined. Finally, we studied a white, 
elderly population, and it remains to be established whether the results can be 
generalized to other ethnicities and to younger individuals.  
 
In conclusion, we have shown that, in women, total body fat is positively associated with 
thrombin generation in plasma. Of the regional fat depots, central fat mass was the 
strongest contributor to this association, which may be explained, at least in part, by 
central-obesity related low-grade inflammation. Prospective and mechanistic studies are 
needed to further clarify the mechanisms underlying the obesity-thrombin generation 
relationships and to ascertain the extent to which higher thrombin generation explains the 
excess of atherothrombotic events associated with obesity.  
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Abstract 
 
Introduction — Type 2 diabetes (DM2) is associated with greater risk for cardiovascular 
disease (CVD), which may, at least partially, be explained by prothrombotic alterations. 
We therefore investigated; first, the extent to which individuals with impaired glucose 
metabolism (IGM) and/or DM2 had greater levels of thrombin generation than those with 
normal glucose metabolism (NGM); and second, whether any differences were 
independent of other cardiovascular risk factors, such as smoking, hypertension, 
dyslipidaemia, (micro)albuminuria, glycemic control and (central) adiposity, and/or were 
potentially 'mediated' by low-grade inflammation (high-sensitivity C-reactive protein 
(hsCRP)). 
 
Materials and Methods— We studied 744 individuals from the Hoorn Study (275 NGM, 
176 IGM and 293 DM2, mean age 68.6 ± 7.1 years). Thrombin generation in platelet-poor 
plasma was measured using the Calibrated Automated Thrombogram and three 
parameters were derived: lag time, peak height and endogenous thrombin potential (ETP). 
Data were analyzed with multiple linear regression analyses. 
 
Results — After adjustment for age, sex, prior CVD and smoking status, individuals with 
IGM or DM2 had a longer lag time [ß = 0.14 min (95% CI: 0.02; 0.26)], higher peak height 
[ß = 7.29 nM (-1.33; 15.91)] and ETP [ß = 35.65 nM*min (0.97; 70.34)] than those with 
NGM. These differences were attenuated to ß = 0.06 min (-0.07; 0.19), 3.82 nM (-5.46; 
13.10) and 16.34 nM*min (-20.92; 53.59), respectively, when further adjusted for waist 
circumference and hsCRP. 
 
Conclusion — Individuals with IGM or DM2 had up to 4% higher thrombin generation 
compared with NGM, which may be explained, to a great extent, by the greater levels of 
central adiposity and related low-grade inflammation characterizing these individuals. 
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Introduction 
 
Individuals with type 2 diabetes (DM2) have a 2- to 3-fold higher risk for cardiovascular 
disease (CVD) as compared with non-diabetic individuals (1). A substantial portion of 
diabetes-related macrovascular complications is due to atherothrombotic events (2) which 
could, at least in part, be explained by an association between impaired glucose 
metabolism and thrombin generation. Indeed, thrombin plays a central role in the 
coagulation cascade (3,4) and elevated levels of thrombin-antithrombin (TAT) complexes 
and prothrombin 1.2 fragments (both in vivo markers of thrombin generation) have been 
reported in patients with DM2 (5–7). 
 
Recently, several new methods have become available which quantitatively measure 
thrombin generation, in vitro, after activation of the coagulation cascade with tissue factor 
(TF), phospholipids and calciumchloride (CaCl2) (8). The Calibrated Automated 
Thrombogram (CAT) is one such method (9,10). Specifically, it generates a thrombin 
generation curve that estimates the overall plasma coagulability potential. The 
endogenous thrombin potential (ETP), or the area under this curve, represents the total 
amount of active thrombin that can be formed after activation of the coagulation cascade. 
Measured as such, the ETP has been shown to be a good indicator of a 
hypercoagulable state in, for example, individuals using oral contraceptives, or who had 
prior venous thromboembolism (9,11–13). Because the CAT method mimics the overall 
potential to clot whenever a thrombogenic stimulus (e.g. TF release after plaque rupture) 
appears, it is thought to provide a more reliable estimation of coagulation under 
pathophysiological conditions than the single point measurement of activation markers 
such as prothrombin 1.2 fragments or TAT complexes (14). 
 
Only one small case-control study has investigated the association between DM2 and 
thrombin generation according to this method (15). However, no studies have been 
performed at the population level. Establishing such an association is a necessary step to 
ascertain its potential value as a tool to estimate atherothrombotic risk in individuals with 
impaired glucose metabolism (IGM) and/or DM2. Furthermore, from an etiological point 
of view, it is not clear whether any such association is independent of other risk factors 
that typically characterize these individuals (e.g. hypertension and central adiposity) or, 
alternatively, is explained by these risk factors and their associated pathophysiological 
mechanisms. Central adiposity and related low-grade inflammation are likely candidates in 
this regard (16). Indeed, individuals with IGM and DM2 have higher levels of high-
sensitivity C-reactive protein (hsCRP) which are, to a great extent, attributable to their 
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higher levels of (central) adiposity (17). In addition, in vivo, hsCRP has been associated 
with increased thrombin generation (assessed by activation markers) (18).  
 
In view of these considerations, we investigated, in a population-based cohort, first, 
whether individuals with IGM and/or DM2 had greater levels of thrombin generation in 
plasma than those with NGM; and second, whether any such differences were 
independent of other cardiovascular risk factors and/or explained by (adiposity-related) 
low-grade inflammation (hsCRP).  
 
Materials and methods 
 
Study population 
For the present investigation, we used data from the 2000 Hoorn Study follow-up 
examination and, to increase the number of individuals with DM-2, data from The Hoorn 
Diabetes Screening Study, both of which were population-based and have been described 
in detail elsewhere (16,19,20). Briefly, the Hoorn Study is a cohort study of glucose 
metabolism in the general population (n=2484), which started in 1989 (20). In 2000, a 
follow-up examination was carried out among all surviving participants who had given 
their permission to be recontacted. We invited all those who had diabetes, as determined 
by an oral glucose tolerance test, or who were treated for diabetes at the previous 1996 
follow-up (n=176). Next, we invited random samples of individuals with normal glucose 
metabolism (NGM) (n=705) and IGM (n=193). Of 1074 individuals thus invited, 648 (60%) 
participated [19]. Additionally, we invited 217 individuals with DM-2 from the Hoorn 
Screening Study (21), of whom 188 (87%) participated. All participants underwent a 
glucose tolerance test, except those with previously diagnosed diabetes (n=67). Data on 
14 individuals were missing because of logistical problems. Glucose tolerance was defined 
according to the 1999 WHO criteria (22). Altogether, the eligible cohort thus consisted of 
822 individuals. For the present study, participants using cumarin derivatives (n=25) 
and/or hormonal replacement therapy (n=3) and/or having missing data on thrombin 
generation parameters (n=54) and/or in whom glucose metabolism status could not be 
ascertained (n=14) were excluded. The present study therefore consisted of 744 
individuals: 275 with normal glucose metabolism (NGM), 176 with IGM (including those 
with impaired fasting glucose and/or impaired glucose tolerance) and 293 with DM2.  
The Ethical Review Committee of the VU University Medical Centre approved the 
study protocol and all participants gave their written informed consent.  
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Thrombin generation parameters  
Venous blood samples were collected in 2000–2001 and 3.2% citrated platelet-poor 
plasmas (PPP) were prepared by two-step centrifugation: at 4000 ×g for 15minutes 
followed by centrifugation at 10000 ×g for 5 minutes. Plasmas were stored at−80 °C until 
analysis in 2008 and had not been thawed before. Thrombin generation in PPP was 
measured using the CAT-method (10), which employs low-affinity fluorogenic substrate 
for thrombin (Z-Gly-Gly-Arg-AMC) to continuously monitor thrombin activity in clotting 
plasma. Thrombin generation was assessed according to manufacturer's instructions 
(Thrombinoscope BV) in a 96-well plate fluorometer (Ascent Reader, Thermolabsystems 
OY, Helsinki, Finland) as previously described (23). Briefly, thrombin generation was 
determined in the presence of 1 pM TF and 4 uM phospholipids in the absence and 
presence of 0.55 nM recombinant soluble thrombomodulin (Paion GmbH, Aachen, 
Germany). The 1 pM TF trigger was a commercial product (PPP Reagent Low; 
Thrombinoscope BV, Maastricht, the Netherlands). Three parameters were derived from 
these analyses, i.e. lag time (min), peak height (nM) and ETP (nM*min). A 
thrombomodulin ratio was calculated by dividing the ETP and peak height in the presence 
by those in the absence of thrombomodulin. This ratio indicates the percentage inhibition 
of thrombin generation by activation of the anti-coagulant protein C pathway. At our lab, 
the intra-assay coefficients of variation (CVs) are <5% (13) and the inter-assay CVs , 
obtained in 2 lots of normal-pool plasma in 25 independent runs during the present study, 
were < 11% for all thrombin generation parameters (calculated using the EP Evaluator 
8.0.0.90 software). 
 
Other measurements 
Health status, medical history, medication use and smoking habits were assessed by 
questionnaires (20). We measured waist circumference, body mass index (BMI), systolic 
(SBP) and diastolic blood pressure (DBP), levels plasma glucose (fasting and post-load), 
HbA1c, total, high-(HDL) and low-density lipoprotein (LDL) cholesterol, triglycerides, 
urinary albumin-to-creatinine ratio and hsCRP as described in detail elsewhere (20,24,25). 
Hypertension was defined as SBP ≥ 140 mmHg and/or DBP ≥ 90mmHg and/or the use of 
anti-hypertensive drugs (26). Participants were classified as having microalbuminuria if the 
albumin-to-creatinine ratio was ≥ 2.0 mg/mmol (24). Prior CVD was defined as described 
previously (16). 
 
Statistical analyses 
Variables with a skewed distribution (i.e. triglycerides and hsCRP) were log-transformed 
prior to further analyses. Comparisons of the clinical characteristics according to 
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individuals’ glucose metabolism status were investigated by means of analyses of variance 
(ANOVA) for continuous variables and chi-squared tests for frequency data.  
 
We used multiple linear regression analyses to investigate the differences in thrombin 
generation parameters between individuals with IGM or DM2 vs. NGM (reference group). 
These analyses were first adjusted for age, sex, prior CVD and smoking status (model 1), 
and additionally for measures of blood pressure, dyslipidemia, (micro)albuminuria, 
glycemic control, (central) adiposity and low-grade inflammation (models 2 to 7). In 
addition, we investigated whether the attenuation by low-grade inflammation was 
adiposity driven by adding adjustments for both waist circumference and hsCRP (model 8). 
In all these analyses individuals with IGM and DM2 were combined into one group, since 
the parameters of thrombin generation examined herein did not substantially differ 
between these two groups. In all analyses described above, dependent variables were the 
thrombin generation parameters obtained in both the absence and presence of 
thrombomodulin.  
Statistical significance was set at a p-value of <0.05. All analyses were performed 
with the use of the Statistical Package for Social Sciences (SPSS) for Windows, version 15.0 
(SPSS Inc., Chicago, IL, USA). 
 
Results 
 
Participants who were excluded from the analyses (n=78) were younger, more often 
obese and more often had diabetes than the ones included (data not shown). The clinical 
characteristics of the participants included (n=744) are shown in Table 1 according to their 
glucose metabolism status. A deteriorating glucose metabolism status was associated with 
a larger waist circumference and higher levels of dyslipidemia, blood pressure, 
microalbuminuria, hsCRP and prior CVD. In addition, participants with IGM and DM2 more 
often used lipid-lowering drugs and platelet aggregation inhibitors those with NGM.  
 
Levels of lag time, peak height and ETP assessed in the absence of thrombomodulin were 
comparable in individuals with IGM and DM2 and greater in these individuals than in 
those with NGM (Table 2, Figure 1). Activating the anticoagulant protein C pathway by 
adding thrombomodulin did not affect the absolute values of lag time but led to lower 
absolute values of peak height and ETP, which were reduced by approximately 14 and 
35%, respectively, in all groups (Table 2). Despite the relatively higher values in individuals 
with IGM and DM2 under these conditions, peak height and ETP did not differ significantly 
from those of individuals with NGM, however lag time remained significantly prolonged.  
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The thrombomodulin ratio of peak height and ETP did not materially differ between the 3 
groups (Table 2). 
 
Table 1: Clinical characteristics according to glucose metabolism status  
 NGM 
(n=275) 
IGM 
(n=176) 
DM2 
(n=293) 
p for linear trend 
Age (years) 68.5 ± 6.0 70.3 ± 6.5 67.6 ± 8.0 0.099 
Sex (% male) 47.3 50.6 50.9 0.397 
Fasting glucose (mmol/l) 5.42 ± 0.37 6.08 ± 0.48 7.71 ± 1.80 <0.001 
Glycated haemoglobin (%) 5.68 ± 0.41 5.88 ± 0.39 6.61 ± 0.92 <0.001 
Body mass index (kg/m2) 26.2 ± 3.3 27.8 ± 4.1 29.1 ± 4.6 <0.001 
Waist circumference (mm) 90.7 ± 11.0 97.3 ± 10.8 101.1 ± 12.0 <0.001 
Total cholesterol (mmol/l) 5.79 ± 1.03 5.79 ± 1.02 5.53 ± 1.06 0.003 
LDL-cholesterol (mmol/l) 3.71 ± 0.91 3.68 ± 0.92 3.46 ± 0.92 0.001 
HDL-cholesterol (mmol/l) 1.51 ± 0.41 1.44 ± 0.40 1.24 ± 0.34 <0.001 
Total-to-HDL cholesterol ratio 4.05 ± 1.09 4.32 ± 1.39 4.71 ± 1.32 <0.001 
Triglycerides (mmol/l) 1.20 [0.90-1.50] 1.30 [1.00-1.70] 1.60 [1.20-2.20] <0.001 
     
Lipid lowering drugs (%) 12.4 15.9 19.9 0.016 
Systolic blood pressure 
(mmHg) 
137 ± 20 143 ± 18 146 ± 21 <0.001 
Diastolic blood pressure 
(mmHg) 
81 ± 11 83 ± 10 85 ± 10 <0.001 
Mean arterial pressure 
(mmHg) 
95 ± 11 100 ± 10 102 ± 11 <0.001 
Use of antihypertensives (%) 23.4 37.5 50.3 <0.001 
Microalbuminuria (%) 9.8 15.9 18.8 0.003 
Smoking (%) 13.9 17.6 12.1 0.525 
Prior CVD (%) 45.1 50.0 53.2 0.053 
Use of Platelet aggregation 
inhibitors (%) 
13.2 16.5 19.8 0.038 
High-sensitivity C-reactive 
protein (mg/l) 
1.52 [0.80; 3.14] 2.19 [1.29; 4.61] 3.14 [1.42; 7.00] <0.001 
Results are expressed as percentages (%), mean ± SD, or median [inter-quartile range] 
NGM: normal glucose metabolism; IGM: impaired glucose metabolism; DM2: type 2 diabetes mellitus; LDL: low 
density lipoprotein; HDL: high density lipoprotein; CVD: cardiovascular disease  
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Figure 1. Thrombin generation curves according to glucose metabolism status i.e. normal glucose metabolism 
(NGM), impaired glucose metabolism (IGM) or type 2 diabetes mellitus (DM2). 
Chapter 7 
 
152 
Table 2. Thrombin generation parameters according to glucose metabolism status 
 NGM 
(n=275) 
IGM 
(n=176) 
DM2 
(n=293) 
p-value  
(IGM + DM2 vs. NGM) 
Analyses without 
thrombomodulin 
    
Lag time (min)  3.98 ± 0.83 4.10 ± 0.80 4.14 ± 0.77 0.021 
Peak Height (nM) 182 ± 57 191 ± 58 189 ± 59 0.067 
ETP (nM*min) 1166 ± 222 1218 ± 237 1192 ± 238 0.034 
     
Analyses with 
thrombomodulin 
    
Lag time (min) 3.91 ± 0.68 4.06 ± 0.71 4.06 ± 0.76 0.005 
Peak height (nM) 159 ± 60 166 ± 60 167 ± 65 0.104 
ETP (nM*min) 776 ± 253 810 ± 256 807 ± 261 0.106 
     
Thrombomodulin 
ratio 
    
TM ratio Peak height 
n=737 
0.86 ± 0.11 0.86 ± 0.10 0.86 ± 0.14 0.867 
TM ratio ETP n=737 0.65 ± 0.14 0.65 ± 0.14 0.66 ± 0.15 0.559 
Results are expressed as mean ± SD  
NGM: normal glucose metabolism; IGM: impaired glucose metabolism; DM2: type 2 diabetes mellitus; ETP 
endogenous thrombin potential; TM: thrombomodulin  
 
 
Additional analyses 
Additional adjustment for use of platelet aggregation inhibitors, or lipid- , blood pressure- 
or glucose-lowering drugs did not materially affect any of the reported associations (data 
not shown). We also investigated whether the association between glucose metabolism 
status and thrombin generation parameters differed between men and women or 
between different age categories, by adding interaction terms to our models. However, no 
such interactions were found (p-values for interaction all > 0.10).
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Table 3. Thrombin generation parameters according to glucose metabolism status 
  Lag time (min) Peak height (nM) ETP (nM*min) 
Model Adjustments ß 95%CI ß 95%CI ß 95%CI 
Without thrombomodulin       
0 Crude 0.14* 0.02; 0.26 7.98 -0.63; 16.58 36.75* 2.17; 71.34 
1 Age, sex, prior CVD, smoking 0.14* 0.02; 0.26 7.29 -1.33; 15.91 35.65* 0.97; 70.34 
2 Model 1 + SBP 0.13* 0.01; 0.25 6.42 -2.34; 15.18 32.80 -2.46; 68.07 
3 Model 1 + total cholesterol/ HDL ratio 
and ln-triglycerides 
0.04 -0.08; 0.16 8.16 -0.79; 17.11 34.29 -1.88; 70.47 
4 Model 1 + microalbuminuria 0.12* 0.01; 0.24 7.10 -1.57; 15.76 34.31 -0.56; 69.17 
5 Model 1 + HbA1c 0.07 -0.06; 0.20 6.95 -2.49; 16.39 41.54* 3.56; 79.52 
6 Model 1 + waist circumference 0.09 -0.04; 0.22 5.48 -3.76; 14.71 23.85 -13.26; 60.97 
7 Model 1 + ln-hsCRP 0.09 -0.03; 0.21 4.57 -4.22; 13.36 22.90 -12.40; 58.19 
8 Model 1 + waist circumference and ln-
hsCRP 
0.06 -0.07; 0.19 3.82 -5.46; 13.10 16.34 -20.92; 53.59 
With thrombomodulin       
0 Crude 0.15† 0.04; 0.26 7.54 -1.66; 16.74 31.21 -6.90; 69.33 
1 Age, sex, prior CVD, smoking 0.15† 0.04; 0.25 6.80 -2.41; 16.02 27.89 -10.28; 66.03 
2 Model 1 + MAP 0.13* 0.03; 0.24 6.18 -3.19; 15.55 26.39 -12.42; 65.21 
3 Model 1 + total cholesterol/ HDL ratio 
and ln-triglycerides 
0.07 -0.04; 0.18 7.95 -1.62; 17.53 34.87 -4.86; 74.60 
4 Model 1 + microalbuminuria 0.13* 0.02; 0.23 6.78 -2.48; 16.04 27.42 -10.95; 65.79 
5 Model 1 + HbA1c 0.08 -0.03; 0.20 6.60 -3.49; 16.69 32.42 -9.37; 74.21 
6 Model 1 + waist circumference 0.09 -0.03; 0.20 5.15 -4.72; 15.02 22.07 -18.83; 62.97 
7 Model 1 + ln-hsCRP 0.09 -0.02; 0.20 4.26 -5.15; 13.66 17.15 -21.80; 56.10 
8 Model 1 + waist circumference and ln-
hsCRP 
0.06 -0.06; 0.17 3.60 -6.34; 13.53 15.43 -25.71; 56.56 
Regression coefficient (ß) with respective 95%CI indicates the difference in thrombin generation parameter (in 
respective units) in IGM/DM2 vs. NGM. *p <0.05, †p <0.01 
 
Discussion 
The main findings of this study were two-fold: first, individuals with IGM and DM2 had 
comparable levels and both had higher levels of thrombin generation than those with 
NGM, but the magnitude of these differences was relatively small (up to 4%). Second, 
central adiposity and related low-grade inflammation explained to a great extent the 
association between glucose tolerance status and thrombin generation, i.e., peak height 
and ETP.  
 
The modest elevations in thrombin generation parameters suggest that thrombin 
generation in PPP only slightly contributes to the hypercoagulable state in IGM and DM2. 
This observation is in line with a recently published case-control study in DM2 patients 
that also reported minimal differences between DM2 patients compared with healthy 
controls (15). Alterations in primary hemostasis and/or the fibrinolytic system may thus be 
more important in establishing the hypercoagulable state in IGM and/or DM2 than those 
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reflected by the thrombin generation assay on which we focused herein. For example, 
DM2 is associated with increased platelet activation and aggregation and von Willebrand 
factor levels (27,28) and  plasminogen activator inhibitor (PAI)-1 levels are elevated in 
DM2, probably due to an increased hepatic synthesis (29). PAI-1 inhibits fibrinolysis, which 
is associated with more resistant clot formation and possibly plays a role in vascular 
complications such as atherothrombosis.  
 
The thrombin generation parameters were elevated to a similar extent in individuals with 
IGM and DM2, which is in line with a previous study (30). These findings support the 
‘ticking clock hypothesis’ suggesting that hemostatic disturbances may be present even 
before fully developed diabetes (31). The prolonged lag time in IGM and DM2 may be 
explained by elevated tissue factor pathway inhibitor (TFPI) levels, which is one of the 
main determinants of lag time at the low TF concentrations used in our study (23). In 
addition, previous studies have shown a positive association between glucose metabolism 
status and TFPI (30,32). In the present study, the association between glucose metabolism 
status and lag time was partially attenuated by dyslipidemia, which is in line with previous 
studies that have shown a positive association between dyslipidemia and TFPI (33,34). 
The associations between glucose metabolism status and peak height and ETP were to a 
great extent attenuated by waist circumference, suggesting that central adiposity may be 
a common antecedent of both IGM/DM2 and increased thrombin generation. We have 
previously shown in this cohort that individuals with a central pattern of fat distribution 
indeed had higher levels of thrombin generation in plasma, which were to a great extent 
explained by adiposity-related increases in hsCRP (16). Furthermore, a recent meta-
analysis supports these findings by suggesting that the elevated hsCRP levels in DM2 are 
probably due to central adiposity (17). One proposed mechanism by which hsCRP, or low-
grade inflammation in general, may lead to increased thrombin generation may be by 
inducing endothelial dysfunction which in turn leads to increased TF expression by 
monocytes (35), a phenomenon which is only observed in the presence of and through 
direct interaction with other leukocytes (36). Taken together, our findings thus suggest 
that adiposity-related low-grade inflammation and not hyperglycemia per se might be one 
of the main driving factors behind the association between glucose metabolism status and 
thrombin generation in PPP. In addition, previous studies have not found an association 
between glycemic control and prothrombin 1.2 fragments and/or TAT-complexes (37,38). 
However, these studies did find an association between glycemic control and thrombin 
generation in platelet-rich plasma, suggesting that associations between glycemic control 
and thrombin generation might mainly be a platelet-dependent phenomenon (39).  
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There are some limitations to our study that need to be mentioned. First, due to its cross-
sectional design, any inferences about causality should be made with caution. Second, as 
we studied a relatively elderly population, we cannot fully exclude the possibility that 
selective mortality in the diabetes group (i.e. many ‘healthy’ survivors included in this 
study) may have explained their comparable (instead of higher) levels of thrombin 
generation parameters as compared with the individuals with IGM. Third, we studied a 
Caucasian, elderly population and it remains to be established whether these results can 
be generalized to other ethnicities and/or to younger individuals. Fourth, measures of 
thrombin generation were performed in plasma samples that were stored for 7 to 8 years. 
Although in our lab we have been able to rule out effects of approximately one year of 
storage time on ex vivo thrombin generation, long term effects, if any, are largely 
unknown. If long term storage introduced a systematic error in measures of thrombin 
generation, we can rule out its influence on the differences found between the groups 
examined in the present study, since storage time was similar for all plasma aliquots. If 
random errors were introduced, or even if storage time reduced the variation of the 
measures as captured by our assay, then the differences between groups reported herein 
were most likely underestimated. Finally, it should be noted that, in the present cohort, it 
is unknown which individuals carried the factor V Leiden mutation. In general, these 
individuals will have a higher thrombin generation due to activated protein C resistance 
and an association between DM2 and the factor V Leiden mutation has been previously 
reported (40). However, several other studies, including a Dutch one, did not find any 
association between DM2 and factor V Leiden mutation (41–43). So far, no studies have 
investigated the association between DM2 and acquired activated protein C resistance. 
We have shown herein that activating the protein C pathway by adding thrombomodulin 
did not materially change the strength of the associations between glucose metabolism 
status and peak height or ETP, which indicates that there were no abnormalities in protein 
C activation in individuals with IGM or DM2.  
 
In conclusion, we have shown that IGM and DM2 are associated with higher thrombin 
generation in PPP, which can be explained, to a large extent, by their greater levels of 
central adiposity and related low-grade inflammation. It remains to be established 
whether the assessment of thrombin generation in PPP constitutes a useful method for 
the characterization of hypercoagulability, relevant to arterial and venous thrombosis, in 
these individuals, since the magnitude of the differences was relatively small. 
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Discussion and Summary 
 
The main objective of this thesis was to increase current knowledge about the underlying 
mechanisms potentially explaining the increased cardiovascular disease (CVD) risk in 
individuals with central obesity, the metabolic syndrome (MetS) or type 2 diabetes (DM2). 
We investigated associations with intermediate phenotypes of CVD such as endothelial 
dysfunction, microalbuminuria, cardiovascular autonomic dysfunction, arterial remodeling 
and hypercoagulability. We used data from the Hoorn study, a population-based cohort 
study on glucose metabolism and its complications in elderly individuals, and the 
Amsterdam Growth and Health Longitudinal Study (AGAHLS), a longitudinal study on the 
life-course relationships between biological and lifestyle risk factors in young adults.  
 
In this final chapter we summarize the main findings, address some methodological 
considerations and discuss potential (clinical) implications and directions for future 
research. 
 
MAIN FINDINGS 
 
In Chapter 2 we investigated, in elderly individuals without and with type 2 diabetes, the 
association between body composition and endothelial (dys)function defined on the basis 
of brachial flow-mediated dilation (FMD) and circulating biomarkers. We observed a 
positive, i.e. beneficial, association between peripheral lean mass and FMD, and a 
negative, i.e. adverse, association between (central) fat mass and circulating biomarkers of 
endothelial function. These findings suggest that not only central fatness, but also 
sarcopenia may independently contribute to endothelial dysfunction in elderly individuals, 
possibly through differential effects on specific aspects of this multifaceted construct.  
 
In Chapter 3 we showed, again in elderly individuals without and with type 2 diabetes, 
that microalbuminuria and cardiovascular autonomic dysfunction were associated with 
cardiovascular mortality independently of each other, which suggests that they may be 
linked with cardiovascular mortality through different biological pathways. 
 
In Chapters 4 and 5 the associations between MetS and structural adaptations of the 
carotid artery were studied in a cross-sectional (Chapter 4) and a longitudinal (Chapter 5) 
setting in elderly and young individuals, respectively. We showed that MetS was cross-
sectionally associated with arterial properties consistent with a pattern of maladaptive 
remodeling of the carotid artery in elderly individuals (Chapter 4). In addition, we showed 
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that persistent MetS over the course of 6 years was also associated with this adverse 
pattern of arterial remodeling in young adults and that recovery from MetS was 
associated with restoration of the arterial properties to levels comparable to the 
individuals who remained without MetS, emphasizing the potential for reversibility 
(Chapter 5).  
 
Finally, Chapter 6 demonstrated that body fat mass, and in particular a central pattern of 
fat distribution, was associated with higher levels of thrombin generation in elderly 
women, but not in men. This association was to a great extent attenuated by adiposity-
related low-grade inflammation. In addition, we showed that individuals with impaired 
glucose metabolism (IGM) and DM2 had comparable levels of thrombin generation, both 
significantly higher than those with normal glucose metabolism, and that this difference 
was explained, to a great extent, by their higher levels of adiposity-related low-grade 
inflammation (Chapter 7).  
 
METHODOLOGICAL CONSIDERATIONS 
 
Study populations and designs – external validity 
Most of the studies included in this thesis (all except Chapter 5) were conducted within 
the Hoorn study, and consisted of (a selection of) of a Caucasian, elderly population with a 
relatively high risk of CVD. Whether our results can be extrapolated to other ethnicities 
and/or younger/healthier individuals is unknown and should be investigated in future 
studies.  
 
The extrapolation of the results obtained in the study conducted within the AGAHLS 
(Chapter 5) may also be limited because this cohort consists of individuals with relatively 
high education and socio-economic levels and of mostly (>95%) Caucasian ethnicity.  The 
prevalence of main risk factors, such as those comprised in the MetS may have been lower 
than in the general Dutch population, as these risk factors tend to be higher among 
subjects with lower socio-economic status and ethnic minorities. 
 However, issues around the representativeness of the cohorts used in the 
present study are not likely to affect the pathophysiological validity of our findings. 
 
Study populations and designs – internal validity 
Potential sources of bias that may obscure the internal validity and thus inferences of 
‘cause and effect’ drawn from observational studies are: selection bias, confounding and 
information bias. 
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Selection bias. As mentioned above, for most studies included in this thesis we used data 
from the Hoorn Study, a population-based cohort study on glucose metabolism and its 
complications that started in 1989. However, our studies – specifically those in Chapters 
2,4,6 and 7 - were based on cross-sectional data from the follow-up examination carried 
out in 2000-2001, when the majority of the intermediate phenotypes of interest (i.e. 
arterial remodeling, thrombin generation, comprehensive set of circulating biomarkers of 
endothelial dysfunction and low-grade inflammation) were measured for the first time. 
Selective attrition could thus have introduced some bias into the estimates reported in 
these studies because individuals who participated in the follow-up examination were 
relatively healthier than the non-responders or those who died. Therefore, most likely our 
estimates reflected an underestimation of the true associations, because risk factors such 
as (central) obesity, MetS and/or DM2 (the main determinants of interest in our studies) 
and maladaptive remodeling, thrombin generation and low-grade inflammation and 
endothelial dysfunction (the main outcomes) are known determinants of mortality (Figure 
1).  
 
The results obtained in the AGAHLS (Chapter 5) were not likely affected by selection bias. 
Although the sample used (n=373 at the age of 36 and 297 of these who had also arterial 
data at the age of 42) was considerably reduced in size as compared with the original 
cohort at baseline (n=698 adolescences), it did not differ from the drop-outs with regard 
to body fatness and other biological risk factors at the beginning of the study (in 1976) (3, 
4). The young age of the cohort probably has prevented the occurrence of selective drop-
out due to (chronic) illness and/or mortality, with drop-outs thus far (often intermittent, 
i.e. at one wave but returning at a subsequent one) being most likely due to the quite long 
follow-up duration of the study (30 years!). 
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Survival/ 
continuation 
• (Central) obesity 
• Metabolic syndrome 
• Type 2 diabetes 
• Endothelial dysfunction 
• (Maladaptive) carotid remodeling 
• Hypercoagulability 
- 
- 
+ 
Outcomes 
• Endothelial dysfunction 
•(Maladaptive) carotid remodeling  
•Hypercoagulability  
Figure 1. Directed acyclic graph (DAG) depicting general causal structure underlying attrition-related selection 
bias in chapters 2,4,6,7 (1, 2). In this DAG, the risk factors of interest directly negatively influence (-) post-
enrolment survival or continuation in the Hoorn study, which is a collider on the path between risk factor and 
outcome (indicated by the box). The outcomes, (current) maladaptive remodeling, thrombin generation, low-
grade inflammation and/or endothelial dysfunction reflect (+) the levels of these parameters prior to study drop-
out. On the other hand, these parameters likely negatively influenced (-) survival or study continuation. Analyses 
restricted to the participants who survived and continued in the study are a form of conditioning (on 
survival/participation) which, in this case (see signs depicting the direction between associations) can have 
induced a downward bias in the associations reported, which results in an underestimation of the effect sizes.  
 
Confounding. Our results could have been affected by residual confounding, that is, a 
variable or variables associated with both the main determinant and the outcome of 
interest, without being in the causal pathway between the two, but that were not 
measured or taken into account in the analyses could have been responsible for the 
associations we reported. Both the Hoorn study and the AGAHLS participants were well 
characterized and an abundant set of potential confounders was measured. All analyses 
were therefore carefully adjusted for potential confounding factors relevant for the 
associations under investigation, as selected based on prior (aetiological) knowledge. 
However, we cannot fully exclude the possibility that unknown/unmeasured confounders 
may still have led to a distortion of the results (either over- or underestimation). Such 
residual confounding is difficult to solve in observational studies. 
 
Information bias. Errors in measurements may have lead to misclassification of subjects 
(either differential or non-differential). Differential misclassification occurs when the 
errors differ across groups or levels of risk factor exposure. The effects of such 
misclassification can vary from an overestimation to an underestimation of the true 
associations (5). Non-differential misclassification occurs when the probability of being 
misclassified is equal for all groups/levels of risk factor exposure. In general, this may lead 
to an underestimation of the true association due to reduced power (6). Below, we discuss 
in more detail the issue of misclassification with regard to the measurements of the 
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specific determinants (i.e. body composition, MetS, DM2) and outcome variables (i.e. 
endothelial dysfunction, cardiovascular autonomic dysfunction, remodeling of the carotid 
artery and thrombin generation) of interest in this thesis. 
 
In addition to the aspects of external and internal validity discussed above, it should be 
noted that inferences of cause and effect drawn from the studies presented in this thesis 
should be made with caution, because all studies were observational and most (except 
Chapters 3 and 5) had a cross-sectional design, and reverse causality therefore cannot be 
ruled out. A cause could be defined as an antecedent event, condition or characteristic 
without which the disease event either would not have occurred at all or would have 
occurred at a later time (7). Causality is one of the most difficult concepts to study and 
cannot fully be tested in a cross-sectional design. Therefore, longitudinal studies are 
needed to further clarify the mechanisms underlying the associations reported in 
Chapters 2,4,6 and 7. 
 
MEASUREMENTS OF THE MAIN DETERMINANTS 
 
Body composition  
Body composition was measured by means of dual energy x-ray absorptiometry (DXA) 
(Chapters 2 and 6). This enables a precise characterization of individuals’ levels of fat as 
accumulated in different body regions (trunk vs. peripheral) and also of the levels of lean 
(muscle) mass and their independent, and potentially opposite, association with outcomes 
of interest (e.g. endothelial dysfunction, low-grade inflammation and hypercoagulability). 
We have examined associations between body composition and these outcomes by 
means of multivariate models, allowing quantification of the expectedly adverse effects of 
central or trunk fat but also of the potential beneficial effects of peripheral fat and lean 
masses (4, 8-10). Because the different fat measures are strongly associated with each 
other, it can be argued that adjustment of these measurements for each other in such 
multivariate models led to overcorrected models. However, although the regression 
coefficients changed considerably after adjustments of body composition variables for one 
other (e.g. Table 3 of Chapter 6), our models were not disturbed by multicollinearity (i.e. 
tolerance was >0.1. in all models). 
 
In addition, trunk fat as assessed by DXA correlates highly with CT measures of visceral fat 
as with total abdominal fat in elderly (11) and younger adults (12), implying associations 
with subcutaneous fat in this region. However, DXA measures do not enable distinctions 
between subcutaneous and visceral fat in the trunk/abdominal region in elderly (11), and 
therefore do not allow direct inference about potential differential ‘effects’ of these two 
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fat depots on the outcome variables of our studies.  Additional measures of such fat 
depots are still thus necessary for a more detailed understanding of the 
pathophysiological mechanisms linking different fat depots to metabolic and vascular 
health.   
 
Definition of Metabolic Syndrome  
The concept of MetS has, and still is, an ongoing subject of discussion, especially with 
respect to its pathogenesis and clinical usefulness. In Chapter 4 we used MetS expressed 
as a continuous variable (i.e. mean of z-scores of each trait) to take into account the 
continuous nature between the MetS traits and CVD. This method is more robust and 
does not suffer from the problem of dichotomization of continuous risk variables (as 
disease risk does not start at a certain cut off point (13)), something for which the 
commonly used definitions of MetS such as those by the National Cholesterol Education 
Program (NCEP) or the International Diabetes Federation (IDF) have been criticized for (14, 
15). Because all MetS traits show a graded association with cardiovascular risk, 
establishing specific cut-off values is an arbitrary decision, but useful from a clinical point 
of view (16).  
 
In Chapter 5, the definition of MetS at changes in MetS status was based on the clustering 
of 3 or more traits defined based on its distribution within the AGAHLS study population 
(i.e. highest sex-specific quartiles of systolic or diastolic blood pressure, waist 
circumference, triglycerides, and glycated haemoglobin (HbA1c) and the lowest sex-
specific quartile of high density lipoprotein (HDL) cholesterol), as measured at baseline. 
We used HbA1c, because fasting plasma glucose levels (FPG) were not available at 
baseline in the AGAHLS. Epidemiological evidence supports the use of HbA1c when FPG is 
missing, because HbA1c, as FPG, is strongly associated with CVD (17-20) and recently, 
HbA1c has also been recommended for the diagnosis of DM2 replacing the traditional oral 
glucose tolerance test (OGTT) values (21, 22). The use of cut-off values based on the 
distribution of traits within the study population (quartiles) potentially lead to some 
degree of misclassification and the estimated prevalence and incidence of the MetS may 
therefore not directly compare to those obtained with standard definitions applied to 
cohorts of comparable age. However, our estimates were comparable to those obtained in 
Cardiovascular Risk in Young Finns Study, a large population based cohort, where MetS 
was defined according to a standard definition (23).  
 
Our approach allowed: 1) the identification of those individuals with the worst MetS 
profile (clustering of MetS traits that could not be explained by chance alone) at baseline 
and its change over time – by  the use of 4 phenotypes: never, incident, recovery and 
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persistent; and 2) the comparison (and illustration) of arterial properties changes over 
time (between the ages of 36 and 42) by changes in MetS status over the same time 
period. With the use of (changes in) a continuous MetS score such arterial changes would 
not be clearly depicted, because in longitudinal analyses, individuals who have a stable 
high or a stable low MetS (continuous) score over time would have a similar change value 
(close to 0). Thus, despite the limited external validity, our approach served the purpose of 
identification of different phenotypes incorporating changes in MetS status over time, 
which was suitable for this study. 
 
Definition of glucose metabolism status 
Hoorn Study participants’ glucose metabolism status, i.e. normal glucose metabolism 
(NGM),  impaired glucose metabolism (IGM), including both those with impaired fasting 
glucose and/or impaired glucose tolerance) and DM2, was defined by means of a standard 
75g OGTT according to the criteria defined by the World Health Organization (WHO) in 
1999 (24), which was the relevant definition at the time (i.e. 2000-2001 follow-up 
definition). More recently, in 2009, an International Expert Committee (representing the 
American Diabetes Association (ADA), the European Association for the Study of Diabetes 
(EASD) and the IDF) has proposed the diagnosis of diabetes to be made primarily on the 
basis of HbA1c levels ≥ 6.5% (47 mmol/mol) (21). Though the investigation of HbA1c levels 
in its continuous range is emphasized in recognition of its association with a continuum of 
risk for micro- and macro-vascular disease risk, values in the range of 6.0-6.5% (42-47 
mmol/mol) are proposed as indicative of a ‘high-risk state’. The use of these criteria for 
the definition of diabetes were not considered appropriate in our studies since indication 
for treatment during the 2000-2001 assessment of the Hoorn Study (i.e. the data used in 
our studies) were based on the criteria in use by then (WHO 1999). 
 
However, when we compared the associations between glucose metabolism status (by 
using either the OGTT-based (as used in Chapter 7) or HbA1c-based definitions) and 
thrombin generation, the two definitions yielded similar results (Table 1). This implies that 
the HbA1c-based definition might also be applicable to our data. It should be noted 
however that, with the currently used cut off points, HbA1c is less sensitive (but more 
specific) in identifying individuals at high-risk for DM2 compared with the OGTT. 
Therefore, some individuals may have been misclassified as ‘normal’ with the HbA1c-
based definition which potentially could have led to slightly underestimated associations.  
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Table 1. Associations between glucose metabolism status according to the old and new definitions and thrombin 
generation.  
 WHO 1999* 
-75g OGTT - 
 International Expert Committee  
(ADA, EASD, IDF 2009) 
- HbA1c - 
 NGM 
(n=275) 
IGM 
(n=176) 
DM2 
(n=293) 
p-value  
(IGM+DM2 
vs. NGM) 
 Normal 
< 6.0% 
(n=305) 
High-risk 
6.0-6.5% 
(n=123) 
DM2** 
≥ 6.5% 
(n=316) 
p-value  
(IGM+DM2 
vs. NGM) 
Lag time (min)  3.98 ± 0.83 4.10 ± 0.80 4.14 ± 0.77 0.021  3.98 ± 0.81 4.09 ± 0.76 4.16 ± 0.79 0.008 
Peak Height (nM) 182 ± 57 191 ± 58 189 ± 59 0.067  183 ± 56 189 ± 60 189 ± 58 0.137 
ETP (nM*min) 1166 ± 222 1218 ± 237 1192 ± 238 0.034  1175 ± 214 1210 ± 255 1194 ± 240 0.171 
Results are presented as means ± standard deviation 
*adapted from Table 2 of Chapter 7; **group consists of all individuals with a HbA1c ≥6.5% or those who used 
antidiabetic drugs 
WHO: World Health Organization; OGTT: oral-glucose tolerance test; NGM: normal glucose metabolism; IGM; 
impaired glucose metabolism; DM2: type 2 diabetes mellitus; ETP: endogenous thrombin potential 
 
MEASUREMENTS OF THE OUTCOME VARIABLES 
 
Endothelial function 
The term endothelial dysfunction has been most often used to refer to impairment of the 
endothelium-dependent vasodilation capacity, but may be better characterized by 
changes of the endothelium, either in the basal state or after stimulation, which are 
inappropriate with regard to the preservation of organ function (25). The endothelium has 
many functions and actively regulates vascular tone and permeability, the balance 
between coagulation and fibrinolysis, the composition of the subendothelial matrix, the 
adhesion and extravasation of leukocytes, and inflammatory activity in the vessel wall 
(26). Therefore, there is no ideal single test to measure (non-invasively) endothelial 
function (27-29). Brachial artery flow-mediated vasodilation (FMD), as assessed by non-
invasive ultrasound, is widely used to investigate the endothelial vasodilatory function. 
Measures of plasma levels of endothelial-derived regulatory proteins (biomarkers) are also 
commonly used. We have therefore used both measures to characterize as 
comprehensively as possible endothelial (dys)function among the participants of the 
Hoorn Study (Chapter 2). Each measure warrants some critical methodological 
appreciations, however.  
 
Flow-Mediated Dilation (FMD) 
Most often FMD is expressed as the change in diameter relative to the baseline diameter 
(D), i.e. Dpeak after cuff-release – baseline D/baseline D, in %. A percentage change statistic 
is not appropriate because baseline diameter varies considerably between individuals and 
is inversely associated with FMD% (30, 31) i.e. the initial baseline D has the potential to 
introduce mathematical bias into the quantification of FMD (in %), with smaller vessels 
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appearing more reactive and vice versa (32). To circumvent this problem analyses of the 
absolute change in diameter (∆D, in mm) adjusted for the baseline D, as a covariate, have 
been proposed (33, 34). Such analytical procedure applies well in the context of 
randomized controlled trials when any imbalances between individuals in baseline 
measures may be assumed to be random and unrelated to the ‘determinant’ of interest 
(35). However, it must be noticed that these assumptions do not hold in the context of 
observational research, where the determinant of interest (e.g. lean mass in Chapter 2) 
may itself be related with the baseline D, in which case adjustment for the baseline D may 
introduce some bias by inflating the true associations (36). For these reasons, and to 
enable a full appreciation, we have shown our results on the associations between body 
composition with FMD as expressed as ∆D (in mm) with and without adjustments for the 
baseline D (Chapter 2). 
 
In addition, when an arbitrary time point or time window (most often after 60s of cuff 
release as in the original work by Celermajer et al (37)) is used to determine the FMD 
response, there can be significant underestimation of the true FMD (38). To circumvent 
this problem to some extent, our FMD protocol included 4 measurements of brachial D up 
to 5 min after cuff release (i.e. at 45s, 90s, 180s and 300s). Dpeak was therefore determined 
as the maximal D after cuff release occurring at any of these time points (and for the vast 
majority of the subjects this occurred at 45 or 90s). These 4 measures also allowed us to 
estimate an incremental area under the FMD curve response (FMDAUC) by means of 
integrals computation (Figure 2) (39), although the 4 time points may have not been 
enough to fully capture its contours and the true Dpeak. Indeed, current automated 
diameter analysis systems enable the continuous measurement of post cuff release 
diameters at 3-5s time points enabling a more precise calculation of the FMDAUC and the 
Dpeak (40). These systems have revealed that the further apart the time points are the 
lower the FMD is, and therefore with our protocol we may have underestimated FMD. 
Likely this was non-differential and if anything led to an underestimation of the 
associations reported.  
 
It is thought that the peak response mainly represents the nitric oxide (NO) and 
prostaglandin availability and that the overall area under the curve potentially represents 
other vasodilating factors such as endogenous hydrogen sulfide (H2S), that functions as a 
neuromodulator and potentially has an effect on vascular diameter by relaxing vascular 
smooth muscle cells (41), and carbon monoxide (CO), which exerts a dilator influence on 
the cerebral circulation and is involved in active hyperaemia, autoregulation, hypoxic 
dilation, and counteracting vasoconstriction (42, 43). Although our findings shown in 
Chapter 2 suggest that the beneficial impact of lean mass in elderly individuals on FMD 
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was mainly NO mediated (as no associations with FMDAUC were observed – data not 
shown), the use of continuous measurements of D as of blood flow velocity (the stimulus) 
by modern systems may shed a better light into these issues and the whether FMDAUC 
offers any additional clinical relevant information for the assessment of endothelial 
dysfunction (44). 
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Figure 2. Illustration of an FMD curve response as estimated by General Estimated Equations (GEE): by regressing 
the observed post-occlusion diameters data on baseline diameter and time (treated as dummy variable). With 
the use on all four post-occlusion diameter data (imputed when necessary) we also estimated an incremental 
area under the FMD curve (FMDAUC, in mm*min) by means of integral computation (39). 
 
 
Circulating biomarkers 
In addition to the assessment of FMD we have measured several circulating biomarkers of 
endothelial dysfunction, i.e. soluble intercellular adhesion molecule-1 (sICAM-1), soluble 
vascular cell adhesion molecule-1 (sVCAM-1), soluble endothelial selectin (sE-selectin) and 
von Willebrand factor (vWf) and also of low-grade inflammation, i.e. C-reactive protein 
(CRP - twice), serum amyloid A (SAA), interleukin-6 and interleukin-8.  Although the 
reproducibility of these measurements was good (45), these assessments were obtained 
recently by means of electro-chemiluminescence technology in frozen samples that have 
Discussion and summary 
 173 
been stored for approximately 10 years, with the exception of vWf and CRP, which were 
measured shortly after the Hoorn 2000-2001 examination (by ELISA methods). We can 
therefore not completely rule out that the long period of storage might have affected the 
absolute levels of these biomarkers. However, this could to a certain extent be excluded, 
because we also obtained CRP measurements with the most recent technology (in frozen 
samples) and, if anything we found higher rather than lower levels of CRP in these than in 
the prior assessments (ELISA) but a very high correlation between the two (r>0.9), 
indicating that the rank between individuals was preserved and no differential error was 
introduced by storage time. The differences in concentrations are thus more likely due to 
the different methodologies and differences on the standards provided by the respective 
commercial kits, which have not yet been sufficiently standardized (46). Furthermore, we 
have previously shown that concentrations of sICAM-1, sVCAM-1, CRP and sE-selectin 
remained stable over a relatively short period (47) and others have confirmed stable 
concentrations of CRP after  3-years of storage (48).  
 
Cardiovascular autonomic dysfunction (C-AD) and (micro)albuminuria  
In Chapter 3, cardiovascular autonomic function was assessed with both the standard 
Ewing tests, which are widely used by diabetologists and newer methods based on heart 
rate variability and baroreflex sensitivity, which are more often used by cardiologists. We 
calculated an overall C-AD total score based on the results of these tests to characterize C-
AD as comprehensively as possibly by a robust measure comprising its several dimensions. 
Given the moderate reproducibility of each test (49), analyzing the association between 
each test separately and cardiovascular mortality would more likely be affected by 
misclassification (probably random) and underestimate the risk than the C-AD total score. 
By combining the tests into an overall score we also avoided the potential problem of 
multiple testing (i.e. type I errors) that would have occurred when each test would have 
been analyzed separately.  
 
The presence of (micro)albuminuria was defined on the basis of albumin-to-creatinine 
ratio measured in only one urine (first voided) sample for most of the Hoorn study 
participants. (Micro)albuminuria is quite variable from day to day and we cannot fully 
exclude the possibility that some subjects were misclassified. Ideally, measurement of 
albumin excretion in a 24-hour urine collection would provide more precise measures of 
individuals’ albuminuria status.  However, these collections are unpractical and 
inconvenient for patients. Furthermore, it has been shown that an albumin-to-creatinine 
ratio is at least as reliable as measuring the gold standard, 24-hour urinary albumin 
excretion, for prediction of cardiovascular morbidity and mortality (50). 
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Remodeling of the carotid artery 
We used non-invasive ultrasound imaging to assess (changes in) properties of the carotid 
artery, i.e. lumen diameter (LD), inter-adventitial diameter (IAD) and intima-media 
thickness (IMT) to ascertain different types of remodeling processes related to the 
prevalence of the MetS in the Hoorn Study (Chapter 4) or with changes in MetS status in 
the AGAHLS (Chapter 5). These structural measurements were complemented with 
estimates of the haemodynamic forces exerted at the arterial wall (i.e. circumferential 
wall tension and stress), providing a more comprehensive view of the remodeling process 
than most of the studies thus far.  The protocol and equipment used in assessment of 
these measurements were similar in both cohorts and within the baseline and follow-up 
assessments of the AGAHLS, and conform the international guidelines for user procedures 
(51, 52) with measures being obtained with very good levels of intra-observer (Hoorn 
Study, 1 observer) (53) and inter-observer (AGAHLS, 2 observers) reproducibility (3). In the 
AGAHLS, the arterial measurements were obtained approximately 6 years apart and by 2 
different observers. Therefore, considerable efforts were made to ensure longitudinal 
reproducibility (i.e. pilot reproducibility study between observers involved in the baseline 
and the follow-up assessments, and use of image prints of exact measurement locations 
as obtained at baseline as aids in the follow-up measurements). Measurement errors 
cannot be fully ruled out, but most likely these led to an underestimation of the 
associations reported as observers were blinded to the individuals’ MetS status. However, 
individuals’ (central) obesity status, a key component of the MetS was of course 
unavoidably open to the observers’ perception, and in a way this could have introduced 
some sort of differential bias. 
  
Finally, a key limitation of ultrasonography is that it does not distinguish between the 
intima from the media layers of the carotid wall. Therefore, whether MetS-related 
increases in IMT reflect atherosis (intima) or arteriosclerosis (media) cannot be made with 
certainty. In addition, and in view of more recent developments in arterial 
ultrasonography technology, all arterial measurements obtained in the Hoorn and AGAHLS 
cohorts were confined to a specific site (marked by a single M-line centered approximately 
1 cm proximal to the carotid bifurcation) but did not cover its length. Recent echotracking 
systems allow measurements over the arterial length (54) and may thus be more precise. 
 
(Hyper)coagulability - thrombin generation 
The measurements of the thrombin generation parameters were performed in 2008 in 
plasma samples that were stored at -80° for 7 to 8 years, but that had not been thawed 
before the thrombin generation analyses were performed. It is not known to what extent 
storage time could have affected the levels of thrombin generation parameters as 
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reported in our studies. Although the Laboratory for Clinical Thrombosis and Haemostasis 
of the Maastricht University Medical Centre, where the measurements of thrombin 
generation parameters were performed, has been able to rule out the effects of 
approximately one year of storage time on ex-vivo thrombin generation, long-term 
effects, if any, remain unknown. If long-term storage introduced an error, most likely it 
was a systematic one since storage time was approximately the same for all plasma 
aliquots. In this case, we can rule out its influence on the associations (Chapter 6) or 
differences found between the different groups of glucose metabolism status (Chapter 7). 
If random errors were introduced, or even if storage time reduced the variation of the 
parameters, then the magnitude of the associations or differences between groups were 
most likely underestimated. Nevertheless, a better insight on the effects of (long) storage 
time need to be provided by newer biochemical assessment methods. In addition, 
standardization and definition of normal or high-risk ranges for the parameters obtained 
by such new methods are necessary to enable a clinical meaningful interpretation and 
comparability of data across different clinical populations.  
 
In this line, we compared the thrombin generation parameters of individuals with NGM, 
IGM and DM2 as measured in the Hoorn study population (reported in Chapter 7) with the 
results of 134 healthy individuals who were also tested in the same lab (55) – Table 2. 
Clear differences in the absolute values of lag time, peak height and endogenous thrombin 
potential were observed between the healthy group and all of the groups in the Hoorn 
Study which could be attributable to age and risk factor differences between the healthy 
individuals and the individuals of the Hoorn Study.   
 
The thrombin generation parameters measured in our population were measured without 
corn trypsin inhibitor (CTI). Corn trypsin inhibitor has been advocated to prevent contact 
activation, but is expensive and only acts when already present in the test tube when the 
blood is drawn. It was previously shown that CTI was not required at tissue factor 
concentrations >0.5 pM (note that in Chapters 6 and 7 a concentration of 1 pM was used), 
though this was only tested in normal pooled plasma, not in patients (56).  
 
Finally, the thrombin generation parameters were measured in platelet-poor plasma, 
which, in the context of arterial thrombosis, is probably not the most accurate reflection 
of the ‘true’ coagulabilty state, as platelets play an important role in the aetiology of 
atherothrombosis. At the moment, new thrombin generation assays are under 
development in whole blood, which may provide more accurate assessments of thrombin 
generation in the context of atherothrombosis. Therefore, the associations examined in 
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Chapters 6 and 7 should be reassessed in platelet-rich plasma before a statement can 
made about the clinical usefulness of the thrombin generation assay. 
 
Table 2. Comparison of thrombin generation parameters of healthy individuals and Hoorn population (stratified 
by glucose metabolism status) 
 Healthy  
 group 
(n=134)* 
Hoorn Study 
 NGM 
(n=275) 
IGM 
(n=176) 
DM2 
(n=293) 
Age, years (range 
or SD) 
54 [20 to 90] 68.5 ± 6.0 70.3 ± 6.5 67.6 ± 8.0 
Sex, % female 52.1 52.7 49.4 49.1 
Lag time (min)  5.84 ± 1.65 3.98 ± 0.83 4.10 ± 0.80 4.14 ± 0.77 
Peak Height (nM) 116 ± 50.8 182 ± 57 191 ± 58 189 ± 59 
ETP (nM*min) 995 ± 289 1166 ± 222 1218 ± 237 1192 ± 238 
* J Thromb Haemost 2008; 6: 125–31. Data are means ± SD or frequencies, except for age in the healthy group 
[mean and range]. 
 
 
PATHWAYS - CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES 
 
To better understand the pathogenesis of CVD and improve risk estimation, considerable 
research effort has been put on the identification of new factors or biomarkers that, in 
addition to the traditional risk factors, are associated with CVD. The studies comprised in 
this dissertation intended to contribute to that effort. We investigated several 
intermediate phenotypes of CVD (such as endothelial dysfunction, C-AD, (maladaptive) 
remodeling of the carotid remodeling and (hyper)coagulabity). Our findings elucidated 
some potential pathways through which individuals with metabolic disorders such as 
central obesity, MetS and DM2 may be at increased risk for CVD (Figure 2). 
 
Although primary prevention of obesity and related metabolic disease remains the best 
strategy to prevent CVD at the population level, treatment interventions targeting the 
pathways we have elucidated may constitute a way to improve the health status of 
individuals who are obese, have MetS and/or DM2 and have difficulties to recover from 
these states. To recover from these conditions considerable lifestyle changes 
requirements are often needed (e.g. severe calorie restriction, dietary pattern changes or 
more exercise) when, at the same time, such individuals may be less amenable to such 
interventions (e.g. due to more physical  limitations, respiratory problems, food habits 
etc.), especially at older ages.  
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Figure 2. Pathways of risk investigated/identified in the present thesis (thick arrows). Note: model is simplified 
and does not include all (and there are many other) possible pathways based on available evidence from other 
studies.  
 
The observation that, in young individuals who recovered from MetS, all carotid artery 
properties were restored to levels that no longer differed from those who never 
developed MetS is supportive of the value of primary prevention. These findings also 
suggest that reversing MetS status could, at least in part, prevent maladaptive arterial 
remodeling and thereby decrease stroke risk. Still, this hypothesis is dependent on 
prospective studies, preferably randomized controlled trials, investigating the extent to 
which ‘curing’ MetS reduces the incidence of stroke in these individuals and how much of 
this beneficial effect can be attributed to favourable changes in arterial (remodeling) 
properties. 
 
The observation, in elderly individuals, that the widening of the arterial diameter was 
mainly dependent on blood pressure (Chapter 4), suggests that the pulsatile component 
of blood pressure exerts a fatiguing effect on the load-bearing elements of the arterial 
wall (i.e. elastin and collagen) (57). In agreement with this, we observed that not only 
arterial widening but also the intrinsic elastic properties of the carotid artery wall (as 
estimated by Young’s elastic modulus), were already impaired at baseline among young 
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adults with MetS and preceded the subsequent steeper increases in IMT among those 
who remained with MetS at follow-up (Chapter 5). These findings support the view that 
arterial enlargement and stiffening may precede and stimulate subsequent wall thickening 
to restore the levels of wall tensile stress. It has been suggested that arterial remodeling 
could primarily reflect an adaptive mechanism of the artery to restore local hemodynamic 
conditions to an equilibrium (58, 59). Our longitudinal study among young individuals 
without overt signs of atherosclerosis served thus as an appropriate model to confirm this 
hypothesis. Still, the process of arterial remodeling related to (persistent) MetS remained 
maladaptive and other MetS components than blood pressure, such as central obesity and 
disturbed glucose metabolism, seemed to contribute to this as well.  
 
Our results also suggest that in elderly individuals not only (central) obesity but also loss of 
peripheral lean mass (at any given level of body fatness) may affect endothelial 
dysfunction, although these associations may be complementary in the sense that central 
fatness was adversely associated with circulating biomarkers of endothelial dysfunction, 
whereas lean mass was adversely associated with FMD (Chapter 2). Therefore, our 
findings emphasize that sarcopenia could be an additional driving factor for the decline in 
endothelial function in elderly. This is a novel observation enabled by our comprehensive 
assessment and investigation of body composition as a determinant of endothelial 
dysfunction. Indeed, most studies thus far focused on the adverse role of (central) fatness 
on endothelial dysfunction, not providing any information on the concomitant role of 
muscle mass. The pathobiological mechanisms linking muscle mass to endothelial 
dysfunction are also not clear and may be distinct from those linking (central) fatness to 
endothelial dysfunction. We hypothesized that low-grade inflammation and/or insulin 
resistance could be involved, and although these explained the associations between 
(central) fatness and endothelial dysfunction (as expressed by the circulating biomarkers), 
they did not explain the lean mass-FMD associations. Factors specifically related to 
sarcopenia, such as androgen deficiency or oxidative stress, may thus be involved (60). 
However, the link between lean mass and endothelial dysfunction may also be non-causal, 
but just a reflection of common underlying factors, such as physical activity and/or 
nutrition status. Therefore, further studies are needed to clarify this pathway.  
Implications of these observations are that lifestyle (diet and/or exercise) or medicinal 
interventions targeting the elderly should not only be focused, as they often are, on loss of 
excessive weight (which is frequently accompanied by loss of muscle mass), but also on 
the preservation of muscle mass. In addition, the evaluation of the beneficial effects of 
diet and/or exercise lifestyle interventions on endothelial dysfunction should also inform 
on the extent to which these can be attributed to changes in muscle mass rather than, or 
in addition to, body fatness.  
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We found that the increase in thrombin generation observed in individuals with IGM 
and/or DM2 could be, to a great extent, explained by their elevated adiposity-related low-
grade inflammation (Chapter 7). In this line, abdominal obesity and low-grade 
inflammation were identified as the main determinants of enhanced thrombin generation 
in young adults (61). There is abundant evidence for a close interaction between 
inflammation and coagulation systems and a bidirectional association between the two 
has also been proposed (62, 63). Which direction is predominant, if any, is not clear. 
Thrombin is associated with a stimulation of pro-inflammatory cytokines (64-67). We 
hypothesized that adiposity-related increases in low-grade inflammation could lead to 
higher thrombin generation, a hypothesis that was to a considerable extent (up to 55%) 
confirmed by our data, although confined to women (Table 4 of Chapter 6). We have also 
investigated the alternative hypothesis, i.e. that body fatness leads to thrombin 
generation, which in turn leads to inflammation. These analyses showed that, in women, 
the associations between body fatness and hsCRP were only very slightly attenuated (by 
~12%) when further adjusted for (parameters) of thrombin generation. Nevertheless, due 
to the cross-sectional and observational nature of the study we cannot fully discard the 
possibility that that low-grade inflammation and thrombin generation are both elevated 
as a consequence of (central) obesity without necessarily being causally related to each 
other. Further mechanistic studies investigating the cross-talk, if any, between hsCRP, but 
also other pro-inflammatory adipose-tissue-related factors, such as interleukin-6, sICAM1, 
serum amyloid A and leptin, and thrombin generation are needed. 
 
Recently, some studies have reported increased levels of thrombin formation in 
individuals with echogenic carotid plaques (68), or with increased IMT (69). In addition, 
thrombin generation was associated with incident ischaemic stroke although not with 
myocardial infarction (70), and notably, this association was present in women but not in 
men. Further studies are thus necessary to establish whether this test is a useful predictor 
of individuals’ risk of atherothrombotic disease in particular, and any potential effect 
modification by sex herein. Prospective data from the Hoorn study may be useful in this 
regard.  
The association between microalbuminuria and cardiovascular mortality was not 
attenuated by cardiovascular autonomic dysfunction (C-AD) and also the association 
between C-AD and cardiovascular mortality was not attenuated by microalbuminuria, 
though C-AD and microalbuminuria were modestly associated with each other (Chapter 
3). This implies that other biological mechanisms underlie these associations. Several 
mechanisms linking C-AD to cardiovascular mortality have been proposed (e.g., QT interval 
prolongation leading to arrhythmias and silent myocardial ischaemia) (71). In this line C-
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AD has been linked to incident CVD, especially in individuals at high risk (DM2, 
hypertension, or prior CVD) (72, 73). It may be useful to test for and treat C-AD (e.g., with 
exercise training, beta blockers or lipid-lowering drugs) in populations at high risk of 
cardiovascular mortality. Finally, in individuals with DM2 and C-AD, tight glycaemic control 
might prevent deterioration of heart rate variability (74). On the other hand, it is unlikely 
that microalbuminuria itself causes cardiovascular mortality; instead, it may be linked to 
CVD by a common pathophysiological process, such as endothelial dysfunction, or low-
grade inflammation or by residual confounding by yet to be discovered factors (75). For 
instance, a cross-sectional study suggested that increased thrombin generation in 
individuals with DM2 explains part of the association between albuminuria and CVD in 
these individuals (76). This needs to be investigated in future prospective studies. 
 
 Finally, whether monitoring of the levels of the surrogate markers discussed above (e.g. 
levels of biomarkers of endothelial dysfunction or thrombin generation, arterial 
remodeling properties), may be useful for the clinical management of elderly individuals 
with (central) obesity, or related metabolic diseases, still depends on the extent to which 
improvement of the levels of these markers result in an improved  
prognosis (77). 
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Samenvatting voor niet-ingewijden  
 
Diabetes mellitus type 2 (DM2), oftewel ‘ouderdomssuikerziekte’ is een steeds vaker 
voorkomende aandoening. Dit heeft onder andere te maken met de vergrijzing en onze 
Westerse leefstijl, waardoor steeds meer mensen te dik worden. Overgewicht kan ervoor 
zorgen dat het lichaam minder gevoelig wordt voor insuline (ook wel insulineresistentie 
genoemd) wat weer kan leiden tot DM2. Deze verminderde insulinegevoeligheid treedt in 
het bijzonder op wanneer het teveel aan vetweefsel zich centreert op de buik, het 
zogenaamde appelfiguur.  
 
De belangrijkste oorzaak van ziekte en sterfte in patiënten met prediabetes en DM2 is 
hart- en vaatziekten. Dit komt ondermeer doordat er vaak gelijktijdig sprake is van een 
aantal risicofactoren op hart- en vaatziekten zoals een toegenomen (buik)vetmassa, 
verminderde insulinegevoeligheid, een te hoge bloeddruk, een te laag ‘goed’ cholesterol 
(bij normaal ‘slecht’ cholesterol) en teveel vetten (triglyceriden) in de bloedbaan. Indien 
men een toegenomen (buik)vetmassa heeft en tevens 2 of meer andere van deze factoren 
gelijktijdig bezit, wordt dit overigens het metabool syndroom (MetS) genoemd. Mensen 
met het MetS hebben een 5-voudig verhoogd risico op het ontwikkelen van DM2 en een 
2-voudig verhoogd risico op het krijgen van hart- en vaatziekten. Echter, bovengenoemde 
risicofactoren kunnen het verhoogde risico op hart- en vaatziekten in patiënten met MetS 
en DM2 niet volledig verklaren. Onderzoek naar andere potentiële mechanismen die het 
verhoogde risico op hart- en vaatziekten in deze patiënten (gedeeltelijk) kunnen verklaren 
is derhalve van belang zodat preventie programma’s en behandelstrategieën hierop 
kunnen worden aangepast.  
 
Het belangrijkste doel van dit proefschrift was om de huidige kennis met betrekking tot de 
onderliggende mechanismen op hart- en vaatziekten in patiënten met toegenomen 
(buik)vetmassa, MetS en DM2 te onderzoeken. In Hoofdstuk 1 van dit proefschrift worden 
de klinische setting en de probleemstellingen geïntroduceerd. Hierbij hebben we gebruik 
gemaakt van 2 grote studies: de Hoorn Studie, een Nederlandse studie naar stoornissen in 
de glucosehuishouding en de complicaties hiervan in mensen tussen de 50 en 75 jaar bij 
aanvang van de studie, en de Amsterdam Growth and Health Longitudinal Study (AGAHLS) 
een studie naar leefstijl risicofactoren in opgroeiende jongeren die gedurende lange tijd 
vervolgd worden. 
 
In Hoofdstuk 2 wordt het verband tussen lichaamsvetverdeling en endotheeldisfunctie in 
ouderen onderzocht. Endotheelcellen zitten aan de binnenkant van de vaatwand van de 
slagader en geven veranderingen in de circulatie door aan de gladde spiercellen van het 
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bloedvat. Op deze manier kan het fysiologische evenwicht worden gehandhaafd. 
Veranderingen in de functie van deze endotheelcellen met dientengevolge 
orgaandisfunctie, wordt ook wel endotheeldisfunctie genoemd. Het is in eerdere 
onderzoeken aangetoond dat endotheeldisfunctie een goede voorspeller is voor 
toekomstige hart- en vaatziekten. Ook weten we dat naarmate mensen ouder worden 
endotheeldisfunctie toeneemt. Mogelijk spelen veranderingen in de lichaamsbouw hierbij 
een rol. In Hoofdstuk 2 hebben we endotheeldisfunctie op 2 verschillende manieren 
gemeten: ten eerste dynamisch door het meten van de mate van verwijding van het 
bloedvat na een periode van bloedleegte (bloedstroomgemediteerde dilatatie) en ten 
tweede door het meten van vaatwandstoffen in het bloed (biomarkers). Vervolgens 
hebben we onderzocht waardoor de gevonden verbanden tussen lichaamsvetverdeling en 
endotheeldisfunctie verklaard konden worden. Als mogelijke verklaring hebben we 
allereerst gekeken naar de rol van laaggradige ontsteking. Dit is een vorm van ontsteking 
die enkel meetbaar is in het bloed maar niet tot ontstekingsverschijnselen zoals koorts 
e.d. leidt. Hiervan is bekend dat dit het risico op hart- en vaatziekten verhoogt. Tevens 
hebben we de rol van verminderde insulinegevoeligheid onderzocht. De belangrijkste 
bevindingen waren dat hoe meer (buik)vet men had des te slechter de endotheelfunctie 
was. Dit werd grotendeels verklaard door de hierboven genoemde laaggradige ontsteking 
en verminderde insulinegevoeligheid. Verder was er een beschermend verband tussen 
vetvrije (dus spier-)massa van de armen/benen en endotheeldisfunctie, wat dus mogelijk 
impliceert dat het behouden van spiermassa in ouderen tevens van belang is voor het 
behoud van endotheelfunctie. 
 
In Hoofdstuk 3 hebben we vervolgens gekeken naar het verband tussen kleine 
hoeveelheden eiwit in de urine (microalbuminurie) en sterfte aan hart- en vaatziekten. 
Het aanwezig zijn van kleine hoeveelheden eiwit in de urine is sterk geassocieerd met het 
later optreden van hart- en vaatziekten. Hoe dit komt is echter onbekend. Een mogelijke 
verklaring hiervoor zou het verminderd functioneren van het onwillekeurige zenuwstelsel 
(cardiovasculaire autonome disfunctie (C-AD)) kunnen zijn. Het is namelijk bekend dat er 
een verband bestaat tussen zowel C-AD en microalbuminurie als tussen C-AD en hart- en 
vaatziekten. Bovengenoemde hypothese hebben we in Hoofdstuk 3 onderzocht waarbij 
bleek dat zowel microalbuminurie als C-AD onafhankelijk van elkaar gerelateerd waren 
aan sterfte aan hart- en vaatziekten, wat suggereert dat beiden via verschillende 
biologische mechanismen leiden tot hart- en vaatziekten.  
 
Herseninfarcten komen vaker voor bij mensen met het MetS. De onderliggende oorzaak 
hiervoor is onduidelijk maar mogelijk spelen veranderingen van de halsslagader hierin een 
rol. Deze veranderingen zijn erop gericht om de slagader te beschermen tegen een te 
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hoge spanning op de vaatwand. In Hoofdstuk 4 hebben we gekeken of er in mensen met 
het MetS (maar zonder DM2) sprake is van structurele en functionele veranderingen van 
de halsslagader. Er bleek inderdaad een verband te zijn tussen het MetS en veranderingen 
van de vaatwand van de halsslagader. Dit verband kon echter niet verklaard worden door 
laaggradige ontsteking of verminderde insulinegevoeligheid en slechts gedeeltelijk door 
de hogere bloeddruk die deze mensen gemiddeld genomen hebben.  
 
Vervolgens is in Hoofdstuk 5 onderzocht of veranderingen in MetS status in jong 
volwassenen geassocieerd zijn met veranderingen in vaateigenschappen van de 
halsslagader. De belangrijkste bevindingen van deze studie waren dat “genezing”van het 
MetS in jong volwassenen gerelateerd was aan verbetering van zowel de structurele als 
functionele veranderingen van de halsslagader. Dit suggereert dus dat het genezen van 
MetS mogelijk het risico op herseninfarcten kan verminderen door gunstige effecten op 
de halsslagader. Deze hypothese zal in toekomstige studies verder uitgezocht moeten 
worden. 
 
Teveel aan (buik)vetmassa is gerelateerd aan zowel trombose in het slagaderlijke systeem 
(hart- en vaatziekten) als trombose in de aders (bijv. trombosebeen). Een mogelijke 
verklaring hiervoor kan zijn een toegenomen stolbaarheid van het bloed in mensen met 
een toegenomen (buik)vetmassa. In Hoofdstuk 6 wordt derhalve het verband tussen 
(buik)vetmassa en toegenomen stolbaarheid van het bloed (gemeten d.m.v. een 
trombinegeneratietest) onderzocht. In deze studie bleek dat er in vrouwen wel een 
verband is tussen (buik)vetmassa en trombinegeneratie, maar in mannen niet. Het is 
bekend dat vrouwen na de overgang meer laaggradige ontsteking hebben dan mannen. 
De gevonden verbanden tussen (buik)vetmassa en trombinegeneratie in vrouwen werden 
ook voor een groot gedeelte (ongeveer 55%) hierdoor verklaard. Een andere verklaring 
kan gezocht worden in hormonale verschillen tussen mannen en vrouwen. Dit valt echter 
buiten het bestek van dit proefschrift en zal in toekomstige studies onderzocht moeten 
worden. Vervolgens wordt in Hoofdstuk 7 gekeken of bij patiënten met prediabetes of 
DM2 een verband gevonden werd met trombinegeneratie. Tevens werd bekeken of een 
dergelijk verband verklaard kon worden door bekende risicofactoren op hart- en 
vaatziekten. In deze studie vonden we dat de relatie tussen mensen met prediabetes of 
DM2 en trombinegeneratie slechts 4% hoger was dan die van mensen met een normale 
glucosehuishouding. Bovendien was deze relatie voor een groot gedeelte toe te schrijven 
aan de toegenomen (buik)vetmassa en daarmee geassocieerde laaggradige ontsteking in 
deze groep patiënten. Derhalve lijkt deze test niet de meest geschikte test om 
toegenomen stolbaarheid in deze patiëntengroepen te meten.  
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Tot slot, worden in Hoofdstuk 8 de belangrijkste bevindingen van dit proefschrift 
samengevat en bediscussieerd. Hierbij worden methodologische kanttekeningen geplaatst 
en aanbevelingen gedaan voor de toekomst. Het voorkomen van vetzucht en gerelateerde 
ziekten (primaire preventie) is de beste manier om hart- en vaatziekten op 
populatieniveau aan te pakken. In dit proefschrift hebben we een aantal mogelijke 
mechanismes/routes onderzocht waarop behandelstrategieën zouden kunnen worden 
ingezet. Hierbij kun je denken aan leefstijl aanpassingen (afvallen, meer bewegen) of toch 
door middel van medicijnen. De toekomst zal ons moeten leren of het meten van de 
hierboven bediscussieerde surrogaatmarkers voor hart- en vaatziekten zinvol zijn voor de 
klinische behandeling van oudere patiënten met toegenomen (buik)vetmassa en 
gerelateerde stofwisselingsziekten zoals DM2.  Eerst is het zaak dat wordt aangetoond dat 
verbetering van deze markers ook daadwerkelijk leidt tot minder hart- en vaatziekten. 
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Dankwoord 
 
In de afgelopen jaren heb ik me begeven in een avontuurlijke reis door de wereld van het 
wetenschappelijk onderzoek. Ik heb het zeker niet altijd gemakkelijk gehad en ik besef ook 
dat dit proefschrift er nooit zou zijn gekomen, zonder medewerking van vele mensen die 
ik eigenlijk  te kort doe door de paar regels/woorden die ik hier aan hen besteed.  
 
Allereerst wil ik uiteraard mijn promotieteam bedanken.  
Prof. Dr. C.D.A. Stehouwer. Beste Coen, dankbaar en vereerd voel ik me dat ik de 
kans heb gekregen tot jouw collectie promovendi te mogen behoren. Groen als gras 
begon ik in 2008 aan een uitdaging waarvan ik vooraf niet zo goed in de gaten had wat het 
allemaal op mijn pad zou gaan brengen. Door jouw goede begeleiding en altijd snelle, 
doch kritische, turquoise-gekleurde commentaar en suggesties is mijn thesis er 1 
geworden waar ik trots op kan zijn!  
Dr. I. Ferreira. Dear Isabel, I’ve always very much appreciated your fast way of 
working and your (very) punctual help and (sometimes confronting) suggestions regarding 
my manuscripts. Are there any epidemiologic pitfalls for you? I appreciate your direct way 
of communicating, which made us in my opinion a good team. Furthermore, and at least 
as important, you were always interested in the person behind the emails and always 
made me able to reflect and laugh whenever I came desperately to your office again. 
Although you have had a hard time recently, you always kept supporting me. Thank you 
very, very much for all your support in every kind of way, without you I would never have 
managed to finish my thesis and I’m very grateful for that. Obrigada! B.t.w.we should still 
play a korfball match once.  
Dr. B. Bravenboer. Beste Bert, in voor- en tegenspoed heb je me gesteund en 
vertrouwen gehad in het feit dat mijn boekje er zou gaan komen. Jij was ook, samen met 
Coen, de initiatiefnemer voor het opzetten van deze AGIKO constructie. Ook als dokter 
heb ik veel van je mogen leren en je hebt tevens mijn enthousiasme voor de 
endocrinologie aangewakkerd! Ondanks je drukke schema en de hele moeilijke periode 
die je hebt doorgemaakt, wist je altijd zinvolle, aanvullende suggesties op mijn 
manuscripten te doen. De eeuwig durende discussies over pleonasmen, bijzinnen voor 
hoofdzinnen en Engels-Engels versus Amerikaans-Engels zullen je af en toe wel vermoeid 
hebben. Ach, ik zal het wel nooit helemaal gaan beheersen...  
 
De leden van de beoordelingscommissie, prof. dr. T. Unger, prof. dr. T. Hackeng, prof. dr. 
C.P. van Schayck, dr. M.B. Snijder en dr. C. van Guldener, wil ik graag bedanken voor de 
tijd die jullie hebben besteed aan het lezen en goedkeuren van mijn proefschrift. Beste 
Coen, in 2008 heb ik mede via jou de kans gekregen aan dit avontuur te beginnen. Ik ben 
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zeer blij en vereerd dat je nu ook het resultaat hebt kunnen lezen en beoordelen als lid 
van de leescommissie. Daarnaast wil ik prof. dr. H.A.J. Struijker-Boudier bedanken voor 
het plaatsnemen in de corona. 
 
Verder wil ik ook graag de mensen van het EMGO instituut en in het bijzonder prof. dr. 
J.M. Dekker en prof. dr. G. Nijpels bedanken. Beste Jacqueline, ondanks de afstand ben je 
zeer laagdrempelig benaderbaar en heb je altijd zeer doordachte aanvullingen op mijn 
manuscripten gegeven. Beste Giel, je immer aanwezige optimisme en humor in het 
reviseren van mijn artikelen heeft regelmatig een glimlach op mijn gezicht doen 
verschijnen. 
 
Dr. R.M.A. Henry. Beste Ronald, ondanks je drukke werkschema en gezinsleven, heb je 
veel tijd en efforts gestoken in het remodelings en endotheeldisfunctie manuscript, 
bedankt hiervoor. 
 
Dan wil ik graag prof. dr. H. ten Cate en dr. H.M.H. Spronk bedanken. Hugo en Henri alias 
de ‘stoljongens’. De trombinegeneratiemetingen zijn door jullie groep uitgevoerd en jullie 
deur stond altijd voor me open als ik weer een onnozele vraag kwam stellen over de 
methodologie van de test. 
 
Mijn paranimfen drs. N. Wlazlo en drs. R.H. van den Eerenbeemt-Olie. Nick, mijn partner 
in crime hier in Eindhoven! Trots ben ik dat jij als paranimf aan mijn zijde wilt staan 
vandaag. Jij weet als geen ander hoe het is om als AiO/AIOS/manusje van alles gevestigd 
te zijn in ‘ons Cathrien’. Jouw (1500 pagina tellend?) boekje is er al ook al bijna (gelukkig is 
het me nog net gelukt je voor te blijven haha). Renske, ik ken jou al sinds dag 1 van mijn 
geneeskunde opleiding en we zijn door de jaren heen goede vriendinnen geworden. We 
hebben veel samen meegemaakt en helaas voor mij was jouw fototoestel altijd (gewenst 
of ongewenst) aanwezig. Ik vond het mooi om te horen dat ook jij aan een promotietraject 
gaat beginnen en dat terwijl je je opleiding tot internist al hebt afgerond! Jouw kennende 
zal jouw boekje geweldig worden. Ik wacht in spanning de dag af waarop jij achter het 
katheder staat. 
 
Mijn bazen en (ex-)collega A(N)IOS uit het Catharina ziekenhuis Eindhoven. Vaak moeten 
jullie je hebben afgevraagd, wat ik dagenlang uitspookte op mijn kamertje achter mijn 
computer, terwijl jullie de benen onder jullie lijf vandaan holden om goede patiëntenzorg 
te leveren. Dankzij jullie is het mogelijk geweest om het schrijven van mijn proefschrift te 
combineren met mijn opleiding. Het Catharina ziekenhuis is een fijn ziekenhuis om te 
werken en ik heb er een goede basis opgedaan voor mijn specialisatie tot internist! 
Dankwoord 
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Collega (ex)AIOs Maastricht. Roel, Lian, Johanna, Bas, Nordin, Katrien, Marcelle, Marjon, 
Amy en Olaf  bedankt dat ik altijd als ‘buitenbeentje’ bij jullie mocht aansluiten bij lezingen 
en congressen. Heel veel succes met jullie verdere (wetenschappelijke) carriere. 
 
Ook wil ik wat mensen bedanken die niet inhoudelijk aan mijn proefschrift hebben 
bijgedragen, maar er altijd voor me waren wanneer ik het even niet meer zag zitten. Mijn 
vriendinnetjes uit de geneeskundeopleiding, ‘de geneesco’s, dank voor alle leuke avonden 
waarop ik altijd de tijd kreeg om mijn AiO(s)-perikelen te spuien. Mijn jaarclubgenootjes, 
ondanks dat we al jaren afgestudeerd zijn en sv KoKo al ver in ons verleden ligt, zijn wij in 
staat gebleken elkaar te blijven opzoeken en de leuke avonden erin te houden. Elke keer 
weer wordt dan bevestigd dat we een heel fijn en hecht clubje zijn samen. 
 
Mijn schoonfamilie. Willem, Loes, Arjen, Karen, Frank en de jongens, vanaf dag 1 heb ik 
me altijd erg welkom gevoeld bij jullie allemaal. Bedankt voor jullie gezelligheid, steun en 
adviezen. 
Pap en mam, ik ben er trots op dat jullie als ‘boertjes uit de Peel’ erin geslaagd zijn om al 
jullie 4 kinderen te laten studeren. Jullie hebben mij altijd gesteund bij het schrijven van 
dit proefschrift, al moet veel ervan abracadabra zijn (geweest). Pap, je wil niet weten hoe 
dankbaar ik ben dat je er, ondanks alles wat er het afgelopen jaar gebeurd is, bij bent 
vandaag. Ik hou van jullie!  
 
Mijn zusjes Fien en Tonneke en broertje Bert. Het is fijn dat we het met z’n vieren (of 
eigenlijk achten want we hebben Martijn, Rudy en Amy er gratis bijgekregen) zo goed 
kunnen vinden. Tonneke, oftewel collega, ik ben ervan overtuigd dat jouw boekje er ook 
zal gaan komen! 
 
De laatste plek in dit dankwoord is voor mijn grote liefde, Marten de Wit. Marten, lieve 
Marten, zonder jou weet ik niet of ik het schrijven van dit proefschrift tot een goed einde 
had kunnen brengen. Altijd was (en ben) je er voor me met je onvoorwaardelijke steun en 
opbeurende woorden, ook als ik het echt niet meer zag zitten. Door jou is de 
zaterdagochtend ‘schrijfochtend’ ingevoerd (en ook weer afgeschaft) om me zo de tijd te 
geven mijn proefschrift af te schrijven. Hoe vreselijk moet het ook voor jou zijn geweest 
als ik tijdens een vakantie waar dan ook op de wereld naarstig naar plekken zocht om mijn 
email te checken of er al een beslissing was over een manuscript. Goed nieuws, Hora Est! 
Vanaf nu zijn de weekendjes en vakanties weer van ons!  
P.S. Ik kan niet wachten tot ik volgend jaar je vrouw ben! 
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